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A bstract
Introduction: Th2 immune signalling is key to the pathological substrate o f asthma. 
The primary objective o f this thesis was to identify the predictive effects o f genetic 
variants o f Th2 signalling at the population level, and to examine interactions between 
different loci, with relation to asthma and associated phenotypes. This genetic 
epidemiological study provided an opportunity to explore also the predictive effects o f 
different measures o f obesity on these phenotypes.
Methods: An unselected population of 1614 young adults was recruited. Responses to 
validated questionnaires and spirometry provided clinical and physiological asthma 
phenotypes. Anthropometry provided the measures o f obesity. Assays on venous blood 
provided immune phenotypes (IgE, eosinophils, eotaxin). Genotyping encompassed 22 
polymorphisms in the IL13, IL4RA and STAT6 genes, representing the Th2 immune 
signalling pathway. Data analysis used linear and logistic regression models, and a 
modified regression to address haplotypes.
Results: Single polymorphisms and haplotypes o f IL13, IL4RA and STAT6 loci 
significantly predicted asthma, eczema and hayfever at the population level. Several 
novel associations were shown for serum IgE levels and airflow obstruction. Significant 
interaction (epistasis) was identified between variants o f IL13 and STAT6 for total IgE 
levels. Adiposity indices (BMI, waist circumference, body fat) showed consistent 
associations with asthma and airflow obstruction, but also with Th2 inflammatory 
markers (IgE, eotaxin and eosinophils) with modulation by sex/smoking status.
Conclusions: Genetic variants of Th2 immune signalling are one important source of 
risk for asthma and allergy in the general population, with variants operating both singly 
and in combination. Obesity and its causes are also likely to be significant contributors 
to the occurrence o f asthma in the population, and may operate through pro- 
inflammatory mechanisms. These findings exemplify the polygenic and multifactorial 
determination of asthma and allergy, through genetic and environmental effects.
Acknowledgements
Diolch yn bennaf i Julian am ei holl gefnogaeth. Mae ei ddoethineb a’i frwdfrydedd 
dros ymchwil wedi bod yn ysbrydoliaeth. Ni allwn wedi gobeithio am well arweiniad 
gyda’r gwaith.
A heartfelt thank you to Mike Gravenor for his considerable contribution to this thesis. 
His encouragement and patience was very much appreciated.
I would like to thank the following for their help during the preparation o f this thesis:
Maria Moller, for her support, and for supervising and assisting with the genotyping, 
and with data collection.
Cathy Thornton, for invaluable advice and for supervising and assisting with the eotaxin 
assays.
Divya Gopalakrishnan and Priyanka Bikhchandani for all the hours they spent helping 
with the data collection and laboratory work, and to Keiko Tanaka, Silas Benjamin, 
Mike Sansbury and Mark Roberts for their help also. Thanks to Mary Cratchley for 
administrative support.
Dr Ann Benton, for undertaking the eosinophil count measurements.
Professor Gareth Morgan for helping to facilitate the total IgE assays and to Graham 
Bishell for overseeing the measurement of total IgE.
Professor Rhys Williams, for his guidance on the obesity and epidemiology aspects.
A warm thanks to all the volunteers who took part in this study.
This thesis was supported by funding from the Stone-Mallabar foundation and Swansea 
Asthma Research Fund, with contributions from Llanelli Asthma Link, and my thanks 
for the generous donations received.
Table of contents
Declaration iv
Abstract v
Acknowledgements vi
Table of Contents vii
List of Figures xi
List of Tables xiv
Abbreviations xvi
Introduction 1
CHAPTER 1 Background 6
1.1 Overview o f the aetiology o f asthma 7
1.1.1 Introduction 7
1.1.2 Genetic susceptibility 7
1.1.3 Environmental factors 11
1.1.4 Occupational asthma 14
1.1.5 Role o f air pollution 14
1.1.6 Role o f smoking 15
1.1.7 Role of diet 15
1.1.8 Role o f infection 17
1.1.9 Role of viruses 19
1.1.10 Role of the epithelial mesenchymal trophic unit 20
1.2 Genetic epidemiology o f the IL-13 signalling pathway in 22
asthma and atopy -  an overview o f the evidence
1.2.1 Introduction 22
1.2.2 The role o f the IL-13 signalling pathway in asthma and 22
atopy
1.2.3 Genetic studies of the IL-13 signalling pathway in 24
asthma and atopy
1.3 Obesity and asthma: potential underlying mechanisms 35
linking two common complex traits
1.3.1 Mechanical effects 3 5
1.3.2 Obesity as a pro-inflammatory state 37
1.3.3 Endocrine factors 39
1.3.4 Common genetic predisposition and overlapping 40
metabolic pathways in asthma & obesity?
1.3.5 Diet, physical activity and the “foetal origins” hypothesis 42
CHAPTER 2 Methodology 44
2.1 Study design 45
2.2 Ethical approval 46
2.3 Subjects 47
2.4 Subject recruitment 47
2.5 Anthropometric measurements
2.6 Phenotyping
2.6.1 Clinical phenotype
2.6.2 Physiological phenotype
2.6.3 Immune phenotype
2.7 Genotyping
2.7.1 SNP selection
2.7.2 Genomic DNA extraction & purification
2.7.3 Genotyping IL13 SNPs by automated DNA sequencing
2.7.4 Outcome o f genotyping IL13 SNPs by automated DNA
sequencing
2.7.5 Genotyping o f selected SNPs in IL13, IL4RA, STAT6
genes
Data analysis
CHAPTER 3 Genetic association of single nucleotide polymorphisms
with asthma and clinical atopy phenotypes
3.1 Introduction
3.2 Methods
3.3 Results
3.3.1 Population characteristics
3.3.2 Genotyping results
3.3.3 Logistic and linear regression analysis
3.4 Discussion
CHAPTER 4 Genetic association of single nucleotide polymorphisms 
with Th2 immune phenotypes
4.1 Introduction
4.2 Methods
4.3 Results
4.3.1 Population characteristics
4.3.2 Linear regression analyses
4.4 Discussion
CHAPTER 5 Genetic association of single nucleotide polymorphisms
with physiological phenotypes
5.1 Introduction
5.2 Methods
5.3 Results
5.3.1 Effect o f genotype on lung function in an unselected 
population
5.3.2 Effect o f genotype on pulmonary function and clinical 126
severity in asthma
5.3.3 Effect o f genotype on lung function and physiological 127
severity in asthma
5.3.4 Genotype associations with severity o f airflow 128
obstruction in asthma
5.3.5 Effects o f genotypes on clinical asthma severity 131
5.4 Discussion 134
CHAPTER 6 Role of epistatic interactions and haplotypes in asthma 139
and atopy
6.1 Introduction 140
6.2 Methods 141
6.3 Results 143
6.3.1 Two locus interaction effects on asthma and immune 145
phenotypes
6.3.2 Haplotype analysis 150
6.4 Discussion 156
CHAPTER 7 The impact of obesity on asthma, lung function & Th2 164
immune phenotypes
7.1 Introduction 165
7.1.1 Cross-sectional studies 165
7.1.2 Prospective studies 166
7.1.3 Effects o f weight change 168
7.1.4 Evidence o f the effects o f obesity on atopy 169
7.2 Study design 120
7.3 Methods m
7.3.1 Anthropometric measurements 121
7.3.2 Clinical variables 122
7.3.3 Spirometry 122
7.3.4 Severity criteria 123
7.3.5 Th2 immune phenotypes 123
7.3.6 Data analysis 124
7.4 Results 125
7.4.1 Population characteristics 125
7.4.2 Logistic regression analysis o f adiposity and clinical 128
outcomes
ix
7.4.3 Asthma severity 183
7.4.4 Linear regression analysis o f adiposity and lung 186
function in an unselected population
7.4.5 Linear regression analysis o f adiposity and Th2 196
immunity in an unselected population
7.5 Discussion 206
CHAPTER 8 Conclusions 216
8.1 Conclusions (I) 217
8.1.1 Effects o f genetic variants o f  IL-13 signalling 217
molecules on asthma, Th2 immunity and 
physiological phenotype
8.1.2 Future directions 223
8.2 Conclusions (II) 227
8.2.1 Effects o f adiposity on asthma, Th2 immunity and 227
physiological phenotype
8.2.2 Future directions 231
REFERENCES 233
PUBLICATIONS AND PRESENTATIONS ARISING FRO M  TH IS 258
THESIS
APPENDICES 259
I. Recruitment
A. Poster advertisement 259
B. Email advertisement 260
II. Consent form 261
III. Data sheet 262
IV. Modified IUATLD bronchial symptoms questionnaire 263
V. Modified ECRHS questionnaire 270
VI. Summary o f variants where overall association with dichotomous 280
outcomes approached significance with p<.05 for difference between 
individual pairs o f genotypes
VII. Summary of variants where overall association with quantitative 281
outcomes approached significance with p<.05 for difference 
individual pairs o f genotypes
x
List of Figures
1.1 A diploid set of human chromosomes, with highlighted regions 
showing the most widely replicated linkage regions with asthma and 
related traits.
8
1.2 The cytokine gene cluster on chromosome 5q31-q33. 9
1.3 An airway diagram illustrating the proteins encoded by asthma- 
susceptibility genes.
11
1.4 Diagram o f the IL-13 signalling pathway. 23
1.5 Molecular model of the IL-13 cytokine-receptor complex. 26
1.6 Diagram illustrating the complex inter-relationships between 
obesity and asthma.
43
2.1 Plates showing eotaxin reactions measured by ELISA. 52
2.2 Example o f a plotted standard curve for eotaxin. 53
2.3 Flow chart o f molecular methods. 55
2.4 PCR products from 12 samples showing borderline DNA yield on 
spectrophotometry.
58
2.5 PCR bands for IL13 SNP 1 at an annealing temperature o f 58°C. 60
2.6 PCR bands for IL13 SNP 1 at an annealing temperature o f 61°C. 61
2.7 PCR products for IL13 SNP 3. 62
2.8a Sequenced genotype at SNP 1 of IL13 for subject 1: C/C. 65
2.8b Sequenced genotype at SNP 1 of IL13 for subject 2: T/T. 66
2.8c Sequenced genotype at SNP 1 of IL13 for subject 3: C/T. 67
2.9 Genomic architecture o f IL13, IL4RA and STAT6 selected SNPs for 
population genotyping.
70
3.1 Linkage disequilibrium (LD) map for IL13. 80
3.2 Linkage disequilibrium (LD) map for IL4RA. 81
3.3 Linkage disequilibrium (LD) map for STAT6. 82
3.4 Odds ratio of asthma at IL13 R110Q (SNP 5). 85
3.5 Odds ratio of asthma at IL4RA I50V (SNP 5). 86
3.6 Odds ratio o f current asthma at STAT6 3TJTR SNP 1. 88
3.7 Odds ratio o f current eczema at STAT6 3 ’UTR G2964A (SNP 1). 89
3.8 Odds ratio of hayfever at STAT6 3 ’UTR SNP 1. 90
4.1 Mean IgE at 3’UTR SNP 6 o f JL13. 104
4.2 Mean IgE at Arg551Gln SNP 13 o f IL4RA. 105
4.3 Mean IgE at STAT6 intronic SNP 8 (C2892T). 106
5.1 Mean % FEV1 by genotype at IL13 -1024 promoter (SNP 1). 120
5.2 Mean % FEV1 by genotype at IL13 -1512 promoter (SNP 10). 120
5.3 Mean PEFR by genotype at IL4RA S478P (SNP 12). 122
5.4 Mean FEF 25-75 by genotype at IL4RA 3’UTR SNP 16. 123
5.5 Mean % FEF 25-75 by genotype at IL4RA 3’UTR SNP 16. 123
5.6 Mean FVC by genotype at IL4RA intron SNP 8. 124
5.7 Mean % FEF 25-75 by genotype at STAT6 intron SNP 11. 125
5.8 Mean % FEV1 by genotype at IL13 -1512 promoter (SNP 10) in 129
asthma.
5.9 Mean % FEF 25-75 by genotype at IL13 -1512 promoter (SNP 10) 129
in asthma.
5.10 Mean FEF 25-75 by genotype at IL4RA intron SNP 8 in asthma. 129
5.11 Mean % FEF 25-75 by genotype at IL4RA intron SNP 8 in asthma. 130
5.12 Mean FEV1/FVC by genotype at IL4RA intron SNP 8 in asthma. 130
6.1 Risk o f asthma for different combinations o f genotypes for IL13 146
Argl lOGln and IL4RA Ile50Val.
6.2 Risk o f asthma for different combinations o f genotypes for IL13 146
SNP 9 and IL4RA Ile50Val.
6.3 Graph showing the interaction effects of high risk genotypes o f 147
IL13 and STAT6 on total IgE level.
6.4 Graph showing the interaction effects o f Ile50Val and Ser478Pro on 149
eosinophil count.
7.1 Baseline characteristics o f the population by weight category, 176
subdivided by gender.
7.2 Prevalence o f asthma according to weight group. 179
7.3 Estimated relationship between probability o f asthma and BMI. 180
7.4 Estimated relationship between probability o f asthma and waist 181
circumference.
7.5 Estimated relationship between probability o f asthma and body fat. 182
7.6 Estimated relationship between daily beta-agonist usage and BMI 185
according to gender.
7.7 Estimated relationship between daily beta-agonist usage and BMI 185
according to smoking status.
7.8 The association between FVC and BMI. 187
7.9 The association between % FEV1 and BMI. 187
7.10 Estimated association between FEV1/FVC and BMI. 188
7.11 The association between FEV 1 and waist circumference. 189
7.12 The association between PEF and waist circumference. 189
7.13 The association between FEF 25-75 and waist circumference. 190
7.14 The association between FEV 1/FVC and waist circumference. 190
7.15 The association between FEV 1 and waist/hip ratio. 191
7.16 Estimated association between FEV1/FVC and waist/hip ratio. 192
7.17 The association between FEV 1 and body fat. 194
7.18 The association between FEV1 and body fat (BF), according to 194
gender.
7.19 The association between % FEV1 and body fat. 195
7.20 Estimate o f relationship between % FEV 1 and body fat. 195
7.21 Estimated relationship between FEV 1/FVC and body fat (BF) 196
according to gender.
7.22 The association between total IgE and BMI for the females. 197
7.23 The association between total IgE and waist circumference (WC) 198
for the females.
xii
7.24 The association between between total IgE and and waist/hip ratio 199
(WHR) for the females.
7.25 The relationship between eotaxin and BMI for males. 200
7.26 The association between between eotaxin and waist circumference. 201
7.27 The association between between eotaxin and waist/hip ratio. 202
7.28 The relationship between eotaxin and body fat (BF) for males. 203
7.29 The relationship between eosinophil count and waist circumference. 204
7.30 The relationship between eosinophil count and waist/hip ratio. 204
8.1 A diagrammatic illustration o f the complex interplay between IL-13 219
and residential effector cells and circulating immune cells in 
asthma.
8.2 A diagrammatic representation o f the overlap between the complex 231
traits of asthma and obesity and the potential common pathways 
linking these conditions.
xiii
List of Tables
1.1 A summary of the evidence on the role o f dietary nutrients in 
asthma.
17
1.2 Summary o f known heterozygosity and associations for selected 
IL13 SNPs.
30
1.3 Summary o f known heterozygosity and associations for selected 
IL4RA SNPs.
32
1.4 Summary of known heterozygosity and associations for selected 
STAT6 SNPs.
34
2.1 PCR primers used in sequencing IL13. 59
2.2 Frequencies of genotypes for IL13 SNP 1-6 in a sample o f study 
population.
68
3.1 Clinical characteristics of Caucasian participants. 77
3.2 Clinical atopy in asthma versus non-asthma. 77
3.3 Description o f IL13 SNPs with allele frequencies and call rates. 78
3.4 Description of IL4RA SNPs with allele frequencies and call rates. 79
3.5 Description of STAT6 SNPs with allele frequencies and call rates. 79
3.6 Crosstabulation for IL13 R110Q and asthma. 84
3.7 Crosstabulation for IL13 SNP 6 and asthma. 84
3.8 Significant associations o f IL13 SNPs with asthma. 85
3.9 Crosstabulation for IL4RA I50V (SNP 5) and asthma. 86
3.10 Crosstabulation for STAT6 SNP 1 and current asthma. 87
3.11 Crosstabulation for STAT6 SNP 11 and current asthma. 87
3.12 Crosstabulation for STAT6 SNP 1 and current eczema. 89
3.13 Crosstabulation for STAT6 3’UTR SNP 1 and hayfever. 90
3.14 Final models o f genetic associations for dichotomous outcomes 
including relevant covariates.
91
4.1 Baseline characteristics of study participants. 103
4.2 Mean total IgE, eotaxin and eosinophil count according to sex and 
smoking status.
103
4.3 Mean IgE level at IL13, IL4RA and STAT6 loci. 107
4.4 Final models o f genetic associations for total IgE after considering 
relevant covariates.
108
4.5 Genetic associations with eosinophil count. 108
4.6 Geometric mean eosinophil count for IL4RA genotypes. 109
4.7 Geometric mean eotaxin for genotypes o f IL13 and STAT6 variants. 110
4.8 Summary o f significant associations o f IL13 signalling variants with 
immune phenotypes.
111
5.1 Mean % FVC by genotype at IL13 R110Q (SNP 5). 121
5.2 Mean % FVC by genotype at 77,73 3’UTR SNP 13. 121
5.3 Mean % PEFR by genotype at IL4RA S478P (SNP 12). 122
5.4 Crosstabulation for STAT6 SNP 11 and sex. 125
5.5 Summary o f significant physiological phenotype-genotype 126
associations at IL13, IL4RA and STAT6 loci in an unselected 
population.
5.6 Asthma severity by % FEV 1 in current asthmatics. 127
5.7 Asthma severity by % PEF in current asthmatics. 128
5.8 Summary o f significant genotype associations with lung function 131
severity in asthma.
5.9 Summary o f clinical characteristics of current asthmatics. 132
5.10 GINA classification o f asthma severity in current asthmatics. 133
5.11 Summary table for associations between IL13, IL4RA and STAT6 138
and clinical, immune and physiological phenotypes.
6.1 Crosstabulation for IL13 ArgllOGln and IL4RA Ile50Val by 145
asthma.
6.2 Geometric mean eosinophil count by individual genotype and 149
genotype combinations for IL4RA SNP 5 and SNP 12.
6.3 IL13 haplotypes based on total genotyped polymorphisms and 150
haplotype frequencies.
6.4 Summary o f IL13 haplotype-phenotype associations. 151
6.5 IL4RA haplotypes based on total genotyped polymorphisms and 152
haplotype frequencies.
6.6 Summary o f IL4RA haplotype-phenotype associations. 154
6.7 STAT6 haplotypes based on total genotyped polymorphisms and 155
haplotype frequencies.
6.8 Summary o f STAT6 haplotype-phenotype associations. 156
7.1 Baseline characteristics o f study participants, by adiposity indices. 176
7.2 Baseline characteristics of study participants in relation to asthma 177
and adiposity indices.
7.3 Baseline characteristics o f asthmatics vs. non-asthmatics, according 177
to weight category.
7.4 Correlations between adiposity indices. 177
7.5 Associations between adiposity indices and clinical outcomes. 183
7.6 Summary o f associations between adiposity indices and asthma and 205
lung function.
7.7 Summary o f associations between adiposity indices and immune 206
phenotypes.
9.1 Summary o f variants where overall association with dichotomous 276
outcomes approached significance with p<.05 for difference
between individual pairs o f genotypes.
9.2 Summary o f variants where overall association with quantitative 277
outcomes approached significance with p<.05 for difference
individual pairs of genotypes.
Abbreviations
AD Atopic dermatitis
ADAM33 A disintegrin and metalloproteinase
AHR Airway hyperresponsiveness
AR Allergic rhinitis
Bp Base pairs
BF Body fat
BMI Body mass index
BSA Bovine serum albumin
Cl Confidence interval
COPD Chronic obstructive pulmonary disease
ECRHS European community respiratory health survey
ELISA Enzyme-linked immunosorbent assay
EM Expectation maximisation
EtBr Ethidium bromide
FEF Forced expiratory flow
FEV1 Forced expiratory volume in 1 second
FRC Functional residual capacity
FVC Forced vital capacity
GINA Global initiative for asthma
HDM House dust mite
HZ Heterozygosity
IgE Immunoglobulin E
IGF Insulin-like growth factor
IL Interleukin
ISAAC International study o f asthma and allergies in childhood
IUATLD International union against tuberculosis and lung disease
L Litres
LD Linkage disequilibrium
LPS Lipopolysaccharide
LREC Local research and ethics committee
mRNA Messenger ribonucleic acid
NCBI National centre for biotechnology information
NHANES National health and nutrition examination survey
OD Optical density
OR Odds ratio
PAPA Poblogaeth Asthma Prifysgol Abertawe (Swansea University Asthma
Population)
PBS Phosphate-buffered saline
PCR Polymerase chain reaction
PEF Peak expiratory flow
RAST Radioallergosorbent test
Rpm Revolutions per minute
RSV Respiratory syncytial virus
SD Standard deviation
SM Smooth muscle
SNP Single nucleotide polymorphism
SNS Sympathetic nervous system
SPT Skin prick test
STAT Signal transducer and activator o f transcription
TARC Thymus and activation regulated chemokine
TGF Transforming growth factor
Th T helper cell
TLR Toll-like receptor
TNF Tumour necrosis factor
UCP Uncoupling protein
UV Ultra-violet
WC Waist circumference
WFIR Waist/hip ratio
xvii
Introduction
1
Asthma is a common disease affecting 1 in 10 children and 1 in 13 adults in the UK and 
represents the commonest chronic disease o f childhood [1]. Asthma is a chronic 
inflammatory disorder of the airways, characterised by variable airflow obstruction and 
an increase in airway responsiveness to a number o f stimuli. Airflow obstruction is 
usually reversible, either spontaneously or with treatment. Patients present with episodic 
wheeze, breathlessness or cough. Subjects vary in the severity o f disease, with some 
requiring only occasional inhaler use whilst others need regular medication to achieve 
disease control. The worldwide prevalence o f asthma has been rising over recent 
decades, pointing to potent environmental effects, and has been mirrored by a similar 
rise in the prevalence o f obesity [2-5]. The aetiology o f asthma remains far from being 
fully understood. The origins o f  asthma lie early in life and include a vital genetic 
component. Environmental factors interact with underlying genetic susceptibility to 
initiate development of this complex trait. Atopy is the main predictor o f asthma 
between the ages of 5 and 25 years, and is a T helper cell type 2 (Th2) driven 
hypersensitivity to innocuous antigens (allergens), clinically manifested by epithelial 
inflammation [6].
More than 60 studies have delineated chromosomal regions/candidate genes associated 
with asthma and its related allergic disorder o f atopy, with heritability for asthma 
ranging around 50-60%. In a recent review, Cookson reported that at least 11 genome 
scans have between them shown ten chromosomal regions to be associated with asthma 
[7]. The evidence for a genetic contribution is strong, not only for asthma, but also for 
atopy, described in terms o f elevated IgE levels.
Prospects o f modifying the progress o f  asthma, through intervention, would be 
substantially advanced by early diagnosis or pre-diagnosis. Because o f the substantial 
contribution o f genetic variation to risk, useful prediction o f disease might be achieved 
by genetic testing. Linkage studies and candidate-gene association studies indicate that 
asthma is a polygenic disorder. Meta-analysis o f genetic association studies supports a 
contribution o f common variants to the susceptibility to common disease and it is likely
2
that several genes contribute interactively to produce the asthmatic phenotype [8]. There 
is now overwhelming evidence that signalling by the Th2 cytokine interleukin (IL)-13 is 
a key molecular pathway driving bronchial inflammation in asthma [9]. This Th2 
pathway involves IL-13, IL-4 receptor alpha (IL-4RA) and the transcription factor 
STAT6, signal transducer and activator o f transcription.
Case-control studies have demonstrated an association between variants o f IL13, IL4RA 
and STAT6 and asthma and associated Th2 phenotypes [10, 11]. Recent work has 
demonstrated the importance o f examining variants in a common pathway in 
conjunction with one another, when individual small changes can lead to a large 
combined effect [12-14].
Case-control studies have not allowed the predictive effects o f variants to be fully 
estimated at the population level. The primary objective o f this thesis was to determine 
which IL13, IL4RA and STAT6 loci -  acting singly and in combination - predict asthma 
phenotypes in a general population. The strength o f these effects, and the interactions 
between different loci, will be clarified. A comprehensive genetic analysis will include 
all potential significant variants spanning each entire gene and examine gene-gene and 
gene-environment interactions. Novel epistatic interactions will be examined. 
Identifying the most important loci predicting asthma will advance the development o f a 
pre-diagnostic genetic test for asthma and further our understanding o f the molecular 
mechanisms underlying this disease.
The population study also provides an excellent opportunity to explore the relationship 
between different measures of obesity and the state o f  asthma, in addition to atopy and 
Th2 immune phenotypes. Therefore a further aim o f the thesis is to examine the 
association between obesity, overweight and asthma and associated Th2 phenotypes. 
Alongside the worldwide increase in asthma prevalence has been a parallel obesity 
epidemic, leading to speculation on a causal link between these two complex traits. 
Obesity has important cultural and environmental causes -  including the availability and 
character o f foods -  but genetic factors are also believed to contribute. There are few
3
well-characterised genetic causes for obesity as it occurs in the substantial minority 
(35%) o f the general population. This contrasts with well-characterised loci such as 
leptin (LEP) and leptin receptor (Lep-R) which have been implicated in individuals with 
extreme, familial obesity [15, 16].
Cross-sectional and prospective studies have largely supported the association between 
asthma and obesity but not all studies have been consistent [5, 17, 18]. Investigators 
have predominantly used body mass index (BMI, weight/height2) as a measure o f 
obesity, with few using measures o f central obesity (waist circumference, waist-hip 
ratio). In this thesis, appropriate measures o f body mass and body composition are used, 
including percentage body fat and measures o f central obesity in addition to BMI, to 
clarify the risk o f asthma conferred by obesity in a young adult population.
The potential mechanistic basis for the apparent association between obesity and asthma 
has yet to be elucidated. Although emerging evidence points to the role o f leptin 
(secreted by adipose tissue) as an inflammatory cytokine, recent work suggests that 
leptin does not explain the link between obesity and asthma [19, 20]. The Th2 
chemokine eotaxin is also secreted by adipose tissue and a recent study found elevated 
eotaxin levels in a small group o f obese humans with weight loss leading to reduced 
eotaxin levels [21]. This thesis examines whether adiposity associates with asthma and 
focuses on the effects o f adiposity on associated Th2 immune phenotypes, namely IgE, 
eotaxin and eosinophil counts, in a large unselected population. The role o f adipose 
tissue in these phenotypes will be further elucidated and the question o f whether Th2 
signalling provides a potential mechanistic basis for the relationship between obesity 
and asthma will be explored.
This thesis specifically addresses the relationships o f both genetics and o f obesity on 
Th2 phenotypes including clinical asthma and atopy, IgE, eotaxin and eosinophil counts 
in an unselected population.
4
Hypotheses
1) Genetic variants of Th2 signalling, acting singly and in combination, are important 
predictors o f asthma and associated Th2 and physiological phenotypes in an unselected 
population.
2) Adiposity promotes asthma and its associated physiological and immune phenotypes.
The study o f the association of Th2 signalling single nucleotide polymorphisms (SNPs) 
with clinical, Th2 immune phenotypes and physiological phenotypes is reported in 
Chapters 4-6. Chapter 5 reports epistatic interactions and haplotype associations 
between Th2 SNPs and clinical, immune and physiological phenotypes. The association 
o f obesity with asthma, Th2 phenotypes and physiological phenotypes is described in 
Chapter 7.
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CHAPTER 1 
Background
1.1. Overview of the aetiology of asthm a
1.1.1. Introduction
The origins of asthma are multifactorial, arising from a complex interaction o f genetic 
and environmental factors. Genetic factors underlie the population susceptibility to 
asthma which is then induced by particular environmental stimuli. Genetic variation 
may influence asthma at a number o f levels -  such as resistance o f the bronchial 
epithelial barrier to insult (e.g. allergen, virus); Th2 immunity (upregulated in asthma 
and atopy); and response o f the whole airway to injury (relevant to airway remodelling). 
Atopy is an inherited tendency to develop IgE mediated allergic disease o f the airways 
and skin, namely asthma, rhinitis, and eczema. Atopy mediates about 80% o f childhood 
asthma and approximately 40-50%  of adult asthma [22]. However, atopy is not 
synonymous with asthma, which occurs without atopy in up to 30% of cases.
The reasons for the recent impressive rise in asthma and atopy in Westernised countries 
are as yet unclear. It is likely that relevant environmental factors are exerting an 
influence early in life, in those with genetic predisposition. Theories include changes in 
microbial exposure in childhood, house dust mite sensitisation, diet and air pollution.
1.1.2 Genetic susceptibility
Human chromosomes
Asthma clusters in families and first-degree relatives o f asthmatics have a significantly 
higher prevalence o f asthma than relatives o f non-asthmatics. Twin studies estimate the 
proportion o f asthma due to genetic variation to be 50-60% [23]. Genome-wide screens 
have shown repeatable linkages of chromosomal regions with asthma and related traits 
o f airway hyperresponsiveness (AHR) and atopy (total IgE levels, IgE to specific 
allergens, skin prick tests) (Figure 1.1). The most replicated linkages are to the 
following regions: 2p; 4q; 5q23-31; 6p24-21; llq !3 -21 ; 12q21-24; 13ql2-14; 16pl2;
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16q21-23; and 19q [10, 11]. Most of these chromosomal regions contain hundreds of 
genes, many of them potential asthma-susceptibility genes. For instance, the 5q region - 
implicated in phenotypes ranging from asthma and AHR to total IgE levels - contains 
the cytokine gene cluster and the gene coding for the B2-adrenergic receptor (Figure 
1.2).
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Figure 1.1 A diploid set of human chromosomes, with highlighted regions showing the 
most widely replicated linkage regions with asthma and related traits. Image by Dr 
Shareen H Doak, School of Medicine, University of Wales Swansea.
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Figure 1.2 The cytokine gene cluster on chromosome 5q31-q33. This region 
contains several genes with well-replicated associations with asthma.
Major genes in asthma, A HR, lgE/atopy
Asthma is a polygenic disease. Variants in 80 genes have been associated with asthma 
or related traits, but it is likely that only a few genes are important, with several 
common variants each exerting a modest functional effect (Figure 1.3).
Genes associated with asthma and related traits include the cytokine cluster on 
chromosome 5 (.IL4, IL13, IL9, IL5, CD14 and B2-adrenergic receptor); the HLA and 
TNF genes on chromosome 6; the B chain of the high affinity lgE receptor and the 
Clara cell secretory protein on chromosome 11; and the alpha chain of the IL4 receptor 
on chromosome 16 [11, 24]. Associations are often not replicated in other populations, 
implying that different populations may have different asthma characteristics associated
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with particular genetic markers.
Good examples o f widely replicated associations are the genes coding for the IL-4/IL- 
13 pathway. This makes biological sense since IL-4 and IL-13 are important Th2 
cytokines, central to the bronchial inflammation seen in asthma, with actions including 
isotype switching to IgE. Asthma/atopy phenotypes have been associated not only with 
variants in the IL4IIL13 genes themselves, but also in their common receptor (IL4RA) 
and transcription factor STAT6. Interactions between these variants increase the risk of 
asthma and atopy further [13]. The IL13 G lnllO  variant reduces binding to a decoy 
receptor, with resultant increased IL-13 levels seen in asthmatics, demonstrating its 
functional effect [25]. The IL-13 signalling pathway will be discussed in further detail 
in the next part of this chapter.
Five novel candidate genes have been identified by positional cloning strategies over the 
last 3 years [26-30]. These fine-mapping techniques allow progress from broad 
chromosomal linkage regions to gene identification. These genes (ADAM33, DPP 110, 
PHF11, GPRA, HLAG) are not involved in known asthma pathways. These genetic 
studies offer new insights into asthma pathogenesis, suggesting that pathways relating 
to tissue growth and remodelling may be important.
The genetic contribution to asthma is complex and involves polygenic inheritance and 
genetic heterogeneity (different combinations o f genes causing asthmatic traits in 
different individuals). Gene-gene and gene-environment interactions underpin the 
aetiology o f asthma, the complexity o f which is just beginning to be unravelled.
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Figure 1.3 An airway diagram illustrating the proteins encoded by asthma- 
susceptibility genes. ADAM, a disintegrin and metalloproteinase; CLCA, calcium- 
dependent chloride channel; RANTES, regulated upon activation, normally T- 
expressed and secreted; TGF, transforming growth factor; TLR, toll-like receptor; 
TIM, T-cell immunoglobulin and mucin containing molecules; CC, clara cell; 
TNF, tumour necrosis factor; DPP, dipeptidyl peptidase; GPRA, G-protein- 
coupled receptor for asthma susceptibility; SPINK5, serine protease inhibitor, 
kazal type 5.
1.1.3 Environm ental factors
Migrants moving to Westernised countries have an increased risk of acquiring asthma, 
emphasising the importance of environment in disease development [31]. Maternal 
asthma confers a greater risk of asthma than paternal asthma [32], and increased IL-13
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production in cord blood has been shown to predict subsequent atopic disease, 
suggesting that the in-utero environment may account for later asthma [33], Since the 
recent rise in asthma and atopy in the developed world has occurred over a matter o f 
decades, environmental factors must be responsible -  but which environmental factors 
have driven the rising prevalence in asthma?
Common allergens
Allergens are defined as antigens that promote IgE sensitisation. They are diverse in 
origin and character and unified by their resistance to heat and protein digestion. They 
can act as proteases (house dust mite antigens); non-specific lipid transfer proteins 
(certain food allergens); or gelsolins that interfere with the actin cytoskeleton o f  cells. 
Allergens important in asthma are common antigens which are efficiently delivered into 
the airways within respired particles. Allergen proteases can trigger epithelial cells 
directly or via protein activating receptors (especially PAR-2), releasing Th2 cytokines 
and chemokines.
House dust mite (HDM) accounts for the highest sensitisation rates in the UK, followed 
by cat and grass pollen. Other common aeroallergens include tree pollens, dog, and the 
moulds Aspergillus fumigatus and Altemaria altemata. In the humid south-eastern 
American states, cockroach sensitisation is more common.
Role o f  allergen sensitisation
Allergens penetrate the mucosal epithelial lining where they induce the allergic 
response. Sensitisation is defined by positive skin prick tests or specific IgE directed 
against common allergens. Early allergic sensitisation, particularly to indoor allergens,
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is a major risk factor for the development o f asthma in genetically susceptible 
individuals. HDM sensitisation is a significant risk factor for the development o f 
asthma, hayfever and eczema [34], Furthermore, sensitisation to common aeroallergens 
is associated with increased AHR [34, 35],
The highest risk o f childhood asthma has been seen in children sensitised very early in 
life [34], However this was only true for children with a family history o f asthma/atopy 
leading to speculation about whether the relationship between allergic sensitisation and 
asthma is actually causal or represents parallel pathways arising from common genetic 
origins.
Role o f allergen exposure
The development o f allergen sensitisation requires exposure to that allergen. Once 
sensitisation has occurred, repeated exposure to that allergen is likely to trigger 
symptoms. Though HDM levels are related to mite sensitisation and wheezy illness 
[36], rising HDM levels are not felt to account for the general increased prevalence o f 
atopic disease. Asthma prevalence has also risen in hot dry areas where mite levels are 
low. It seems unlikely that increased allergen exposure accounts for the rise in atopy, 
since sensitisation to all allergens has increased simultaneously, suggesting a generally 
heightened allergic response [37]. Higher allergen exposure may mean more 
sensitisation to that allergen but does not necessarily translate into increased childhood 
asthma [38].
Having a cat or dog at home may actually be protective against the development o f 
atopy and wheeze [39-41]. Hence the relationship between allergen exposure and 
asthma is far from being completely resolved. Whilst cats have been shown to be
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protective against wheeze in children without a maternal history o f asthma, risk o f 
wheeze was increased in those with a maternal history, indicating the importance o f 
gene-environment interactions [41].
Finally, primary prevention studies involving reduction o f HDM exposure have been 
disappointing [42]. Allergen exposure is not a proven risk factor for childhood asthma. 
Allergen exposure may increase the risk o f atopic disease, but outcome is highly 
dependent on dose, type o f allergen, age at exposure and host susceptibility [43].
1.1.4 Occupational Asthma
Occupational irritants can worsen pre-existing asthma. Occupational asthma per se is 
asthma caused by exposure to a particular occupational agent. These agents can be 
divided into reactive chemicals (e.g. isocyanates) or organic antigens (e.g. wheat flour). 
For both, the pathological and physiological changes in the airway are similar, but the 
mechanisms underlying the development can be different. Organic antigens promote 
IgE response. Reactive chemicals act in various ways - the acid anhydrides produce 
haptens with native proteins, resulting in IgE production to these complexes. The 
mechanism for the highly reactive isocyanates remains unclear. High exposures to 
occupational agents increase the risk o f asthma. Other risk factors interact e.g. smoking 
increases the risk o f isocyanate occupational asthma. Pre-existent atopy predisposes to 
occupational asthma from organic antigens (e.g. flour). HLA Class 2 variation 
influences risk o f response to reactive chemicals (e.g. D QB1 for isocyantes; D RB1 for 
Western Red Cedar).
1.1.5 Role of air pollution
Air pollutants such as ozone can exacerbate asthma. It is less clear whether air
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pollutants - including nitrogen dioxide, ozone, sulphur dioxide and particulate carbons - 
contribute to the development o f asthma [44-48]. Declining air pollution in Western 
industrialised countries has occurred concurrently with increasing asthma prevalence 
which argues against a strong effect on asthma causation. Asthma rates were lower in 
former East Germany (with greater air pollution) compared with West Germany, with 
similar findings from large surveys elsewhere [49, 50].
Pollution is unlikely to be a primary cause o f asthma but epidemiological and 
experimental evidence suggests that diesel exhaust particulates and ozone promote 
allergen sensitisation. Individuals with particular genotypes related to antioxidant 
defences (e.g. glutathione S-transferase variants) may be more susceptible to the effects 
o f pollution [44, 45, 51].
1.1.6 Role of smoking
Exposure to tobacco smoke in-utero is associated with increased risk o f allergic 
sensitisation and asthma. Passive smoking - especially maternal smoking - confers an 
increased risk o f  wheezing and/or asthma at least until a child reaches 7 years and active 
smoking increases the risk o f adult-onset wheeze [52-54]. If  the father also smokes, the 
risk o f childhood wheeze increases but maternal smoking confers the greatest risk [54]. 
A recent study has shown that parental smoking impairs vaccine responses in children 
with atopic genotypes, highlighting the importance o f gene-environment interactions 
which underpin the aetiology o f asthma and atopy [55].
1.1.7 Role of diet
Change in the Western diet, with reduced intake o f antioxidants, has led to speculation
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on the role o f nutrients (including antioxidant vitamins, omega-3 fatty acids, selenium, 
magnesium, sodium and zinc). Some cross-sectional studies support an association but 
there is no conclusive evidence (Table 1.1) [56-59].
Early life studies show breast-feeding to reduce eczema but remain inconclusive 
regarding protection against asthma [60]. Diet in pregnancy may affect the developing 
immune system and omega-3 fatty acid supplementation has shown beneficial effects 
[61-63].
An “obesity epidemic” has paralleled the rise in asthma in the Western world. An 
increased prevalence of asthma has been observed in overweight individuals, especially 
females [5, 17]. Weight loss trials have shown a reduction in asthma signs and 
symptoms but may be confounded by related factors o f diet and physical activity [64- 
66]. The effects o f obesity on asthma, lung function and Th2 immunity are examined in 
this thesis in Chapter 7. The potential mechanisms underlying any association between 
obesity and asthma are discussed in part 1.3 o f this chapter.
Table 1.1 A summary of the evidence on the role o f dietary nutrients in asthma 
[56-59]
Nutrient Cross-sectional Case-control Longitudinal Interventional
Vitamin C I risk o f asthma 
Mixed results
Protective 
Mixed results
No effect 
on asthma 
incidence
Limited evidence o f 
protection, given with 
other antioxidants
Vitamin E No effect Protective 
Mixed results
Limited 
evidence o f 
protection
Limited evidence o f 
protection, given with 
other antioxidants
Vitamin A 
or beta- 
carotene
Inconclusive Protective 
Mixed results
No effect 
on asthma 
incidence
Limited evidence o f 
protection, given with 
other antioxidants
Omega-3 
fatty acids
N/A Limited 
evidence o f 
protection
No effect 
on asthma 
incidence
Protective 
Mixed results
Selenium No effect Protective N /A 1 No effect
Magnesium Protective Protective N/A No effect
Sodium Mostly no effect Limited 
evidence of 
f airway 
reactivity
N/A Some evidence o f 
t  risk
N/A, Not applicable
1.1.8 Role of infection
The “Hygiene Hypothesis ”
The pattern o f microbial exposure in childhood has changed considerably in 
Westernised countries, as a result o f a cleaner environment, widespread antibiotic use 
and immunisations. The “hygiene hypothesis” suggests that lack o f exposure to 
childhood infection, endotoxin and microbial products causes persistence o f Th2 
responses, thus increasing the likelihood o f atopic disease [67-69].
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Observations supporting the hygiene hypothesis are that asthma and atopy are:
1 less common in children with more siblings or in those attending day-care, 
presumably due to increased exposure to childhood infections [70-73],
2 strikingly less common in children living on livestock farms, who have a higher 
exposure to endotoxin [74-76],
3 more common in Westernised countries.
Further refinements to the hygiene hypothesis stem from the suggestion that specific 
infections occurring at critical times in immune development are most important:
1 Mycobacterial infection. Some epidemiological studies have suggested an inverse 
relationship between mycobacterial exposure and asthma/atopy [77, 78].
2 Intestinal flora. The gut is a critical regulator o f  the immune response and an 
adequate intestinal flora may be important in guarding against atopy [79]. This is 
supported by the association between enteric infection (Hepatitis A), family size and 
absence o f atopy in Italian recruits [80]. Probiotics studies are underway, with one 
showing reduced risk of eczema by age 2, but no change in allergic sensitisation nor 
asthma [81].
3 Helminth infection. The Th2 response forms the basis o f  the natural immune 
response against parasites, with increased IgE production and eosinophilia. 
Interestingly, worm infestation appears to be protective against asthma despite the 
marked Th2 response common to both [82-84]. The STAT6 variant G2964A and IL-13 
variant -1024C/T -  both associated with asthma - have been shown to be protective 
against ascaris and schistosoma infestation respectively and the survival advantage 
conferred may explain the persistence o f these alleles in the population [84-86]. 
Moreover, anti-helminth treatment appears to increase allergen sensitisation [87], One 
explanation is that helminths stimulate exuberant IL-10 production which reduces
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specific IgE to aeroallergens, thus causing deviation away from an atopic phenotype 
[88].
Toll-like receptors (TLRs) are recognised to be key molecules in innate and adaptive 
immunity [89]. These are pathogen associated molecular pattern receptors that 
recognise extracellular microbes and trigger anti-pathogen signalling cascades. TLR 
activation has been shown to induce antigen-presenting cells to produce cytokines that 
favour Thl-type immune responses. TLRs, such as TLR9, TLR7, and TLR8, are 
considered to be good potential target candidates to modulate immune responses. TLR 
ligands, such as CpG DNA, are effective adjuvants, and induce downregulation o f both 
IL-5 and eosinophilia, and their relation to allergen epitopes could offer opportunities 
for the development o f allergen-specific immunotherapy [90]. There is evidence to 
suggest that reduced microbial stimulation o f TLRs in early life, may lead to a weaker 
Thl response and a stronger Th2 response to allergens. The individual immunological 
response is shaped by the interplay between the dose and timing o f endotoxin exposure, 
other environmental factors and genetic predisposition.
1.1.9 Role of viruses
The sensitive method o f reverse transcriptase-DNA amplification, detecting viruses in 
respiratory materials, emphasises the role o f viral infections in exacerbations o f asthma 
(85% in children, 70% in adults) [91, 92]. Asthmatic respiratory epithelial cells appear 
more susceptible to viruses, though it is unclear whether this is a primary epithelial 
defect or the result o f Th2 induced inflammatory damage. Viral infection promotes 
further inflammation in the airway - with prominent actions from NF Kappa B and A PI, 
and specific enhancement of Th2 induced inflammation by CD8+ T-lymphocytes and 
chemokines CCL3 and CCL5.
It has been suggested that viral infections, in particular respiratory syncytial virus
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(RSV), act as an independent risk factor for asthma and atopy [93-95]. Recent work 
suggests a common genetic background in children with severe RSV infection and 
bronchial asthma, with an association found between IL13 variant -1024C/T and severe 
RSV infection, with stronger associations seen for certain haplotypes [96]. Bronchiolitis 
associated with viruses apart from RSV may be associated with an even greater risk o f 
childhood asthma [97].
This would appear to contradict the hygiene hypothesis which suggests childhood 
infections to be protective against the development o f asthma. However, since RSV 
infection is almost universal by the age o f 2 years, host susceptibility must play a part in 
which children go on to develop asthma. Fascinating interactions between genes and 
environment may explain these apparent paradoxes e.g. differential responses o f 
specific genotypes to viral infections and day-care [98]. Another explanation is that 
viral infection with wheeze acts as a marker for asthma and reflects impaired viral 
handling by the asthmatic lung [99-101]. Studies are ongoing to answer this intriguing 
question.
1.1.10 Role of the epithelial mesenchymal trophic unit
Whilst the central role o f Th2 inflammation is undisputed, bronchial remodelling 
represents a crucial component o f bronchial hyper-reactivity in established asthma, and 
is an important cause o f declining lung function with time [102]. This remodelling 
includes epithelial goblet cell hyperplasia, thickening o f the basement membrane by 
collagen deposition and smooth muscle hypertrophy. Is it simply the result o f chronic 
Th2 inflammation or has it a more primary causation? The interaction between 
epithelium and mesenchyme is exemplified by transforming growth factor (TGF) beta 2 
release from injured or stimulated epithelial cells, which acts on fibroblasts to cause 
myofibroblast development and smooth muscle hypertrophy. Variants o f  ADAM33 (a 
zinc dependent metalloprotease) are strongly linked with bronchial reactivity, and this
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protein is specifically expressed in smooth muscle and myofibroblasts - therefore innate 
susceptibility within the mesenchyme may be a primary disposer towards remodelling 
[103]. Hence the epithelium and the mesenchyme together play important mechanistic 
roles in asthma, complementing Th2 immune mechanisms and IgE sensitisation.
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1.2 Genetic epidemiology of the IL-13 signalling pathway in asthma and atopy 
-  an overview of the evidence
1.2.1. Introduction
An overview o f the genetic basis of asthma has already been provided in part 1.1. 
Genetic factors at a number o f loci have been associated with the disease. Some o f the 
most replicated loci are genetic variants in the IL-13 signalling pathway. Here there will 
follow a more detailed summary o f  the current state o f knowledge on this Th2 signalling 
pathway in asthma and atopy, in terms o f evidence from immunological and genetic 
studies.
1.2.2. The role of the IL-13 signalling pathway in asthma and atopy
There is now overwhelming evidence that signalling by the Th2 cytokine IL-13 is a key 
molecular pathway driving bronchial inflammation in asthma. IL-13 promotes IgE 
isotype switching, CD23 induction, epithelial cell damage, stimulation o f eosinophils, 
goblet cell hyperplasia with mucus production and bronchial smooth muscle activity [9]. 
IL-13 also stimulates airway fibrosis, mainly by the induction o f matrix 
metalloproteinases 9 and 12 which activate pro-fibrotic transforming growth factor-pi 
(TGF-pi) [104]. Although exerting many similar biological activities to IL-4, IL-13 has 
several unique activities. Unlike IL-4 deficient mice, IL-13 null mice fail to generate 
goblet cells, fail to recover basic IgE levels after IL-4 stimulation and fail to clear 
helminth [105]. Recent murine studies on dendritic cells suggest that IL-4 promotes the 
secretion o f Th2 cytokines, whereas IL-13 acts by suppressing T cell secretion o f IFN- 
gamma, an inhibitory cytokine for the Th2 immune pathway [106].
The IL13 gene is located only 25 kilobases away from the IL4 gene which is in the same 
orientation, leading to the suggestion that these genes may have arisen from a 
duplication event during evolution. IL-13 and IL-4 share a common receptor chain, IL-4 
receptor alpha (IL-4RA), giving rise to the overlapping functions o f these two
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cytokines. IL-13 acts via a heterodimer receptor composed o f IL-4RA and IL-13RA1 
and intracellular signalling is initiated through the Janus tyrosine kinase mediated 
phosphorylation of signal transducer and activator of transcription (STAT)6 (Figure 
1.4). STAT6 plays a crucial role in this pathway, by transducing the signal to the 
nucleus: once phosphorylated, STAT6 molecules form homodimers, which penetrate 
the nucleus, activating the transcription of target genes involved in the multiple 
functions of IL-13 [9]. STAT6 is not only involved in the regulation of its own pathway 
but is also a key regulator of Th2 immune responses, activating several Th2 specific 
gene promoters. STAT6 deficient mice lack IgE production, have an impaired 
proliferative response to IL-4 and cannot differentiate naive T cells into Th2 cells [107].
1 I L - 1 3 R a l
Figure 1.4 Diagram of the IL-13 signalling pathway. IL-4 and IL-13 share a 
common receptor, the alpha chain of the IL4 receptor (IL4RA). Phosphorylation of 
the kinases (Jak, Janus kinase; Tyk, tyrosine kinase) and IRS (insulin receptor 
substrate) results in activation of STAT6, signal transducer and activator of 
transcription which transduces the signal to the nucleus, leading to the transcription 
of multiple genes involved in asthma pathogenesis.
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1.2.4. Genetic studies of the IL-13 signalling pathway in asthma and atopy
Genome wide screens have revealed repeated linkages to the chromosomal regions 
housing genes along the IL-13 signalling pathway. Linkages have been found with the 
regions 5q23-31 (including the Th2 cytokine gene cluster); 12q21-24 (including signal 
transducer and activator o f transcription-6: STAT6); and 16pl2 (including IL4 receptor 
alpha: IL4RA) [10, 11].
Candidate gene association studies have demonstrated an association between variants 
o f IL13, IL4Ra, STAT6 and asthma phenotypes and these studies are summarised in 
Tables 1.2-1.4. However, many case-control studies have been conducted in small 
samples and findings have not been replicated in further studies [108-110]. Publication 
bias is likely to lead to the reporting o f initial striking positive findings in small case- 
control studies, which fail to be replicated in larger populations, emphasising the 
importance o f replication in an unselected population study to confirm true positive 
associations with disease [111, 112].
IL13
The human I I I 3 gene on chromosome 5q31 encompasses 2938 bp and includes four 
exons, 56 bp of 5'UTR and 828 bp o f 3'UTR. Argl30Gln (+2044G/A) is the only 
coding SNP in a block o f common SNPs in almost complete linkage disequilibrium 
(LD), which spans the third intron, the fourth exon, and the 3' UTR o f the gene. Two 
SNPs in the promoter (-1512A/C and -1024C/T) are also in strong, but not complete, 
LD with the distal polymorphisms [113].
Association studies examining the IL13 SNPs considered in this thesis are summarised 
in Table 1.2. Van der Pouw Kraan et al first described a C/T nucleotide exchange at 
position -1055 in the IL13 promoter region and found that the T/T genotype associated 
with allergic asthma, altered regulation o f IL-13 production and increased binding o f 
nuclear proteins [99]. This variant - located in a region containing a nuclear factor o f 
activated T cells transcription factor binding site - was subsequently described at
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position -1111 (or -1112) and reported in association with asthma, bronchial hyper- 
responsiveness and skin test positivity [114]. Hummelshoj et al then reported the 
variant to be located at position -1024 relative to ATG translation initiation codon, with 
an association between the T/T genotype and inhalation allergy [115]. The -1512 A/C 
promoter polymorphisms has been described in association with IgE levels in various 
populations (see Table 1.2).
In vivo, in vitro, and in silico analyses have shown that the 7Z73-1024T allele (found to 
be the ancestral allele) enhances IL13 promoter activity in primary human and murine 
CD4(+) Th2 lymphocytes, and attenuates STAT6-mediated repression o f IL13 
transcription [116]. IL-13 secretion was increased in 7Z73-1024T/T homozygotes and it 
is interesting to note strong associations between 7Z75-1024T and protection from 
Schistosoma hematobium in Africa [85], lending support to the hypothesis that asthma 
susceptibility variants arise in part due to an evolutionary protection against worm 
infestation (discussed further in section 1.1.8).
To date, the only coding variant in IL13 results in an amino acid change from arginine 
to glutamine at position 110 (Figure 1.5). Several studies have reported positive 
associations between Argl lOGln (R110Q) and asthma and various atopic markers, but 
other studies show conflicting results. Heinzmann et al found A rgl lOGln to be 
associated with asthma rather than IgE levels in case-control populations from Britain 
and Japan and the variant predicted higher serum IL-13 levels in a general Japanese 
paediatric population [117].
Molecular modelling studies have found the A rgl lOGln variant to be crucial to ligand 
receptor interactions and functional studies have demonstrated A rgl lOGln to be 
significantly more active than wild-type IL-13 in inducing STAT6 phosphorylation and 
CD23 expression in monocytes and hydrocortisone-dependent IgE switching in B cells 
[117]. Furthermore, mutant IL-13 was neutralized less effectively than wild-type IL-13 
by an IL-13R2 decoy, which could contribute to its enhanced in vivo activity [118]. 
This variant has also been shown to upregulate IL-13 concentration in vivo [25].
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Q110R
QC motif
Figure 1.5 Molecular model of the IL-13 cytokine-receptor complex. This 
illustrates the proximity of the Argl lOGln (Rl I0Q) polymorphism to the binding 
regions of the IL-13 receptor (pink). On the receptor (yellow), a conserved QC motif 
(at positions 181-182 in IL-4RA, positions 80-81 in IL-13RA1, and positions 86-87 
in IL-13RA2), is likely to be involved in cytokine binding. The variable residues 
surrounding this motif provide the basis for the different affinities observed between 
different receptor chains and IL-13 variants. Molecular modelling by Dr Jonathan 
Mullins, School of Medicine, University of Wales Swansea.
IL4RA
The human IL4RA gene on chromosome 16p 12.2 encompasses 50374 bp and is highly 
polymorphic, including 12 exons, with 13 polymorphisms that result in amino acid 
substitutions. Three of these SNPs are associated with functional alterations o f the 
receptor. Association studies examining the IL4RA SNPs considered in this thesis are 
summarised in Table 1.3.
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Mitsuyasu et al found that the Ile50 variant (of an amino acid in the extracellular part o f 
the receptor subunit) associated with atopic asthma and IgE in a Japanese case-control 
population. Furthermore, they demonstrated that Ile50 augmented STAT6 activation 
and increased IgE production [119]. However, other case-control studies have shown 
inconsistent results (Table 1.3). The Arg551 variant has been associated with increased 
CD23 expression in peripheral blood mononuclear cells after IL-4 challenge [120]. 
However Kruse et al showed that the Pro478 and Arg551 variants -  in the intracellular 
part o f the receptor -  associated with lower IgE levels and downregulated signal 
transduction [121]. Studies in other populations have shown the commoner Ser478 
allele to be associated with higher IgE, asthma and atopy [13, 122]. Despite some 
conflicting results, there is now a robust body o f evidence that the IL4RA locus has a 
role in IgE regulation, and specific alleles are likely to have different effects in different 
ethnic populations, depending in part on allele frequency.
STAT6
Human STAT6 (12ql 3.3-14.1) spans 19 kb o f genomic DNA containing 23 exons. The 
first 2 exons o f the STAT6 gene are non-coding regions. The AUG translation initiation 
codon, encoding the first amino acid, is located within exon 3 [123]. During the 
progress o f this thesis, four non-synonymous substitutions have been identified but none 
are common (http://www.ncbi.nlm.nih.gov/proiects/SNP).
In comparison with IL13 and IL4RA, there have been relatively few case-control 
association studies on STAT6 variants, with several o f these studies having negative 
findings. Association studies examining the STAT6 SNPs considered in this thesis are 
summarised in Table 1.4. Gao et al demonstrated the association o f the 3 ’UTR G2964A 
variant with atopic asthma in a Japanese population [124]. This association was not 
replicated among the British patients, nor in later studies on Japanese populations and 
German/Swedish sibpairs [125-127]. Another 3’UTR variant (rsl059513) has been 
associated with IgE but not examined in relation to asthma [128]. Intronic variants 
C2892T and C1570T have been associated with IgE levels rather than asthma [127-
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129], A GT repeat polymorphism in exon 1 was associated with eosinophil count in the 
German/Swedish study and with allergic diseases and childhood asthma in Japanese 
studies [126, 127, 130, 131].
Genetic studies using unselected populations
There have been few unselected population studies to ascertain which loci may be of 
clinical use in predicting asthma, in comparison to case-control studies. Case-control 
studies provide an indication o f some o f the loci contributing to asthma susceptibility 
but only unselected population studies can estimate the actual risk conferred by a single 
variant, or combinations o f variants, at the population level.
A recent analysis o f the 1958 British Birth Cohort has robustly confirmed several IL13 
variants - including promoter polymorphisms and A rgl lOGln -  to be associated with 
IgE levels [132]. A large German cross-sectional paediatric study showed the IL13 - 
1024C/T promoter variant and STAT6 variant C2892T to be associated with IgE levels 
with the IL13 variant also associated with asthma, with synergistic effects from 
combinations o f loci in this signalling pathway [12]. A German adult study also showed 
C2892T was associated with IgE levels [129].
Epistatic effects
Recent work has demonstrated the importance o f examining loci in the same pathway in 
combination, since small individual effects on phenotype may combine to produce 
much larger synergistic effects. Kabesch et al found that by combining polymorphisms 
in 4 major IL-4/IL-13 signalling pathway genes, the risk for high serum IgE levels 
increased 10.8-fold and the risk for the development o f asthma increased by a factor of 
16.8-fold compared with the maximum effect o f  any single polymorphism [12]. Chen et 
al demonstrated functional synergistic effects o f IL13 and IL4RA polymorphisms on IL- 
13-dependent gene induction, when both variants occurred in combination [133]. Thus 
variants may only be relevant to population risk when occurring in combination. This
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may be true not only for gene-gene (epistatic) interactions but also for haplotype 
combinations on the same gene. Risma et al found that the association o f two common 
IL4RA variants (Val50/Arg551) with atopic asthma was greater than for either allele 
alone, the association for Arg551 being dependent on the presence o f  Val50 [14]. 
Epistatic and haplotype effects will be discussed further in Chapter 6.
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Table 1.2 Summary of known heterozygosity and associations for selected IL13
SNPs.
Location HZ1 Population Associations
SNP 10 
rs 1881457
5’UTR
1512A/C
.25 British
Japanese
German & 
American
IgE [132]
Eosinophils
Negative for AD2, IgE [134]
IgE (only in SPT3 negative group) 
[113]
SNP 1 
rs 1800925
5’UTR
1024C/T
.39 British
Dutch
Icelandic
Danish
German
German &
American
European
American
White
Canadian
African
Americans
Chinese
Japanese
IgE [132]
Allergic asthma [135]
Asthma, AHR4, SPT 
Non-significant for IgE [114]
Negative for atopic asthma [136]
Inhalation allergy, AD [115] 
(IgE,RAST5,SPT)
Asthma [12]
Total IgE [12, 137], RAST [138]
IgE (only in SPT3 negative group) 
[113]
Negative: IgE [139]
Negative: atopy, AD [140]
Asthma/ atopy [141]
RAST (house dust mite)
Negative for total IgE, AR6 [142], AD 
[143]
Negative for AD, eosinophils, IgE 
[1341
SNP 7 
rs2066960
Intron 1 .22 British IgE [132]
SNP 2 
rs 1295686
Intron 3 .45 British
Icelandic
European
American
IgE [132]
Negative for atopic asthma [136] 
Negative: IgE [139]
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Location HZ1 Population Associations
SNP 5 
rs20541
Exon 4 
R110Q
.32 British
British
Japanese
Hutterites
Icelandic
Dutch
German 
German & 
American 
American
White 
Canadian 
Costa Rican 
Chinese
Japanese
Korean
IgE [132]
Asthma, negative for IgE [117]
Negative for asthma/atopy 
(SPT) [144]
Negative for atopic asthma [136] 
Negative for asthma, AHR, SPT, IgE 
[114]
A D , IgE [145]
IgE (only in SPT3 negative group) 
[113]
Atopy (grouped: eosinophils, IgE, 
SPT), eosinophils [110], IgE (aged 1 
year) [139]
Negative for asthma, lung function, 
AHR [110]
Atopy, AD [140]
Negative for asthma, IgE, SPT [146] 
Total IgE [142, 143, 147]
Negative for asthma, AD [143], RAST, 
AR6 [142]
AD
Negative for eosinophils, IgE [134] 
Asthma [148]
SNP 13 
rs 1295685
3’UTR .26 Dutch Asthma, SPT
Negative for AHR, IgE [114]
SNP 6 
rs848
3’UTR .45 Icelandic Negative for atopic asthma [136]
SNP 9 
rs847
3’UTR .33
HZ, Heterozygosity on SNP database http://www.ncbi.nlm.nih.gov/proiects/SNP
2 AD, atopic dermatitis
3 SPT, skin prick tests
4 AHR, airway hyperresponsiveness
5 RAST, radioallergosorbent test
6 AR, allergic rhinitis
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Table 1.3 Summary of known heterozygosity and associations for selected IL4RA SNPs
Location HZ] Population Associations
SNP 3 
rs2283563
5’UTR .44
SNP 5 
rs 1805010
Exon 5 
I50V
.50 British
German
Danish
Italian
European
American
Mexican
Asian
(mixed)
Chinese
Singapore
(mixed)
Japanese
Korean
Negative: IgE [132]
IgE: in haplotype with SNP 12 & 13 [149] 
Negative: RAST2 [138], IgE [12, 137], 
asthma [12]
Negative: RAST [150]
Negative: atopic asthma, AHR3, IgE, SPT 
[109]
Negative: IgE (aged 1 year) [139]
Negative: atopic asthma [151]
IgE (Malay; negative in Indian/Chinese) 
[152]
Negative: asthma, IgE [1531 
Negative: IgE, RAST, S P r -5 [154]
Atopic asthma [119, 155], IgE [119], 
cedar pollinosis [156], Negative: atopic 
asthma [108],
Negative: AD6 [157,158]
Negative: atopic asthma, AHR, IgE, 
eosinophil (%) [159]
SNP 7 
rs3024622
Intron 7 .47
SNP 8 
rs2891058
Intron 8 .46
SNP 12 
rs 1805015
Exon 12 
S478P
.30 British
Dutch
German
Italian
European
American
Korean
Negative: IgE [132]
Asthma, AHR, IgE, SPT [13]
IgE [121]
IgE: in haplotype with SNP 12 & 13 [149] 
Negative: RAST [138]
Negative: atopic asthma, AHR, IgE, SPT 
[109]
Negative: IgE (aged 1 year) [139]
Negative: atopic asthma, AHR, IgE, 
eosinophil (%)[159]
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Location HZ1 Population Associations
SNP 13 
rs 1801275
Exon 12 
R551Q
.47 British
German
Danish
Italian
Spanish
Canada
American
European
American
Chinese
Japanese
Asian
(mixed)
Korean
Atopic asthma [ [160], IgE [132]
Asthma [161], IgE [121]
IgE: in haplotype with SNP 5 & 12 [149]
RAST (to cat, if  maternal smoking; negative 
for other RAST) [138]
Negative: RAST [150]
Negative: atopic asthma [109, 162], AHR, 
IgE, SPT [109]
Negative IgE (except in subgroup with 
family history) [163]
FEV1 [164]
Asthma (and severity) [165]
AD, Hyper-IgE syndrome, IgE/RAST [120] 
Negative: IgE (aged 1 year) [139]
Atopic asthma [166], asthma [167]
Negative: IgE [167], AD [143]
AD [157]
Negative: Asthma, IgE/RAST [108], 
Negative: Atopic asthma [155], AD [158] 
Negative : asthma, IgE [167]
Atopic asthma, AHR, eosinophil (%), 
negative for IgE [159]
SNP 16 
rs 1049631
3’UTR .49
HZ, Heterozygosity on SNP database http://www.ncbi.nlm.nih.gov/proiects/SNP 
2RAST, radioallergosorbent test
3 AHR, airway hyperresponsiveness
4 SPT, skin prick tests
5 Except in Indian subgroup where Val50 associated with atopy
6 AD, atopic dermatitis
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Table 1.4 Summary of known heterozygosity and associations for selected STAT6 SNPs
Location HZ1 Population Associations
SNP 8 
rs324011
Intron 2 
C2892T
.37 German
Swedish
IgE [127-129]
Negative: asthma [12, 127]
Negative: asthma, IgE [168]
SNP 12 
rs841718
Intron 16 .47 German IgE [127]
Negative: asthma [127]
SNP 11 
rs3024974
Intron 17 
C1570T
.19 German IgE [127]
Negative: IgE (positive in haplotype) 
[128, 129]
SNP 1 
rs324015
3’UTR
G2964A
.45 British
German
Swedish
Japanese
Negative: atopic asthma [124] 
Nut allergy [169]
Negative: asthma, IgE [127] 
Negative: asthma, IgE [168] 
Atopic asthma [124]
Negative: allergic disease [125]
SNP 2 
rs703817
3’UTR .49 Swedish Negative: asthma, IgE [168]
SNP 3 
rs 1059513
3’UTR .15 German IgE [128]
Weak A H R1, negative IgE [127]
SNP 4 
rs4559
3’UTR .42 German
Swedish
Weak: IgE [127]
Negative: IgE (positive in haplotype) 
[129]
Negative: asthma, IgE [168]
HZ, Heterozygosity on SISP database http://www.ncbi.nlm.nih.eov/proiects/SNP
2 AHR, airway hyperresponsiveness
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1.3 Obesity and asthma: potential underlying mechanisms linking two 
common complex traits
Evidence for the association between obesity and asthma will be summarised in Chapter 
7. In this section I will provide a summary o f the potential mechanisms for an 
association between obesity and asthma, and including the possibility that both 
conditions are linked by an upregulation in Th2 immunity. This thesis will present data 
addressing this possibility, in addition to exploring more generally the relationship 
between different measures o f obesity and the asthma syndrome.
The majority o f cross-sectional studies show a consistent association between obesity 
and asthma with prospective studies lending support to that association being causal. 
Further support comes from the observation o f a dose-response effect and the 
association o f obesity with intermediate asthma phenotypes [5, 17] (discussed in detail 
in Chapter 7).
There are potential confounders in the association between obesity and asthma. These 
include the effects o f diet, exercise, gastro-oesophageal reflux and sleep-disordered 
breathing. However it is possible that some o f these factors, rather than being 
confounders, may be part o f a causal pathway between obesity and asthma. 
Notwithstanding these potential confounders, there is increasing evidence that obesity is 
a pro-inflammatory state and therefore predisposes to asthma. Evidence for adipocytes 
being pro-inflammatory cells will be outlined in the following section and other 
mechanisms explaining obesity in asthma causation will be discussed. A diagrammatic 
schema illustrating potential interactions between these two complex traits is shown in 
Figure 1.6.
1.3.1 Mechanical effects
It has long been accepted that obesity causes a restrictive defect in lung function, with a
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generalised reduction in lung volumes including tidal volume, functional residual 
capacity (FRC) and expiratory reserve volume [170]. Accumulation o f fat around the 
ribs, diaphragm and abdomen leads to an approximately 25% reduction in chest wall 
compliance in simple obesity [171]. Central obesity has been found to further reduce 
lung volumes [172]. The European Prospective Investigation into Cancer and Nutrition 
(EPIC) examined a general population o f older adults and found abdominal obesity to 
be inversely related to FEV1 and FVC, but not to airflow obstruction. Waist/hip ratio 
was a better predictor o f lung function than body mass index (BMI), although body fat 
was not measured [173]. Increased visceral fat mass causes increased intra-abdominal 
pressure so that the diaphragm is pumped upwards, compressing the lung parenchyma. 
Additionally, over-stretching of the diaphragmatic muscle leads to reduced 
diaphragmatic contractility [174]. Another explanation is that compression o f the 
abdominal viscera by fat causes increased blood volume to be redistributed to the 
thorax, thus reducing vital capacity which explains the fall in vital capacity that occurs 
in the supine position. Moreover, increased pulmonary blood volume may lead to 
congestion o f airway submucosal vessels, thickening o f the airway wall, and smaller 
airway size [175]. Increased epicardial fat may also reduce vital capacity.
In contrast to earlier studies showing a purely restrictive defect, more recent studies 
have shown chronic obesity to be associated with peripheral airways obstruction, 
independent o f smoking [176, 177]. Since lung volume is an important determinant of 
airway diameter, a decrease in FRC is likely to unload airway smooth muscle resulting 
in an excessive shortening on activation [178].
The “Latch-bridge Hypothesis” has been formulated to explain the association between 
obesity and asthma (characterised by airflow obstruction) [17]. This suggests that 
smaller lung volumes lead to reduction in smooth muscle stretch or “latching”, giving 
rise to smaller tidal breaths during exercise and thus altering smooth muscle contraction. 
This vicious cycle leads to further deconditioning o f  the smooth muscle. The smooth 
muscle effects are mediated by the conversion o f normal rapidly cycling actin-myosin 
cross-bridges to slowly cycling latch-bridges [179]. Reduced tidal expansion impairs
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force fluctuations acting on the airways, which exert potent bronchodilatory effects. 
Reduced tidal volumes in the obese are thus associated with a loss o f bronchodilation 
which may lead to increased aiway hyperresponsiveness (AHR) [178]. Furthermore, it 
has been shown that obese subjects lose the protective deep inhalation prior to a 
methacholine challenge, leading to greater bronchoconstriction compared with non- 
obese subjects [180]. Moreover, morbid obesity can cause extra-thoracic obstruction.
Mechanical factors are likely to play a role in the relationship between obesity and 
asthma. However, obese mice have persistent AHR even when mechanical load is 
removed (by opening the chest wall and fixing tidal volume by artificial ventilation) 
suggesting that alternative mechanisms exist to explain this association [181].
Obesity may exert an effect on airway bronchoconstriction via gastro-oesophageal 
reflux. Obesity leads to relaxation o f the oesophageal sphincter resulting in acid reflux. 
This can cause bronchoconstriction either by microaspiration into the airways or by 
vagally mediated reflexes [182]. Since obesity, asthma and gastro-oesophageal reflux 
are all conditions o f high prevalence in the population, it is difficult to disentangle the 
relationships between them and much work remains to be done in this field.
1.3.2 Obesity as a pro-inflammatory state
Evidence is mounting for the role o f the adipocyte as an inflammatory cell, releasing 
pro-inflammatory cytokines. The adipocyte releases tumour necrosis factor (TNF), IL-6 
and monocyte chemoattractant protein 1. Obesity is associated with a low-grade 
systemic inflammation, with increased levels of C reactive protein and markers o f  lipid 
peroxidation [183-185]. Obesity and asthma are both associated with upregulation o f the 
TNF pathway. TNF is associated with a more severe relatively steroid-resistant asthma 
phenotype and is upregulated by allergen exposure. It is possible that obesity-related 
TNF contributes to the development o f an asthmatic phenotype.
It has been suggested that obesity-related hormones such as leptin, adiponectin, insulin
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and neuropeptide may exert important immune effects in asthma. Leptin is produced by 
adipocytes, acting as a satiety signal on the hypothalamus to increase basal metabolic 
rate and is elevated in obesity [186]. Leptin also has pro-inflammatory effects and 
whereas it generally promotes T helper type 1 cytokines via IL-12, leptin also promotes 
IL-6 release which in turn stimulates Th2 cytokines [187].
Leptin levels may reflect sex differences in the natural history o f asthma, with higher 
levels in asthmatic boys than girls and higher levels in adult women, both o f which 
groups have a higher prevalence o f asthma [188-190]. Moreover, leptin levels are higher 
in obese asthmatic subjects compared with obese non-asthmatic subjects [191]. 
Correlations have been found between leptin and IgE levels in allergic subjects, with 
positive findings only for boys in one study [188, 192],
Obese mice have been shown to have innate AHR and increased AHR and airway 
inflammation in response to ozone, in comparison to their lean wild-type counterparts
[193]. Leptin administration increases Th2 cells’ proliferative responses to T-cell 
mitogens and increases AHR and Th2 cytokine production in ovalbumin-sensitized 
mice but its potential molecular mechanisms in asthma development remain unclear
[194]. Conversely, adiponectin is lower in obese subjects, who may develop AHR and 
airway inflammation partly as a result o f the loss o f adiponectin’s anti-inflammatory 
properties [178]. Adiponectin is reduced by allergic pulmonary responses and attenuates 
allergic airway inflammmation in mice [195]. Adipocytes also release plasminogen 
activator inhibitor (PAI-1) which is a potent inhibitor o f fibrinolysis and plasmin 
activation and is increased in the obese and reduced by weight loss [196]. Experimental 
data from murine asthma models suggest that PAI-1 is required for airway 
hyperresponsiveness and remodelling in response to lipopolysaccharide (LPS) 
sensitisation and chronic challenge [178].
An intriguing link between fatty acid metabolism and allergic inflammation was 
suggested by Shum et al [197]. They report that the adipocyte fatty acid-binding protein 
aP2, which regulates systemic glucose and lipid metabolism, was markedly upregulated
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on human airway epithelial cells following stimulation with IL-4 and IL-13. Moreover, 
regulation o f aP2 mRNA expression by Th2 cytokines was highly dependent on 
STAT6, which has a major regulatory role in allergic inflammation. Eosinophilic airway 
infiltration was highly dependent on aP2 function. Bronchial epithelial cells were 
implicated as the likely site o f action o f aP2 in allergic airway inflammation, thus 
providing a potential link between adipocyte metabolic pathways and asthma.
1.3.3 Endocrine factors
There has been increasing interest in the idea o f asthma as an endocrine condition [198]. 
The stronger association o f obesity with asthma in women has led to the hypothesis that 
the effects may be related to female sex hormones. Pre-puberty, asthma is commoner in 
boys but post-puberty and into adulthood, females are at an increased risk o f developing 
asthma [199, 200]. Aromatase, the enzyme which converts androgens to oestrogen, is 
found in adipose tissue. Obesity tends to increase oestrogen levels, and is therefore 
associated with early menarche in females and delayed puberty in males [201, 202]. 
Data from the Nurses Health Study suggested exogenous oestrogen to be an 
independent risk factor for the development o f asthma in adult women [203, 204]. 
Hormonal influences have also been implicated in asthma severity. Varraso and 
colleagues found severity to increase with BMI in women only, and the association was 
stronger in women with early menarche [205]. Another study suggested hormone 
replacement therapy (HRT) to be associated with asthma in lean women only, whilst it 
appeared to confer protection in obese women, suggesting that the interactions between 
obesity and hormonal influences with asthma are unlikely to be straightforward [206]. 
In clinical practice, severe refractory steroid-resistant asthma is seen more often in 
obese females than in other groups but the question o f whether this is oestrogen- 
mediated and if so, by what mechanism, is as yet unanswered. However, animal models 
have shown oestrogen to increase AHR; effect a shift from Thl to Th2 immune 
responses; and increase eosinophil recruitment, all changes typically found in asthma 
[207-209]. Oestrogen has also been shown to increase production o f  IL-4 and IL-13 
from human blood monocytes [210]. Effect modulation by sex may indicate different
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causative mechanisms in the association between obesity and asthma in men and 
women.
Svanes et al found a strong association between asthma, atopy and menstrual 
irregularity in a study o f 8000 women [211]. They proposed an intriguing explanation 
whereby these conditions are linked by insulin resistance, with asthma as another 
manifestation o f metabolic syndrome, which would explain the previous documented 
association between insulin resistance and lung function [212].
Other hormones may also play a role. Leptin’s role as a pro-inflammatory cytokine has 
already been discussed. In addition, leptin activates the sympathetic nervous system 
(SNS), which controls airway tone and diameter; factors o f central importance in the 
airflow obstruction seen in asthma. If  leptin is administered to normal weight mice, 
stimulation o f the SNS ensues but obese mice already have high circulating leptin levels 
and are resistant to its effects [213]. This is similar to the insulin resistance seen in the 
metabolic syndrome associated with obesity and the possible overlap between these 
phenomena and asthma warrants further research.
1.3.4 Common genetic predisposition and overlapping metabolic pathways
in asthma & obesity?
A common genetic pathway to obesity and asthma may underlie their association in the 
population. Genes are usually pleiotropic (having multiple effects) and so upregulation 
in specific genes could lead to increased susceptibility to both obesity and asthma 
development. The authors o f a large twin study recently concluded that the covariation 
between obesity and asthma is predominantly caused by shared genetic risk factors for 
both conditions [214]. Genes which may contribute to the control o f both traits include 
those encoding for the beta2-adrenergic receptor, tumour necrosis factor-alpha (TNF- 
alpha) and the insulin-like growth factor 1 (IGF-1). Genome wide linkage studies have 
identified several consensus linkage peaks: the chromosomal regions 5q, 6p, l lq ,  12q 
and 17q might be important in both these complex traits.
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The 5q region contains the gene for the adrenergic B2 receptor, involved in SNS 
activation with effects including control o f airway tone and metabolic rate. The Glu 27 
variant o f this receptor has been associated with an increased prevalence o f obesity 
[215] as well as increased serum IgE and protection against methacholine challenge 
[216, 217], The 5q region also contains the glucocorticoid receptor gene (modulating 
inflammation seen in both conditions); and the genes for the Th2 cytokines IL-4 and IL- 
13. The 6p region contains the HLA gene cluster and TNF., related to immune and 
inflammatory responses in both conditions. TNF polymorphisms are associated with 
asthma, and bronchial hyper-responsiveness [218, 219] and a linkage has also been 
found between obesity and a marker near the TNF-a locus [220]. Chromosome l lq  
contains genes encoding the uncoupling proteins (UCP2 and UCP3) which influence 
metabolic rate (with as yet no known role in asthma), in addition to the low affinity 
immunoglobulin E receptor (FCeRB) which is associated with allergic inflammation 
and not yet examined in obesity. The 12q region contains the inflammatory cytokine 
genes STAT6, IGF1, ILIA and LTA4H with potential roles in inflammatory pathways in 
both conditions [11, 221], An IGF1 variant is associated with body mass index [222] 
and IGF-1 secreted by bronchial epithelial cells has been shown to stimulate 
myofibroblast proliferation after injury [223],
Intriguingly, a recent study has found significant evidence o f linkage to BMI on 
chromosome 17q23-q24 amongst female Costa Ricans (with modest linkage for males 
on chromosome 6p) [224]. Both these chromosomal regions have previously been 
shown to demonstrate linkage with asthma and investigators are currently exploring 
which genes may be responsible for these linkage peaks.
Genetic differences may underlie common immune and endocrine mechanisms already 
discussed. For instance, a polymorphism of oestrogen receptor 1 has recently been 
associated with airway hyperresponsiveness and lung function decline, particularly in 
female asthmatic subjects [225].
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1.3.5 Diet, physical activity and the “foetal origins” hypothesis
An imbalance between dietary intake and physical activity leads to obesity. There is a 
postulated link between asthma and inadequate antioxidant intake (e.g. vitamin C and E) 
which has been discussed in detail in section 1.1.7. It is feasible that individuals eating 
an unhealthy diet are less likely to have an adequate intake o f  potentially protective 
nutrients in addition to an excessive energy intake leading to obesity.
Likely to be o f more interest is the effect o f maternal diet and physical activity on 
prenatal programming. Diet in pregnancy may influence the developing immune system 
and omega-3 fatty acid supplementation has shown modifying effects on allergen 
specific immune responses and clinical outcomes [61-63]. Maternal diet and physical 
activity may affect the “programming” of foetal genes, thus influencing foetal growth, 
birth weight and immune development. These factors may be responsible for the later 
development o f asthma and obesity: the so-called “foetal origins” hypothesis where 
foetal programming is suggested to account for chronic disease in later life [226]. Low 
birth weight is associated with higher body fat later in life [227]. The association 
between asthma and birth weight (independent o f gestational age) appears to be U- 
shaped with increased asthma risk at both extremes o f  birth weight [228, 229] and 
modest positive associations between birth weight and lung function on meta-analysis 
[230].
Maternal diet and physical activity may influence foetal sympathetic nervous system 
(SNS) development [231]. As previously discussed, the SNS is relevant to both asthma 
and obesity because o f its roles in regulating smooth muscle tone and basal metabolic 
rate. Physical activity activates brown fat, regulated by the SNS, resulting in increased 
basal metabolism via activation o f  uncoupling proteins [232]. B adrenergic receptors are 
important in SNS signalling (and modulate airway tone) and are expressed by adipose 
tissue. It is plausible that prenatal defects in SNS development - modulated by maternal 
diet and physical activity - may contribute to both asthma and obesity in later life.
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Figure 1.6 Diagram illustrating the complex inter-relationships between obesity and 
asthma. The pro-inflammatory and mechanical effects o f obesity are likely to 
influence both asthma pathogenesis and severity of disease. Conversely, factors such 
as corticosteroid use and reduced physical activity may contribute to increased 
overweight and obesity.
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CHAPTER 2 
Methodology
2.1 Study design
This is a cross-sectional population study designed to test which genetic variants o f 
IL13, IL4RA and STAT6, acting singly and in combination, predict asthma phenotypes 
in an unselected population of young adults. Our subjects were recruited from a 
population o f university students and staff, many o f whom had varying degrees o f mild 
asthma while some 10-15% would be expected to have clear asthma requiring treatment 
periodically or regularly. The objective o f the population recruitment was to assemble 
as far as possible an unselected population of young adults who would be o f dominantly 
Caucasian ethnic type.
Researchers have previously performed case-control studies on smaller groups of 
subjects confined to marked asthma and controls, which do not allow for the predictive 
effects o f the variants to be fully estimated at a population level. Here asthma was 
treated as a spectrum o f disease rather than a single disease entity. Comprehensive 
phenotyping encompassed clinical, physiological and immune asthma phenotypes. 
Clinical phenotype included measures o f disease severity, such as symptom frequency 
and volume o f medication use.
Asthma is a complex trait, consisting o f overlapping phenotypes giving rise to the triad 
o f airway inflammation, bronchial obstruction and airway hyperresponsiveness. Given 
the heterogeneity o f asthma phenotypes, asthma is difficult to define for the purposes o f 
clinical research. A large number o f studies support our use o f  a self-report o f 
“physician diagnosed asthma” as a robust definition for epidemiological research [233- 
235]. In this thesis the aim was to provide a comprehensive view both o f asthma and 
Th2 immune phenotypes and o f a range o f Th2 genotypes spanning entire loci. To this 
end, phenotypes encompassed clinical, immune and physiological parameters to build a 
comprehensive picture o f the role of genetic variants o f  Th2 immunity in predicting 
asthma and associated phenotypes.
This association study matched genetic variants to fully quantitative assays o f lung
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Junction and immune manifestations o f asthma. Multiple genetic variants were 
examined - through molecular analysis o f specific immune regulatory genes in one key 
pathway -  and risk was defined against quantitative traits including asthma severity, 
lung function and immune allergic disorder, utilising logistic and linear regression 
models.
IL-13 and STAT6 variants previously associated with asthma in case-control studies 
were validated by examining their effects in a large population thus giving a true 
estimation o f the population risk conferred by these genetic factors. In addition, 
common polymorphisms in these genes were examined where an association with 
asthma had not yet been documented and epistatic relationships between these genes in 
asthma were investigated. Thus a population risk at each o f these loci, acting singly and 
in combination, was provided, building a unique population picture o f the genetic 
epidemiology o f asthma in relation to the IL-13 signalling pathway.
This population study provided an opportunity to clarify genetic factors that 
significantly predict asthma in the general population. This might allow the 
identification o f at-risk individuals at a young age where early interventions would be 
important and could prevent asthma from continuing into later life. New targets for 
therapeutic interventions in asthma are needed and in the future it may be possible to 
identify particular subgroups o f patients who would benefit from particular therapies 
from their genotypes. We know that the IL-13 signalling pathway is vital in asthma. The 
interaction between different variants in this pathway (i.e. IL-13 and STAT6) in 
promoting asthma has not been properly clarified. Improved understanding o f the 
interplay between such genetic variants may clarify potential targets for therapeutic 
intervention as well as population risk. This population-based approach offers valuable 
opportunities to identify significant genetic predictors o f allergic asthma.
2.2 Ethical approval
Ethical approval was obtained from the local research and ethics committee, LREC for
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Bridgend, Neath Port Talbot & Swansea (REC reference number 04/WMW02/29). 
Informed consent was obtained from all volunteers (Appendix II).
2.3 Subjects
Subjects comprised 1614 unselected volunteers (aged 18-30) from students and staff at 
Swansea University, Swansea Institute and Singleton Hospital, Swansea. The 
population was named the PAPA population (Poblogaeth Asthma Prifysgol Ahertawe, 
Swansea University Asthma Population). Exclusion criteria were significant lung 
disease other than asthma (e.g. single lung) and pregnancy since these states would act 
as a potential confounders for the associations studied. Subjects were studied when free 
of acute lower respiratory infection which would be likely to result in transient reduced 
lung function.
2.4 Subject recruitment
Subjects were recruited by the following methods:
1. A manned stall at the students’ Freshers ’ Fair
2. A week spent recruiting/collecting data at Swansea Institute 
5. Announcements and advertisements in undergraduate lectures
4. Posters around the University and at the University Health Centre (Appendix IA)
5. Sandwich board outside the University reception area
6 . Advertisement by email to all students and staff (Appendix IB)
7. Use o f  flier advertisements
2.5 Anthropometric measurements
The following measurements were recorded on a data sheet (Appendix III).
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1. H eight measured by staediometer to 0.1cm (Leicester; Chasmors, UK)
2. W aist and hip circum ference to 0.1cm (D loop non-stretch fibreglass tape; 
Chasmors, UK).
3. W eight to 0.1kg (Seca 873 digital scales; Cranlea, Birmingham, UK).
4. Percentage body fat to 0.1% (Tanita digital scales, Tanita UK Ltd, Yiewsley, UK)
The following were then calculated:
1. W aist/hip ratio
2. Body mass index (BMI) = weight (kg)/ [height (m)]2
2.6 Phenotyping
2.6.1 Clinical phenotype
Clinical phenotype was defined by validated questionnaire. Demographic data were 
collected and subjects completed a validated bronchial symptoms questionnaire which 
included questions on symptoms (e.g. wheeze, chest tightness) and presence o f asthma, 
hayfever and eczema (Appendix IV) [236]. Smoking status (pack-years) was recorded. 
Those who answered positively to "doctor-diagnosed asthma" completed a further 
validated asthma and allergy symptom questionnaire, based on the European 
Community Respiratory Health Survey (Appendix V) [237]. Quantitative traits were 
defined e.g. asthma severity was graded as mild intermittent, moderate persistent or 
severe persistent according to GINA criteria [50]. Further quantification o f severity 
included recording symptom frequency, volume o f medication and number o f doctor 
visits over the previous 12 months.
2.6.2 Physiological phenotype
Given recent evidence that airway remodelling is an early phenomenon [238], a 
spirometric measure was included in the phenotyping. Morning spirometry (before
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noon) capitalised on the diurnal variation in asthma and maximised the discriminatory 
value o f this test in subjects with airflow obstruction. Forced Expiratory Volume in 1 
second (FEV1), Forced Expiratory Flow at 25-75% o f expired vital capacity (FEF 25- 
75), Forced Vital Capacity (FVC), FEV1/FVC ratio and Peak Expiratory Flow (PEF) 
were measured by standardised protocol [239], using a dry spirometer (Vitalograph, 
UK). The best value o f three manoeuvres was expressed as an absolute and percentage 
o f the age-gender-stature predicted value. If  on inhaler treatment for asthma, volunteers 
were asked to omit their morning dose until after the spirometry measurements were 
taken.
2.6.3 Im m une phenotype
Since there is an established association between atopy and asthma, serum total IgE 
levels were measured, providing a prediction o f immune phenotype in addition to 
clinical and physiological phenotype. Immunophenotype also included eosinophil count 
and plasma eotaxin (a chemokine effector molecule o f IL-13).
Total IgE
Whole blood was collected in vacutainers (serum separator clotted tube) and centrifuged 
for serum separation (2500 rpm, 4°C for 10 minutes). Serum total IgE (klU/L) was 
measured using an ELISA-type sandwich assay (Roche Diagnostics, Lewes, UK) at 
Morriston Hospital Chemical Pathology. A "sandwich type" assay utilising 
electrochemiluminescent technology was performed using the Roche Elecsys Modular 
E analyser. The method has a similar principle to the ELISA (enzyme-linked 
immunosorbent assay) method: rather than the antibody being attached to a microplate 
well, it is attached to magnetic particles, and separated by magnet to allow quantitation. 
Further details are as follows:
a. First incubation: IgE from 10 pi serum sample, a biotinylated monoclonal IgE- 
specific antibody and a monoclonal IgE-specific antibody labelled with a ruthenium
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complex form a sandwich complex.
b. Second incubation: After addition o f streptavidin labeled microparticles, the 
complex produced is bound to the solid phase via biotin-streptavidin interaction.
c. The reaction mixture is aspirated into the measuring cell where the microparticles 
are magnetically captured onto the surface o f the electrode. Unbound substances are 
then removed with ProCell. Application o f a voltage to the electrode then induces 
chemiluminescent emission which is measured by a photomultiplier.
d. Results are determined via a calibration curve. This curve is instrument-specifically 
generated by 2-point calibration and a master curve provided via the reagent barcode.
Eotaxin
Materials (BD OptEIA™, BD Biosciences)
Capture Antibody: Anti-human eotaxin monoclonal antibody.
Detection Antibody: Biotinylated anti-human eotaxin monoclonal antibody.
Enzyme Reagent: Streptavidin-horseradish peroxidase conjugate (SAv-HRP).
Standards: Recombinant human eotaxin, lyophilised
Buffers and solutions (BD OptEIA™, BD Biosciences)
Coating Buffer: 0.1 M Sodium Carbonate, pH 9.5, 8.4 g N aH C03, 3.56 g N a2C03; q.s. 
to 1.0 L; (prepared from carbonate-bicarbonate buffer capsules; Sigma).
Block Buffer: 1% Bovine serum albumin (BSA) in phosphate-buffered saline (PBS). 
Wash Buffer: PBS with 0.05% Tween-20.
Assay Buffer: 1% BSA in PBS/0.05% Tween-20.
Substrate Solution: Tetramethylbenzidine (TMB) and Hydrogen Peroxide (TMB 
substrate set; BD Biosciences).
Stop Solution: 2 N H2SO4.
Whole blood was collected in EDTA vacutainers and centrifuged for plasma separation 
(2500 rpm, 4°C, 10 minutes). Plasma eotaxin (pg/ml) was measured using ELISA (BD
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OptEIA™, BD Biosciences), under the supervision o f  Dr Cathy Thornton, Senior 
Lecturer in Newborn Immunity. Assays were performed in duplicate and assay 
procedure was as follows.
a. Dilution o f capture antibody (1:250) into coating buffer and 50 pi added to each 
well (Costar Vi area 96 well plate) and incubated overnight at 4°C.
b. Coating antibody tipped off and 150 pl/well blocking buffer added. Incubated for 1 
hour at room temperature.
c. Blocking buffer tipped off and plate washed 3 times (Wash Buffer).
d. Standard curve: Stock eotaxin at 20ng/ml. Standard curve o f 400, 200, 100, 50, 25, 
12.5, 6.25 and 0 pg/ml in duplicate for each plate, at 50 pl/well.
e. Samples added at 50 pl/well, following optimal dilution in assay buffer (initially 1:2 
and further dilutions in repeat assays if needed). Incubated for 2 hours at room 
temperature.
f. Standards/samples tipped o ff and plate washed 4 times (Wash Buffer).
g. Detection complex diluted in assay buffer: (1:250 detection antibody and 1:250 
enzyme reagent), 50 pl/well added and incubated for 1 hour at room temperature.
h. Detection complex tipped off and plate washed 6 times (Wash Buffer).
i. Addition o f 50 pl/well substrate solution and blue colour allowed to develop (Figure
2 .1a).
j. Reaction stopped with 50 pl/well 2N H2SO4, with colour changing to yellow (Figure 
2 .1b).
k. Absorbance read at 450 nm (Multiskan Ascent; Thermo Labsystems).
1. Calculation o f results: mean absorbance calculated for each set o f duplicate
standards and standard curve plotted for each plate. An example o f plotted standard 
curve is shown in Figure 2.2. Mean absorbance was calculated for each set o f duplicate 
samples and eotaxin level calculated from the derived equation from the standard curve 
(Excel 2003).
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Figure 2.1 Plates showing eotaxin reactions measured by ELISA. Eotaxin 
standard curves were derived from the first two columns containing stock solution 
of 400, 200, 100, 50, 25, 12.5, 6.25 and 0 pg/ml in duplicate for each plate. Upper 
plate, after addition of TMB substrate; lower plate, after reaction stopped by 
H2S 0 4.
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Figure 2.2 Example of a plotted standard curve for eotaxin. Mean 
absorbance was calculated for each set of duplicate samples and eotaxin 
level calculated from the derived equation from the standard curve
Eosinophil counts
Whole blood was collected in EDTA vacutainers and eosinophil counts were measured 
by Haematology staff at Singleton Hospital, Swansea NHS Trust, under the supervision 
o f Dr Ann Benton, Consultant Haematologist. All samples were processed on the same 
day as collection on a Sysmex XE-2100 automated analyser which provides a full 
blood count including a five part differential o f the white cell count (neutrophils, 
lymphocytes, monocytes, eosinophils and basophils). Full blood counts were reviewed 
and validated as per standard protocol and blood films were made on all samples in case 
a manual differential was needed (if analyser unable to produce results) and in case 
review was required for abnormalities found on full blood count.
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2.7 Genotyping
2.7.1 SNP selection
The approach to single nucleotide polymorphism (SNP) selection was that o f ensuring 
comprehensive coverage o f the entire IL13, IL4RA and STAT6 loci. Therefore, SNPs 
were selected in the 5’UTR; intronic and exonic regions; and the 3’UTR. The SNPs 
with highest heterozygosities were chosen from these regions. Heterozygosities were 
initially obtained from the NCBI SNP database: 
http://www.ncbi.nlm.nih.gov/proiects/SNP (and further examined in our own population 
when necessary, see below). In addition, through extensive literature review, SNPs were 
chosen on the basis o f their association with asthma and atopy in previous studies; these 
were primarily non-synonymous SNPs causing an amino acid change.
In the case of STAT6, previous work by our unit and other groups and the choice o f  high 
heterozygosity SNPs to attain comprehensive gene coverage, yielded 11 SNPs o f 
interest across the STAT6 gene. In the case o f IL13, several o f  the SNPs were similar in 
location and heterozygosity and so were examined further in our population in order to 
refine our selection and choose the SNPs most likely to be important. This was achieved 
by genotyping a small sample o f our population for the IL13 SNPs o f interest by 
sequencing. The IL4RA is highly polymorphic with multiple SNPs causing amino acid 
change: SNPs in this gene were chosen on the basis o f location, heterozygosity and 
previous literature.
Figure 2.3 outlines the molecular methods o f DNA extraction, polymerase chain 
reaction (PCR) and sequencing which will be described in detail in the subsequent 
section.
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Genomic DNA extraction & 
purification
Quantification o f DNA yield
Genotyping by sequencing
Optimise PCR conditions
PCR clean-up
Primer design
PCR to identify DNA quality in 
samples with borderline yield
PCR
SEQUENCING I
Precipitation reactions
Discard SNPs with low  
heterozygosity___
SEQUENCING II
Figure 2.3 Flow chart of molecular methods.
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2.7.2 Genomic DNA extraction & purification
Materials (QIAamp 96 DNA Blood Kit, Qiagen, Germany)
OLAGEN Protease.
Buffers and solutions (QIAamp 96 DNA Blood Kit, Qiagen, Germany)
Lvsis Buffer AL.
Wash Buffer AW1 & AW2.
Elution Buffer AE (lOmM TrisCL, 0.5 mM EDTA, pH 9.0).
See QIAamp 96 DNA Blood Handbook for further details 
(http://www 1 .qiagen.com/literature/handbooks/default.asp). Further details regarding 
buffer composition are proprietary.
Whole blood was collected in EDTA vacutainers and stored at -80°C. Genomic DNA 
was isolated from whole blood using the QIAamp 96 DNA Blood. The kit utilises the 
selective binding properties o f a silica-gel membrane with a high-throughput 96-well 
format, allowing us to process 190 samples at a time (with one negative control in each 
plate for quality control). A 200pl sample of whole blood yields 3-12 fig o f DNA 
(average final concentration o f 34 ng/pl). The purified DNA ranges in size up to 50 kb, 
mainly comprising fragments o f 20-30 kb.
a. Lysis was initiated by adding 200pl o f whole blood to 20pl o f QIAGEN 
Protease stock solution in a 96 well block.
b. 200pl o f lysis Buffer AL was added to each sample.
c. The samples were centrifuged briefly at 3000 rpm and incubated at 70°C for at 
least 10 minutes.
d. The samples were centrifuged briefly at 3000 rpm to collect any lysate from the 
caps.
e. Purification on the QIAamp membrane
■ 200 |fr o f ethanol ( 100%) was added to each well to optimise the binding
of DNA to the QIAamp membrane
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■ The wells were sealed before centrifuging briefly at 3000 rpm.
■ The lysates were loaded onto the QIAamp plate and the DNA adsorbed 
onto the QIAamp membrane in a brief centrifugation step (6000 rpm for 4 minutes).
■ DNA bound to the membrane was then washed in two centrifugation 
steps: two wash buffers AW1 and AW2 were used (500pl). Samples were centrifuged at 
6000 rpm between these washes and at 6000 rpm after the second wash.
f. DNA was eluted from the membranes using 200pi o f elution buffer.
g. Purified DNA was stored at -20 °C.
Quantification o f DNA yield
Following DNA extraction, DNA was quantified in ng/pl by measuring and comparing 
its optical density (OD) at 260nm and 280nm using a NanoDrop 1000 
Spectrophotometer. Pure DNA has an A260/A280 ratio o f 1.7-1.9. An OD o f 1 is 
equivalent to 50pg/ml o f dsDNA. DNA extraction and purification were repeated for 
samples with low DNA concentrations (defined as < 20ng/pl) and/or unsatisfactory OD 
ratios. I f  the values were borderline, then PCR was done to decide whether repeat DNA 
extraction was necessary.
PCR to identify DNA quality in samples with borderline yield
Materials 
Purified DNA.
Forward and reverse primers for SNP 5 [IL13(5)F and IL13(5)R].
ABgene PCR Master Mix [1.25 units Taq DNA polymerase, 75mM Tris-HCl, 20mM 
(NH4)2S 0 4, 1.5mM MgCl2, 0.01% Tween 20, 0.2mM each o f  dATP, dCTP, dGTP, 
dTTP].
• Twelve samples were deemed to show borderline DNA yield on
spectrophotometry and PCR was performed on these samples. SNP 5 primers were 
chosen for PCR because o f their consistently good performance.
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• In a total volume of 20jnl, 1 (nl (approx. 50ng) DNA was added to 17pl 
ABgene PCR Master Mix, and lOpmol of each primer.
• PCR conditions were as follows: 1 cycle o f 5 min at 95°C; followed by 35 
cycles of 30s at 94°C, 30s at 60°C, 40s at 72°C; and a final extension of 10 min at 72°C.
• PCR products were run on 1.5% agarose gel at MOV for 15 minutes and 
visualised with ethidium bromide (EtBr) staining in a UV dark chamber.
• All 12 PCR products showed satisfactory bands (Figure 2.4).
Figure 2.4 PCR products from 12 samples showing borderline DNA yield on 
spectrophotometry (lane 1-12), negative control (lane 13), size ladder (lane 14). 
Satisfactory bands are seen on gel electrophoresis.
2.7.3 Genotyping IL13 SNPs by autom ated DNA sequencing
Aim : To determine the heterozygosities of IL13 SNPs in a small sample o f our 
population in order to select the highest heterozygosity SNPs when genotyping the total 
population.
Up to 30 randomly selected samples were sequenced from our study population in order 
to ascertain whether any of the IL13 SNPs 1-6 could be discarded on the basis o f low 
heterozygosity.
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Primer design
A website was used to aid primer design 
(www.wi.mit.edu/genome software/other/primer3.html). A sequence surrounding the 
SNP o f interest (60 base pairs upstream, 50 base pairs downstream) was cut and pasted 
into the Primer3 design website and the best sequence match primers (Primer F, 
forward; Primer R, reverse) were selected and ordered from MWG (Germany, 
www.mwgbiotech.com) (Table 2.1).
Table 2.1 PCR primers used in sequencing IL13.
Forw ard  prim er (5*-3’) Reverse p rim er (5’-3’)
IL13 SNP 1 
rs 1800925
AGGAAGTGGGTAGGGGAGAA GCAGAATGAGTGCTGTGGAG
IL13 SNP 2 
rsl295686
GTCAGGTCCTGTCTCTGCAA TCCGTGAGGACTGAATGAGA
IL13 SNP 3 
rs2069744
TGCACGTGCTTTATGTGTCA GCCACTGTTGACCAAGACAA
IL13 SNP 4 
rs3212145
CAGCTCACATGTCTGAGCACT CATGGACACTCTGGTGTTGG
IL13 SNP 5 
rs20541
CAGCACAGGCTGAGGTCTAA CGAGACACCAAAATCGAGGT
IL13 SNP 6 
rs848
GTTCTGCCCCTCTCCTGAC AGTGTGTTTGTCACCGTTGG
Optimising PCR conditions
In a total volume o f 20pl, lp l (approx. 50ng) o f DNA from each o f 6 subjects was 
added to 17pl ABgene PCR Master Mix (ABgene, as previous), and 12pmol o f  each 
primer. This was done for SNP 1- 6 .
PCR was then performed at different annealing temperatures (56°C, 58°C and 60°C) 
(GeneAmp PCR System 9700, Applied Biosystems). PCR conditions were as follows: 1 
cycle o f 5 min at 95°C; followed by 35 cycles o f 30s at 94°C, 30s at 56/58/60°C, 30s at
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72°C; and a final extension of 10 min at 72°C.
PCR products (lOpl) were run on 1.5% agarose gel at 140V for 15 minutes and 
visualised with EtBr staining in a UV dark chamber. A lOObp DNA ladder was loaded 
for comparison.
Temperatures 56-60°C yielded satisfactory bands, except for SNP 1 where at least one 
other PCR product was identified at these temperatures (Figure 2.5) and an optimal 
temperature o f 61°C was selected (Figure 2.6). For SNP 2-6, a temperature o f 56°C was 
selected.
|
Figure 2.5 PCR bands for IL13 SNP 1 in 14 samples (lane 1-14), negative control (lane 
15), lOObp size ladder (lane 16). At least 2 PCR products were present at an annealing 
temperature o f 58°C and bands were not demonstrated for some samples. PCR was 
repeated until an optimal temperature of 61°C was found (Figure 2.6).
i
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Figure 2.6 PCR bands for IL13 SNP 1 at annealing temperature o f 6I°C in 15 samples 
(lane 1-15), lOObp size ladder (lane 16). Satisfactory bands are shown.
PCR amplification
In a total volume of 20pl, Ipl (approx. 50ng) o f DNA from each subject was added to 
17pl ABgene PCR Master Mix (ABgene), and 10 pmol o f each primer.
PCR conditions were as follows: 1 cycle of 5 min at 95°C; followed by 35 cycles o f 30s 
at 94°C, 30s at 56°C (61°C for SNP 1), 30s at 72°C; and a final extension of 10 min at 
72°C.
PCR products were loaded onto 1.5% agarose gel and run at 140V for 15 minutes, as 
previously outlined. Representative bands are shown for SNP 3 (Figure 2.7). If bands 
were unsatisfactory (e.g. for 3 of 20 samples for SNP 2), PCR was repeated for those 
samples and the bands rechecked before proceeding to PCR clean-up.
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Figure 2.7 PCR products for IL13 SNP 3 for 15 samples (lane 1-7, 9-16) with lOObp 
size ladder (lane 8). Satisfactory bands are shown.
Purifying PCR products
Prior to sequencing, the PCR products were purified using the microCLEAN™ DNA 
clean-up reagent (Microzone) which works on differential precipitation o f DNA by size.
a. 15pl microCLEAN added to 15jo.l o f PCR product, and allowed to stand at room 
temperature for 5 minutes.
b. Spun at high speed (13000 rpm in microfuge) for 7 minutes, supernatant 
removed, spun again to remove dregs and pellet then resuspended in 20jil distilled water 
(dfhO). Allowed to stand for 5 minutes to rehydrate DNA and stored at 4°C.
The purity o f cleaned PCR products was checked by running 5^1 of cleaned PCR 
product on 1.5% agarose gel at MOV for 15 minutes. This was done on 5 samples for 
each SNP.
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Automated DNA sequencing
Aim : To sequence up to 30 samples from our population for SNP 1-6, to ascertain 
whether any o f SNPs could be discarded on the basis o f low heterozygosity.
Sequencing I
a. In a total volume o f 8pi, the master mix comprised 2pl BIG DYE, 1 pi BIG DYE 
sequence buffer (ABgene), 5pmol o f primer (Primer F chosen) and 4pi o f H2O. 
Quantities were multiplied according to number of samples to be sequenced.
b. 2pl cleaned PCR product was added to the master mix in each well
Sequencing reactions were performed under the following conditions: 1 cycle o f 1 min 
at 96°C; followed by 25 cycles o f 10s at 96°C, 5s at 50°C, and 4 min at 60°C.
Precipitation reactions
Aim: To remove residual dye terminators from sequencing reactions
a. After completion o f sequencing reaction, the extension products (lOpl) were 
added to lOpl dF^O.
b. The following reagents were added:
■ 2pl o f 3M NaOAc, pH 4.6
■ 50pl o f 95% EtOH at room temperature
c. The tubes were capped, vortexed briefly and allowed to stand at room 
temperature for 15 minutes to precipitate the extension products.
d. The capped tubes were centrifuged for 20 minutes at maximum speed (13000 
rpm).
e. Without disturbing the pellet, the supernatant was carefully aspirated and 
discarded.
f. The pellet was rinsed with 250pl o f 70% EtOH, vortexed briefly and centrifuged
63
at maximum speed for 5 minutes.
g. The supernatant was carefully aspirated again and discarded.
h. The pellets were dried in a heat block at 90°C for 1 minute.
i. The samples were resuspended in lOpl template suppressant reagent (TSR) and
stored at 4°C.
Sequencing II
Samples were denatured by incubation at 90°C for 2 minutes and put on ice for 2 
minutes. Samples underwent capillary electrophoresis in an ABI PRISM™ 310 Gene 
Analyser.
Figure 2.8a-c shows the sequenced genotype at the SNP 1 locus for subjects 1,2 and 3.
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Figure 2.8a Sequenced genotype at SNP 1 of IL13 for subject 1: C/C. Blue peaks, C
allele; red peaks, T allele.
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Figure 2.8b Sequenced genotype at SNP 1 of IL13 for subject 2: T/T. Blue peaks, C
allele; red peaks, T allele.
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A variable number o f samples were needed to confirm or refute that the SNP was 
present in sufficient heterozygosity in our population sample (Table 2.2). For instance, 
for SNP 1, the first 3 samples sequenced were C/C, C/T and T/T (Figure 2.8a-c) and 
adequate frequencies were demonstrated after genotyping 14 subjects. Conversely, more 
subjects were genotyped when the heterozygosity was low or not demonstrated e.g. 30 
subjects were genotyped for SNP 3, with only one being heterozygous. After 24 
subjects had been genotyped for SNP 4 with all showing the same homozygous 
genotype, it was felt that this SNP was unlikely to be sufficiently informative in our 
population.
Table 2.2 Frequencies o f genotypes for ILJ3 SNP 1-6 in a sample o f study population.
HOMOZYGOUS (1) HETEROZYGOUS HOMOZYGOUS (2)
SNP 1 C/C 9 C/T 4 T/T 1
SNP 2 G/G 14 A/G 6 A/A 2
SNP 3 C/C 29 C/T 1 T/T 0
SNP 4 C/C 24 C/A 0 A/A 0
SNP 5 C/C 17 C/T 8 T/T 0
SNP 6 C/C 12 C/T 6 T/T 1
2.7.4 O utcom e of genotyping IL13 SNPs by autom ated DNA sequencing
SNP 3 and SNP 4 occurred in low heterozygosity in this sample o f our study population 
(Table 2.2), with no heterozygotes identified for SNP 4. SNP 3 and SNP 4 were thus 
eliminated from further investigation. SNP 1, SNP 2, SNP 5 and SNP 6 were added to 
the other three IL13 SNPs already chosen for reasons o f genetic location and high 
heterozygosity (SNP 7, SNP 9, SNP 10, SNP 13). SNP 8, 11 and 12 had been discarded 
having reviewed the literature and heterozygosities from the SNP database 
http://www.ncbi.nlm.nih.jJQv/proiects/SNP.
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2.7.5 Genotyping of selected SNPs in IL13, IL4RA, STAT6 genes
Figure 2.9 shows a schematic representation o f the SNPs chosen for genotyping o f the 
population in the IL13, IL4RA and STAT6 genes. For IL4RA, SNP 1, SNP 4 and SNP 6 
were initially selected but the assay validation set-ups for genotyping were unsuccessful 
and so SNP 2, SNP 3 and SNP 7 were then substituted for reasons o f  genetic proximity 
and high heterozygosity. Four exonic SNPs were discarded for reasons o f low 
heterozygosity in the SNP database nttp://www.ncbi.nlm.nih.gov/proiects/SNP. For 
logistic reasons, it was decided to look at the highest heterozygosity SNP in the 3 ’UTR 
and so an alternative SNP in this region was not selected. For STAT6, SNP 5 was 
rejected for reasons o f low heterozygosity in a British population [82]. On panel testing, 
SNP 6, 7 and 9 were monomorphic in a population sample (n=42) and so no further 
genotyping was done. The assay validation set-ups were unsuccessful for SNP 10 which 
was therefore not genotyped.
Following SNP selection, genotyping o f our population was performed by KBioscience 
(www.kbioscience.co.uk). A competitive allele specific PCR system (KASPar) was 
used, utilising fluorescently labelled primers. This proprietary system has been 
developed from the Ampliflour system (no further details are disclosed by 
KBioscience).
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Figure 2.9 Genomic architecture o f IL13, IL4RA and STAT6 selected SNPs 
for population genotyping. Reference SNP ID (rs) shown 
(httn:/Av\v\v.nchi.nlm.nih.gov/proiects/SNPI and polymorphism defined for 
well-described SNPs.
2.8 Data analysis
Published odds ratios (OR) for risk o f asthma and variants in the genes considered in 
this study tend to be in the region o f 1.5 to 3.0. Thus in a targeted population o f 2000, 
and assuming an asthma prevalence o f 10%, the study has a power o f between 70% (OR 
= 1.5) and <99% (OR = 3.0) to detect a risk factor that is present in approximately 25% 
o f the (control) population. Power is reduced for more rare risk factors, for example 
between 47% (OR = 1.5) and <99% (OR = 3.0) for variants present in only 10% o f the 
population [240]. However the power o f the design is strengthened by the additional 
information provided by quantitative phenotypes, which typically require much smaller 
sample sizes. The above calculation therefore represents a conservative assessment o f 
statistical power.
For the realised study (asthma prevalence o f ‘current asthma’ o f 11.1% and ‘physician 
diagnosed asthma ever’ o f 23.9%, and the Caucasian population (n = 1445), estimates 
o f study power are as follows.
•  For current asthma, and an exposure present at a frequency o f 25% (in the
normal population), the power is approximately 61% (OR=1.5), 97% (OR=2.0) and 
>99% (OR=3.0). For an exposure present at a frequency o f only 10% (in the normal 
population), the power is approximately 40% (OR=1.5), 83% (OR=2.0) and >99% 
(OR=3.0).
•  For 'physician diagnosed asthma ever’, and an exposure present at a
frequency o f 25% (in the normal population), the power is approximately 85% 
(OR=1.5), >99% (OR=2.0) and >99% (OR=3.0). For an exposure present at a frequency 
o f only 10% (in the normal population), the power is approximately 60% (OR=1.5), 
97% (OR=2.0) and >99% (OR=3.0).
The database was compiled using Access 2003 software. The analysis o f the association 
between genotype/haplotype and risk o f asthma took the form o f a series o f standard
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logistic regression models, with adjustment made for relevant covariates (age, sex, 
smoking, height etc). The analysis was expanded upon to include the quantitative 
asthma phenotypes, using general linear models. Linear and logistic regression analysis 
was performed using SPSS 13.0.
Our model building approach was as follows. Initially the relationship between the 
primary predictors (e.g. genotype) and outcome was explored in a univariate manner. 
The effect o f adjustment for relevant covariates (age, sex, height, smoking) was 
explored by adding the variables to the model in a stepwise manner and (at each step) 
retaining the covariates if there was either 1) a significant (p<.05) improvement in the 
likelihood o f the fit of the new model, or 2) the covariate caused a substantial alteration 
o f  the coefficients representing the effect o f the primary predictor. Lastly, when the 
above process had settled on a ‘final model’ for individual predictors, all pairwise 
interactions involving the primary predictors were tested.
Since this was a hypothesis generating study, generating candidate associations, 
adjusting for multiple comparisons was not applied (e.g. Bonferroni correction) [241]. 
Using the adjustments results in a large loss o f power (for those relationships that are 
not null), in particular for the testing o f the rarer genotypes with the risk that we would 
overlook potentially important genotypes. Bonferroni is only valid under a strict set o f 
circumstances. By applying the Bonferroni adjustment, the null hypothesis would be 
universal, that “none o f these genotypes have any effect on asthma” and chance 
underlies the full set o f observations. Since the selected loci are part o f a functional 
pathway known to be related to asthma pathogenesis, with known previous associations 
and physiological effects in case-control studies, we would assume that this global null 
hypothesis is wrong (i.e. some variants are likely to have true associations with asthma 
at the population level) but the adoption o f the Bonferroni method results in a lack o f 
power to reject the global null hypothesis i.e. an unacceptably high false negative rate. 
This approach means that some false positive associations may be generated and so 
identified candidate genotypes in the study need to be interpreted in light o f previous 
studies and should be confirmed in additional populations o f sufficient size, a strategy
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advocated by reviewers in this field [242, 243].
Haploview software was used to calculate linkage disequilibrium. The haplo.stats 1.3.0 
package and the haplo.glm function were used for haplotype analysis. Haplotype 
frequencies were estimated from genotype data -  at the IL13, IL4RA and STAT6 loci - 
using the Expectation Maximisation (EM) algorithm [244, 245] and R statistical 
environment package [246]. Further details of this more complex statistical analysis are 
given in Chapter 6.
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CHAPTER 3
Genetic association of single nucleotide 
polymorphisms with asthma and clinical 
atopy phenotypes
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3.1 Introduction
A number o f case-control studies have reported associations between polymorphisms in 
the IL-13 signalling pathway and asthma, allergic rhinitis and atopic dermatitis (Tables 
1.2-1.4). In IL13, the main polymorphisms examined have been A rgllO G ln in exon 4 
and the promoter polymorphism 1024C/T. Many positive associations are reported but 
there are several inconsistent findings, especially for ArgllO G ln, with two studies 
finding a positive association with asthma [117, 247], but a further seven studies 
reporting no significant association [114, 136, 144, 146, 147, 153, 248]. IL4RA is a 
highly polymorphic locus, containing twelve reported non-synonymous SNPs resulting 
in amino acid change. Reported associations with asthma have focussed mainly on the 
Ile50Val variant in exon 5 and Arg551Gln in exon 12, with several conflicting reports 
regarding association and very few reports on clinical atopic disease other than asthma 
(Table 1.3). Gao et al found a positive association between a 3 ’UTR variant o f STAT6 
and atopic asthma in a Japanese population [124]. However, this finding has not been 
replicated in other diverse populations where STAT6 variants have primarily been 
reported in association with IgE levels rather than clinical atopic disease (Table 1.4).
Case-control studies provide an indication o f some o f the loci contributing to asthma 
susceptibility but only unselected population studies can estimate the actual risk 
conferred by a single variant, or combinations o f variants, at the population level. 
Moreover, given the degree o f inconsistent results in case-control studies, unselected 
population studies are required in order to estimate the true population risk conferred by 
a polymorphism, or groups o f polymorphisms. There have been few unselected 
population studies examining asthma and related atopy phenotypes to date. Only one 
German study has examined asthma in the context o f IL-13 signalling polymorphisms; 
only one polymorphism was examined at each o f the IL13, IL4RA and STAT6 loci. The 
IL13 -1024C/T promoter polymorphism was found to associate with asthma [12]. No 
unselected populations have been used to examine IL-13 signalling variants relating to 
the clinical atopic phenotypes o f hayfever and atopic eczema.
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In this chapter, associations between IL-13 signalling variants and asthma, hayfever and 
atopic eczema will be examined in an unselected population, in order to estimate the 
actual population risk conferred by these single nucleotide polymorphisms. Selected 
polymorphisms span each o f the IL13, IL4RA and STAT6 genes.
3.2 Methods
An unselected population o f 1614 adults aged 18-30 years was recruited according to 
General Methodology outlined in Chapter 2. O f these, genotyping results are reported 
on the majority ethnic population, the Caucasian group (n=1445). Clinical phenotyping 
o f “physician diagnosed asthma ever” was obtained by validated questionnaire 
(Appendix IV) [236] (answering affirmatively to “Have you ever had asthma?” and 
“Was it confirmed by a doctor?”). Those classified as having “current eczema” had 
answered affirmatively to “Have you ever had eczema?” and “Do you still have it?” and 
those with hayfever had answered affirmatively to ”Do you have any nasal allergies 
including hayfever?” Genotyping was performed for a total o f  22 polymorphisms; eight 
spanning the IL13 locus and seven spanning each o f the IL4RA and STAT6 loci, with 
polymorphisms spanning each entire gene, including non-synonymous SNPs and SNPs 
in intronic and 3 ’ and 5’ untranslated regions (see Chapter 2 for further detail). The 
analysis o f the association between genotype/phenotype took the form o f a series o f 
standard logistic regression models, with adjustment made for relevant covariates (age, 
sex, smoking, height etc). Logistic regression analysis was performed using SPSS 13.0.
3 3  Results
3.3.1 Population characteristics
There were 1614 participants in our cross-sectional sample. O f these, 829 (51.4%) were 
men, 1445 (90%) were white, 53 (3.3%) were Chinese and 24 (1.5%) were Indian. The 
mean (standard deviation, SD) age o f the participants was 21 (2.89) years. Self-reported 
subjects with “physician diagnosed asthma ever” represented 23.3% of the study
76
population (n=374) with “current physician diagnosed asthma” represented by 10.9% 
(n=176). Bronchodilators were taken by 10.8% (n=175) and 3.5% (n=56) were taking 
regular inhaled corticosteroids. Subjects reporting “smoking for as long as a year” 
represented 26.8% o f the population (n=433) with 16.9% reporting current smoking 
(n=271). A summary o f the characteristics o f the Caucasian group is shown in Table 
3.1.
As expected, there was a high correlation between asthma and other clinical 
manifestations o f atopy, namely hayfever (or allergic rhinitis) and current eczema (or 
atopic dermatitis) (Table 3.2). Odds ratios measuring the association o f asthma with 
hayfever and eczema were 5.0 (95% Cl 3.6-7.0) and 2.7 (95% Cl 1.7-4.2) respectively.
Table 3.1 Clinical characteristics o f Caucasian participants.
Male Female All
Current asthma1 79 (10.6) 82 (11.7) 161 (11.2)
“Asthma ever” 187 (25.2) 159 (22.8) 346 (24.0)
Hayfever 246 (33.1) 258 (37.1) 504 (35.0)
Current eczema 60 (8.1) 87 (12.6) 147 (10.2)
Data are number (percentage) o f subjects.
' ’’Asthma” refers to a subjective report o f physician diagnosed asthma.
Table 3.2 Clinical atopy in asthma1 versus non-asthma.
Current asthma Never asthma
Hayfever 106 (65.8) 300 (27.9)
No hayfever 55 (34.2) 772 (71.8)2
Eczema 31 (19.3) 88 (8.2)
No eczema 130 (80.7) 980 (91.2)2
Data are number (percentage according to asthma status) o f subjects.
1’’Asthma” refers to a subjective report o f physician diagnosed asthma. 
2 Total less than 100% due to missing data.
77
3.3.2 Genotyping results
All genotype frequencies were concordant with Hardy-Weinberg equilibrium. Allele 
frequencies and call rates for each SNP are shown in Tables 3.3-3.5. Call rates were 
over 97% for all SNPs. For IL13, SNPs 10, 2, 5, 13, 6 and 9 were in strong linkage 
disequilibrium (LD) (Figure 3.1). The IL4RA SNPs showed considerably less linkage 
disequilibrium, with SNP 3, 7 and 13 showing strong LD (Figure 3.2). STAT6 showed 
the highest LD with all SNPs in strong LD except SNP 12 and SNP 3 (Figure 3.3). 
Figures 3.1-3.3 show LD for the Caucasian population but patterns were almost 
identical when considering all ethnicities together (with only a very slight reduction in 
LD of D ’ -.01 for the majority o f  SNPs).
Table 3.3 Description o f IL13 SNPs with allele frequencies and call rates
Location Allele frequency Call rate
SNP 10 5’UTR C 0.18 0.991
rsl881457 -1512A/C A 0.82
SNP 1 5’UTR T 0.17 0.991
rsl 800925 -1024C/T C 0.83
SNP 7 Intron 1 A 0.11 0.996
rs2066960 C 0.89
SNP 2 Intron 3 A 0.20 0.994
rsl 295686 G 0.80
SNP 5 Exon 4 A 0.18 0.989
rs20541 ArgllOGln G 0.82
SNP 13 3’UTR T 0.17 0.992
rsl 295685 C 0.83
SNP 6 3’UTR T 0.19 0.994
rs848 G 0.81
SNP 9 3’UTR A 0.18 0.973
rs847 G 0.82
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Table 3.4 Description of IL4RA SNPs with allele frequencies and call rates
Location Allele frequeny Call rate
SNP 3 5’UTR A 0.33 0.986
rs2283563 G 0.67
SNP 5 Exon 5 G 0.44 0.993
rsl 805010 Ile50Val A 0.56
SNP 7 Intron 7 G 0.36 0.978
rs3024622 C 0.64
SNP 8 Intron 8 G 0.15 0.991
rs2891058 A 0.85
SNP 12 Exon 12 G 0.40 0.993
rsl 805015 Ser478Pro A 0.60
SNP 13 Exon 12 G 0.23 0.985
rsl 801275 Arg551Gln A 0.77
SNP 16 3’UTR T 0.41 0.991
rsl 049631 C 0.59
Table 3.5 Description o f STAT6 SNPs with allele frequencies and call rates
Location Allele frequeny Call rate
SNP 8 Intron 2 T 0.40 0.993
rs324011 C 0.60
SNP 12 Intron 16 C 0.41 0.991
rs841718 T 0.59
SNP 11 Intron 17 T 0.09 0.996
rs3024974 C 0.91
SNP 1 3’UTR A 0.24 0.997
rs324015 G 0.76
SNP 2 3’UTR A 0.49 0.995
rs703817 G 0.51
SNP 3 3’UTR G 0.12 0.990
rsl 059513 A 0.88
SNP 4 3’UTR G 0.35 0.989
rs4559 A 0.65
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Figure 3.1 Linkage disequilibrium (LD) map for IL13. D’ 
values are shown with higher LD shown in darker red. Strong 
LD is demonstrated between variants in an extended 
haploblock spanning intron 3, exon 4 and the 3’UTR.
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Figure 3.2 Linkage disequilibrium (LD) map for 
1L4RA. D’ values are shown with higher LD shown in 
darker red. IL4RA is a highly polymorphic gene with 
relatively low LD between the majority of variants 
examined.
81
Figure 3.3 Linkage disequilibrium (LD) map for 
STAT6. D’ values are shown with higher LD shown 
in darker red. STAT6 is a highly conserved gene with 
strong LD between polymorphisms.
3.3.3 Logistic and linear regression analysis
For all genotype analysis, genotype-phenotype associations were analysed for the 
Caucasian group initially (n=1445) since numbers in other ethnic subgroups were small, 
the largest being the Chinese (n=53) and Indian subgroups (n=24). Sex, age and height 
are unlikely confounders as they are expected to be distributed randomly with respect to 
genotype. This was confirmed and these variables did not alter the relationship between 
asthma and genotype. Logistic regression also confirmed no associations between these 
variables and asthma. Both BM1 and current smoking status were associated with a 
physician diagnosis of uasthma ever” and these variables were therefore adjusted for in 
subsequent logistic analysis although they were again unlikely to confound the genotype
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effects: for association o f BMI with “asthma ever”, p=.004 (see Chapter 7 for full 
details); for current smoking and “asthma ever”, OR 1.50 (95% Cl 1.11-2.02, p=.008). 
“Asthma” refers to a subject reported physician-diagnosis o f asthma. Asthma severity 
data are presented with the lung function data in Chapter 5, where Table 5.11 
summarises the main findings for genotype associations with clinical, immune and 
physiological phenotypes from Chapters 3-5.
There was an association between age and “eczema ever” (OR 1.05, 95% Cl 1.00-1.09, 
p=.03) and between sex and “current eczema” (OR 1.63, 95% Cl 1.15-2.31, p-.006 for 
females compared to males). Therefore age and sex were considered and interactions 
examined. There was an association between short stature and current eczema (for 
height, p.006, beta =-.026) and a trend towards an association with hayfever. Height 
was therefore included in the model and is likely to be a marker for sex.
Crosstabulations were performed and odds ratios plotted. In cases where the genetic 
association appeared clearly additive, the locus was modelled as a continuous variable 
whereas if  there was a clear dominant effect, the locus was considered as two 
categories. Unless otherwise stated, p values are given for associations after adjusting 
for relevant covariates, which are summarised in the relevant Tables.
Logistic regression
Asthma
IL13
Table 3.8 summarises the significant associations seen. The ArgllOGln variant 
(R110Q) associated with asthma with an OR o f  1.38 for genotypes Q/Q and R/Q 
compared with R/R (p=.015, 95% Cl 1.06-1.79) (Figure 3.4). The heterozygotes had the 
highest odds: OR 1.80 (95% Cl 1.00-2.60) for Arg/Gln; OR 1.25 (95% Cl 0.47-2.03)
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for Arg/Arg versus Gln/Gln respectively (p=.018). Genotype data are presented in two 
rather than three categories due to small numbers in the Gln/Gln group (n=43).
The 3’UTR SNPs 6, 9 and 13 associated with asthma. As previously noted, this is 
expected since these 3’UTR loci are in strong linkage disequilibrium with A rgilOGln 
(D’>0.98). Crosstabulations for SNP 5 and 6 are shown in Tables 3.6 and 3.7. Table 3.7 
for SNP 6 is almost identical to Table 3.6 for SNP 5, illustrating the effects o f strong 
linkage disequilibrium. There were no significant interactions with sex/BMI/smoking. 
There were no other significant associations in the Caucasian group. The overall 
association between the intronic SNP 2 and asthma approached significance (p=.056) 
with OR 1.65 (95% Cl 0.89-2.41) for G/G and G/A versus A/A group.
Table 3.6 Crosstabulation for IL13 R110Q (SNP 5) and asthma.
Q/Q Q/R1 R/R
Asthma2 216 *22.2) 116 (29.1) 8 (18.6)
No asthma 756 (77.8) 282 (70.9) 35 (81.4)
Total 972 (100) 398 (100) 43 (100)
Data are number (percentage, %) o f subjects, with % having asthma in each 
genotype group highlighted in red.
R, Arginine; Q, Glutamine.
2 “Asthma” refers to a subjective report o f physician diagnosed asthma ever.
Table 3.7 Crosstabulation for IL13 SNP 6 and asthma.
G/G T/G T/T
Asthma1 218 (22.4) 117 (28.7) 8 (18.2)
No asthma 754 (77.6) 290 (71.3) 36 (81.8)
Total 972 (100) 407 (100) 44 (100)
Data are number (percentage, %) o f subjects, with % having asthma in each 
genotype group highlighted in red.
“Asthma” refers to a subjective report of physician diagnosed asthma ever.
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Table 3.8 Significant associations of IL13 SNPs with asthma1.
Location Odds ratio 95% Cl P value
SNP 5 
rs20541
Exon 4 
R110Q
1.38 for A/A+A/G vs G/G 1.06-1.79 .015
SNP 13 
rs 1295685
3’UTR 1.38 for T/T+C/Tvs C/C 1.07-1.79 .014
SNP 6 
rs848
3’UTR 1.33 for T/T+G/T vs G/G 1.03-1.72 .029
SNP 9 
rs847
3’UTR 1.34 for A/A+A/G vs G/G 1.03-1.73 .029
After adjusting for relevant covariates, see Table 3.14.
2
1.8
1.6
Q/Q + Q/R R/R
Figure 3.4 Odds ratio o f asthma at IL13 R110Q (SNP 5). Very similar results were 
seen for the three 3’UTR variants in strong linkage disequilibrium with R110Q.
85
IL4RA
SNP 5 (IIe50Val) associated with asthma with an additive effect demonstrated shown in 
Table 3.9 and Figure 3.5: OR 1.25 for G/G vs G/A and A/G vs A/A, where the A allele 
codes for Isoleucine (1) and the G allele for Valine (V) (p=.013, 95% Cl 1.05-1.49). 
There were no significant interactions with sex/BMI/smoking.
Table 3.9 Crosstabulation for IL4RA I50V (SNP 5) and asthma.
V/V V/I I/I
Asthma1 77 (28.3) 173 (24.7) 90 (20.1)
No asthma 195 (71.7) 526 (75.3) 357 (79.9)
Total 272 (100) 699 (100) 447 (100)
Data are number (percentage, %) of subjects, with % having asthma in each
enotype group highlighted in red.
“Asthma” refers to a subjective report of physician diagnosed asthma ever.
Figure 3.5 Odds ratio of asthma at IL4RA I50V (SNP 5). An additive effect is 
shown for the Valine variant.
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STAT6
When examining the association with current asthma (which is likely to provide a more 
robust diagnosis o f asthma than that made during childhood which has now remitted), 
dominant effects were seen for 3 ’UTR SNP 1 (Figure 3.10) and intronic SNP 11. These 
variants were associated with the highest odds ratios o f  current asthma: SNP 1, OR 2.21 
(1.17-4.17, p=.014) for A/A vs A/G and G/G, after adjusting for relevant covariates 
(BMI); SNP 11, OR 3.60 (1.10-11.84, p=.035) for T/T vs C/T and C/C. However, the 
association at SNP 11 did not quite reach significance after adjusting for BMI with OR 
3.24 (95% Cl 2.01-4.47, p=.061). Crosstabulation tables 3.10 and 3.11 are shown: 
although heterozygote A/A numbers are small for SNP 1 (n=62), the association with 
current asthma remained significant after adjusting for relevant covariates. There were 
no significant interactions with sex/BMI/smoking.
Table 3.10 Crosstabulation for STAT6 SNP 1 and current asthma.
A/A A/G G/G
Current asthma1 13 *21.0) 49 (9.5) 97 (11.4)
No asthma 49 (79.0) 467 (90.5) 751 (88.6)
Total 62 (100) 516 (100) 848 (100)
Data are number (percentage, %) o f subjects, with % having asthma in each 
genotype group highlighted in red.
“Asthma” refers to a subjective report o f physician diagnosed asthma.
Table 3.11 Crosstabulation for STAT6 SNP 11 and current asthma.
T/T C/T C/C
Current asthma1 4 (30.8) 19 (8.4) 136 (11.5)
No asthma 9 (69.2) 206 (91.6) 1051 (88.5)
Total 13 (100) 225 (100) 1187 (100)
Data are number (percentage, %) o f subjects, with % having asthma in each 
genotype group highlighted in red.
“Asthma” refers to a subjective report o f physician diagnosed asthma.
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A /A  A/G  and G/G
Figure 3.6 Odds ratio of current asthma at STAT6 G2964A (SNP 1).
Clinical atopy 
STAT6
An association between the 3’UTR SNP 1 and “eczema ever” was of borderline 
significance after adjusting for age (p=.050). When including only those with current 
eczema (which, like asthma, is likely to exclude some cases where the diagnosis is 
uncertain e.g. neonatal eczema), the association with SNP 1 became more significant 
(p=.010 overall): OR 2.62 (1.40-4.89, p=.003) for A/A vs. A/G and G/G, after adjusting 
for relevant covariates (Figure 3.7). SNP 1 also associated with hayfever: OR 1.99 
(1.19-3.32, p=.008) (Figure 3.8). Crosstabulations are shown (Tables 3.12, 3.13) with a 
strong recessive effect seen for homozygotes A/A. There were no significant 
interactions with sex/BMI/smoking.
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Table 3.12 Crosstabulation for STAT6 SNP 1 and current eczema.
A/A A/G G/G
Current eczema 14 (22.6) 52 (10.1) 80 (9.5)
No asthma 48 (77.4) 462 (89.9) 763 (90.5)
Total 62 (100) 514 (100) 843 (100)
Data are number (percentage) o f subjects, with % having current eczema in each 
genotype group highlighted in red.
6
5
4
o
A /A  A /G  and G/G
Figure 3.7 Odds ratio of current eczema at STAT6 3’UTR G2964A (SNP 1).
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Table 3.13 Crosstabulation for STAT6 3’UTR SNP 1 and hayfever
A/A A/G G/G
Hayfever 32 (51.6) 169 (32.8) 300 (35.5)
No hayfever 30 (48.4) 346 (67.2) 545 (64.5)
Total 62 (100) 515 (100) 845 (100)
Data are number (percentage, %) of subjects, with % having hayfever in each 
genotype group highlighted in red.
3.5 
3
2.5
A /A  A /G  and G/G
Figure 3.8 Odds ratio of hayfever at STAT6 3’UTR SNP 1.
IL13 and IL4RA
IL13 and 1L4RA SNPs showed no significant associations with hayfever or eczema. A 
summary of variants where associations approached significance and where p<.05 for 
differences between individual pairs of genotypes (rather than for the overall factor 
‘genotype’) is provided in Appendix VI.
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Table 3.14 Final models o f genetic associations for dichotomous outcomes including 
relevant covariates (sex, smoking, BMI, age, height if  significant at 5% level)1
Location Outcome P value
IL13
SNP 5 Exon 4 Asthma ever .016^
ArgllOGln
SNP 5 + smoking3 + BMI .017
SNP 13 3’UTR .017
SNP 13 + smoking + BMI .016
SNP 6 3’UTR .029
SNP 6 + smoking + BMI .028
SNP 9 3’UTR .043
SNP 9 + smoking + BMI .038
IL4RA
SNP 5 Exon 5 Asthma ever .010
Ile50Val
SNP 5 + smoking + BMI .013
STAT6
SNP 1 3’UTR Current asthma .027
SNP 1 + BMI .031
SNP 11 Intron 18 Current asthma .046
SNP 11+ BMI .071
SNP 1 3’UTR Current eczema .007
SNP 1 + sex + height .010
SNP 1 Hayfever .015
SNP 1 + sex + height .018
1. Covariates shown if p<.05 when included in final model.
2. Overall p value at this locus before considering relevant covariates.
3. Refers to current smoking status.
3.4 Discussion
Associations were demonstrated for a “physician diagnosis o f  asthma ever” with all 
three loci -  IL13, IL4RA and STAT6. In IL13, the non-synonymous substitution 
ArgllOGln in exon 4, associated with asthma, consistent with findings from case-
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control studies in British, Japanese and German populations previously [117, 247]. This 
is the first time this variant has been confirmed in association with asthma in an 
unselected population study and is a relevant finding since several case-control studies 
have failed to confirm this association. This is likely to be due to the differing frequency 
o f the variant across ethnic groups [249], Moreover, G lnllO  is o f particular interest 
since this variant is found in approximately 33% o f our population and previously 
observed in 25% of a mixed American/German general population [113]. Heterozygotes 
were observed to have the highest odds o f asthma, which is likely to be simply due to 
low numbers in the Gin homozygote group but the potential functional relevance o f  this 
observation, with regard to epistatic interactions, is discussed further in Chapter 6. 
Structural and functional analyses provide insights into the mechanistic basis for the 
increased activity o f Gin 110. The SNP results in the non-conservative replacement o f a 
positively charged arginine with a neutral glutamine at position 130 (this numbering 
includes the signal peptide; 130 is referred to as position 110 when numbering does not 
include the signal peptide) [117, 133]. The Argl lOGln substitution occurs in a-helix D, 
the region o f IL-13 that is thought to interact with IL-4RA/IL-13RA1 heterodimers
[250]. Thus, Argl lOGln has the potential to affect IL-13-dependent signalling events.
The observed association for ArgllOGln is strengthened by the finding o f  almost 
identical quantitative associations with the three 3 ’UTR SNPs which are in almost 
complete linkage disequilibrium (LD) with the non-synonymous SNP. This extended 
LD haploblock spans intron 3, exon 4 and the 3’UTR and poses difficulties in 
identifying the mechanisms underlying observed associations. While it is not possible to 
exclude that the association with clinical phenotype may be due in part to the biologic 
activities o f these 3’UTR SNPs, they are not located in consensus sequences known to 
regulate gene-splicing, gene expression nor EL-13 mRNA stability, and it seems 
reasonable to conclude that the association with asthma is more likely due to the 
biological activity o f A rgl lOGln.
However, in the absence o f functional studies investigating all IL13 SNPs, it is not 
possible to exclude the presence o f other functional SNPs in this region. There is the
92
possibility o f allelic heterogeneity, that is, several disease-associated 1L13 variants may 
exist. Population theory suggests that for common disease, only a few alleles in a gene 
are likely to contribute to disease i.e. allelic heterogeneity is low for common conditions
[251]. It is possible that the causal variant remains untyped, but in linkage 
disequilibrium with the examined SNPs and is located elsewhere in this chromosome 
region, possibly regulating IL-13 expression. This can only be ascertained through 
analysis o f a complete polymorphism and linkage disequilibrium map o f the whole 
region in a large sample set, and thereby excluding regions where a causal variant is 
unlikely to exist.
A rgllOGln has known functional effects with upregulation o f IL-13 activity 
demonstrated in vivo [25, 118]. Functional studies show that this may be due to 
decreased affinity o f the minor variant for the decoy receptor IL-13R2. This receptor is 
part o f a complex feedback loop involved in controlling IL-13-dependent responses, 
acting as a key negative regulator o f IL-13 (by binding the cytokine with high affinity) 
whilst IL-13 itself enhances decoy receptor expression. The minor variant was more 
active than wild-type IL-13 in inducing STAT6 phosphorylation and CD23 expression 
in monocytes and hydrocortisone-dependent IgE switching in B cells [118].
No associations with clinical phenotype were demonstrated for the IL13 promoter 
polymorphisms. The -1512A/C SNP has not previously been examined in association 
with asthma. However, the -1024C/T SNP has been associated with asthma in Dutch, 
German and African-American case-control populations [12, 114, 135, 141], although 
not in an Icelandic population [136]. This could be postulated to be due to the strong LD 
observed previously between this promoter SNP with ArgllOGln in the German 
population [113], but not in our population. However, LD was not observed between 
these variants in the Dutch population [114] and the lack o f  association in our 
population may be due to the -1024C/T variant not been clinically relevant at the 
population level, or due to differences in allele frequencies between British and Dutch 
populations.
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This is the first time the Ile50Val variant o f IL4RA has been found to be associated with 
asthma at the population level, having been previously reported in Japanese case-control 
studies [119, 155]. A gene-dosage effect was observed, with increasing odds o f asthma 
for each Valine allele. However in contrast, the Japanese studies found Ile50 to confer 
asthma risk, whereas Val50 was associated with increased risk in our study, 
emphasising that susceptibility loci may differ in diverse ethnic populations (and 
discussed further in Chapter 6). Furthermore, Ile50 differs in frequency between 
populations, for instance reported at 59% vs 41% in European and Japanese populations 
respectively [119, 252] and the association between IL4RA gene polymorphisms, its 
haplotypes and asthma have been noted to vary between different Asian populations 
[152]. Interestingly, Risma et al reported that the Val50Arg551 haplotype was 
associated with allergic asthma and enhanced IL-4R function [14]. Kabesch et al did not 
find an association when the Ile50Val variant was examined singly in a German 
population [12] and several case-control studies have reported negative findings (Table 
1.2). This thesis clearly demonstrates that the Val50 allele confers an additive effect for 
asthma risk at the population level in a British Caucasian population.
This thesis describes a novel association with asthma at the population level for the 
STAT6 3 ’UTR variant G2964A, which demonstrated the highest odds ratio for asthma 
(2.21, Cl 1.17-4.18). Only one Japanese case-control study has previously reported a 
positive association for this (or any other) STAT6 variant with asthma [124], with recent 
data showing association on haplotype analysis [82], and negative findings in other 
diverse populations on single polymorphism analysis [124, 127, 168]. In contrast to our 
population, the G/G genotype (rather than A/A) related to mild atopic asthma in the 
Japanese population. This may be due to ethnic differences in allele frequency and risk 
susceptibility and it is worth noting also that 2964G/G was only associated with mild 
atopic (rather than marked atopic) asthma in the Japanese and no association was found 
in the British population [124]. Kabesch et al reported negative findings in a German 
unselected population for the C2892T promoter SNP which is in strong LD with 
G2964A [12]; our study confirmed these negative findings in a British population.
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With regard to our findings o f increased asthma susceptibility conferred by IL4RA- 
Val50 and STAT6-2964A, there are now several examples o f established associations 
with different functional variants within the same gene or with opposite alleles at the 
same SNP in different populations [11]. Cameron et al found that the 7Z/3-1024T allele 
enhanced IL13 promoter activity but only in the context o f Th2 differentiation [116]. 
Thus it can be speculated that seemingly contradictory results for specific alleles in 
different populations may in some cases be the result o f complex interactions between 
genes (their transcription and the actions o f their products) and the environmental 
milieu.
It is perhaps surprising that only the STAT6 3’UTR variant G2964A associated with 
asthma, whereas this SNP (and almost all STAT6 SNPs) are in strong LD with the other 
STAT6 SNPs. However, a biological role for this variant is suggested by highly 
consistent associations for this SNP demonstrated in addition for current eczema and 
hayfever in this population, and the high odds ratio found. The highest odds ratio was 
demonstrated between this SNP and current eczema (2.62, Cl 1.40-4.89). Associations 
with eczema and hayfever were only demonstrated at the STAT6 locus, for the G2964A 
polymorphism, and these associations are novel. Only one previous Japanese case- 
control study has examined this variant in association with eczema (a composite o f 
“allergic diseases” was examined), with negative findings [125]. This variant has not 
previously been examined in relation to hayfever/allergic rhinitis. There are few reports 
o f IL-13 signalling variants being examined in the context o f rhinoconjunctivitis: an 
association has been reported between IL-4RA Ile50Val and Japanese cedar pollinosis 
and Ser478Pro showed a trend towards a protective effect against allergic rhinitis [149, 
156]. Whilst our study did not specifically document an atopic component for 
hayfever/eczema, previous epidemiological studies show these definitions to be robust 
markers for atopic rhinitis/atopic dermatitis [253, 254]. We examined total IgE levels 
separately since this is more robust than using a composite clinical/IgE score where the 
parameters are likely to be under different genetic influences [255,256].
Populations o f different ethnic origin have been observed to have different allele
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frequencies for many genes, which provides one explanation for non-replication of 
genetic association in different populations. For instance, the observation o f differential 
allele frequency and disease association for STAT6 G2964A emphasises the genetic 
heterogeneity o f atopic disease, even within one locus in different ethnic groups [124, 
257]. Whilst founder effects and genetic drift may account for some o f these 
differences, consistent observations have been made relating to IL-13 signalling 
pathway genes, suggesting that evolutionary pressures may also be important [86].
Whilst asthma is a genetically heterogenous disease, findings from this study, and 
across ethnically diverse populations, support a role for IL-13 signalling variants in 
asthma and atopy susceptibility. When examining IL13 haploblock structure across 
ethnic groups, investigators have shown a significant excess o f high frequency-derived 
SNPs in Caucasian and Chinese populations suggesting a positive selection effect [249]. 
Conserved regions o f  the gene are likely to confer some evolutionary advantage and 
there is evidence that Th2 variants conferring asthma/atopy susceptibility may have 
arisen due to their evolutionary protection against worm infestation [82, 84, 86]. The 
STAT6 variant G2964A and IL13 variant -1024C/T, both associated with asthma, have 
been shown to be protective against ascaris and schistosoma infestation respectively and 
the survival advantage conferred may explain the persistence o f these alleles in the 
population. Moller et al recently reported that STAT6 haplotypes relate to IgE levels, 
allergy and worm burden, with a cross-population comparison in Chinese and British 
subjects showing that haplotypes relating to low worm burden/high IgE confer 
increased risk o f asthma and allergic disorder [82]. Since genes exhibit pleiotropy, 
having multiple roles within living organisms, it is entirely plausible that alleles 
conferring advantage in one system may confer disadvantage when different 
environmental pressures apply. Thus Th2 immune variants offering protection against 
helminth infestation in non-western environments, confer increased susceptibility to 
asthma and associated Th2 allergic disease in the context o f a western environment.
This thesis suggests that genetic variation at the IL13, IL4RA and STAT6 loci is 
implicated in asthma and atopy susceptibility. In particular, identification o f the
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underlying mechanisms remains difficult for IL13 due to the extended haploblocks in 
chromosome 5q31 and requires clarification by functional studies. Moreover this region 
has been found to show a high level o f diversity across different ethnic populations, 
emphasising the importance o f determining allele frequencies and analysing haplotype 
structure across ethnically and geographically diverse populations. This has important 
implications for the HapMap initiative, which is based on the premise that it will be 
possible to identify a common pattern o f  haplotype structure (and htSNPs) for gene 
mapping studies across geographic regions [258].
The definition o f asthma gives rise to difficulties since the term encompasses a 
heterogenous spectrum o f disorder rather than a single clinical entity. The diagnosis can 
be difficult to make clinically at a single timepoint and is usually made over a period of 
observation, based on symptoms, peak flow lability and bronchodilator reversibility. For 
the purposes o f epidemiological study, the definition o f ‘physician-confirmed asthma’ is 
regarded as robust and the bronchial symptoms IUATLD questionnaire (similarly the 
ISAAC questionnaire in children) has been validated and widely used in asthma 
research [233-235]. Given the age range o f this study, the majority o f volunteers with 
asthma are likely to have atopic asthma. Oryszczyn et al found in a recent 
epidemiological study that almost 90% o f  their asthmatic subjects had a co-existing 
marker for atopy, and in our younger population, we found co-existent hayfever and 
eczema in 63.1% and 19.9% o f asthma subjects respectively [259]. The data on clinical 
atopy, in addition to quantitative markers o f  Th2 immunity and lung function provided 
comprehensive additional phenotypic information.
There are inherent difficulties in obtaining a truly random sample representative o f the 
general population, which apply to any epidemiological study. An advantage o f  this 
study was that volunteers were recruited from one particular city rather than being 
recruited via hospital clinic or family members with the associated potential 
confounding effects therein, and the study was inclusive o f all volunteers within the 
stated age range.
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It is possible that the nature o f the recruitment process may have enriched the 
population for those with asthma and smokers. However, the prevalence o f current 
asthma and smoking was not higher than expected in a young adult (predominantly 
student) population, at 10.9% and 16.9% respectively. Furthermore, many fit non- 
smokers were keen to participate in order to obtain a measure o f their health status, and 
conversely, some students with asthma declined to take part since they felt they did not 
wish to perform further testing; effects which are likely to counterbalance any potential 
enrichment o f the population described above. Since this was not a study designed to 
test the prevalence o f asthma or smoking, potential enrichment o f the sample is not 
relevant, and smoking was adjusted for in the statistical analysis.
Since the selected 22 SNPs span the three loci, it is unlikely that important associations 
were missed. It is possible that observed associations were the result o f non-genotyped 
SNPs in LD with selected SNPs, but this seems unlikely given the consistency of 
results, and gene coverage achieved. Results o f haplotype analysis also showed these 
particular SNPs to be mainly responsible for the haplotype results, as described in 
Chapter 6. The possibility o f extended LD beyond the examined loci cannot be excluded 
and has been previously reported [260].
This thesis examined non-coding region polymorphisms in addition to the coding 
variants traditionally thought to be o f paramount importance. The observations 
presented here indicate a contributory role for a non-coding variant o f STAT6 in asthma 
and associated atopic conditions. Emerging evidence suggests that SNPs in non-coding 
regions may have important functional activities in gene regulation and expression. A 
3’UTR polymorphism in the E-Cadherin Gene has recently been found to be associated 
with primary open angle glaucoma [261]. It is o f note that G2964A is located in a C- 
rich region o f the 3 ’UTR regulatory elements o f STAT6, where there is increasing 
evidence that these elements regulate gene expression in a variety o f ways, including the 
determination o f mRNA transcript half-life [262]. The next step will be functional 
studies to unravel the biological role o f this non-coding variant, and determine the 
underlying basis o f the association with asthma and clinical atopy.
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CHAPTER 4
Genetic association of single nucleotide 
polymorphisms with Th2 immune 
phenotypes
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4.1 Introduction
The asthmatic response is characterised by elevated production o f IgE, cytokines, 
chemokines, eosinophilia, mucus hypersecretion, airway obstruction, and airway hyper­
responsiveness to allergens. Clinical and functional studies have shown a strong 
correlation between the presence o f  CD4+ Th2 cells, eosinophils, and disease severity, 
suggesting a crucial role for these cells in the pathophysiology o f asthma. Although 
recently it has become apparent that the Thl/Th2 paradigm is insufficient to completely 
explain the underlying basis o f allergic disease, Th2 cells are recognised to be critical to 
the development o f allergic responses [263].
Th2 cells induce asthma through the secretion o f specific cytokines, in particular IL-13 
and IL-4, which activate inflammatory and residential effector pathways both directly 
and indirectly. IL-13 has been shown to induce a complex array o f  genes in resident 
airway cells (smooth muscle cells, fibroblasts, epithelial cells and 
monocyte/macrophages) independently o f  traditional effector cells such as mast cells 
and eosinophils. Effector cells contribute to disease via their ability to produce IL-13 in 
response to IL-13-induced mediators, thus perpetuating the allergic response and 
leading to disease chronicity [9]. The importance o f early life immunomodulatory 
effects on asthma inception is demonstrated by easily detected levels o f IL-13 in the 
placenta and the secretion o f IL-13 by neonatal T cells [118].
Experimental work has shown chemokines to have an important role in the allergic 
inflammation characteristic o f asthma and related atopic disease, mediated by their 
functions as potent leukocyte chemoattractants, cellular activating factors, and 
histamine-releasing factors. Recent evidence points to the role o f the eotaxin subfamily 
o f chemokines and their receptor CC chemokine receptor 3 (CCR3) in promoting IL-13- 
associated Th2 allergic responses. Epithelial and endothelial cells express eotaxin-1 
while its receptor, CCR3 is highly expressed on eosinophils [264]. IL-13 upregulates 
eotaxin expression in the airway -  which is increased in asthmatics - by STAT6 
dependent mechanisms [265,266].
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The main role o f eotaxin is as a potent attractant for eosinophils, which are the main 
effector cells in airway inflammation, and an important cellular source o f IL-13 [267]. 
Recent murine studies o f gene deletions eliminating eosinophils emphasise their role in 
asthma [268]. Transgenic mice over-expressing IL-13 have a marked increase in 
eotaxin-1 along with other characteristics o f asthma including eosinophil infiltration 
[269]. A complex integrated pathway exists whereby IL-13 promotes inflammation 
partly by induction o f eotaxin-1, which provides regulatory feedback on IL-13 
production, directly via eosinophils and indirectly via Th2 cells [270]. Eotaxin-1 can be 
regarded as a downstream effector molecule o f the IL-13 pathway, with roles including 
eosinophil recruitment, activation and degranulation [270]. This thesis considers total 
IgE, eotaxin-1 (CCL11) levels and eosinophil counts as the primary Th2 immune 
phenotypes in asthma and related atopic disease.
Events mediated by IgE are integral to allergic reactions and induction o f IgE is likely 
to be critical to the role o f IL-13 signalling variants in asthma and atopy. Isotype class 
switching from IgM to IgE is a result o f the activation o f the IL-4/IL-13 cytokine 
pathway and genetic variants within this pathway may influence the regulation o f IgE 
levels. STAT6 activates germline transcription from the epsilon heavy chain gene locus, 
and induces isotype switching in B cells (in combination with signals from the B cell 
surface molecule CD40) and activates other genes involved in IgE production [271]. 
Genetic susceptibility to heightened IgE responses is likely to be caused by a pattern of 
polymorphisms in several genes involved in Th2 immunity.
Association studies have suggested that IgE levels are under genetic control but case- 
control studies have shown conflicting results for many common variants o f IL-13 
signalling [117, 121, 145, 152]. There have been very few studies on unselected 
populations to test whether these variants confer risk o f higher IgE levels in a general 
population. Studies in British and German populations have found that some o f these 
variants confer susceptibility to higher IgE levels at a population level [12, 129, 132]. 
This chapter describes the largest unselected study to date, to examine the role o f
variants o f IL13, IL4RA and STAT6 in relation to IgE regulation, and the only study to 
examine these IL-13 signalling variants with relation to the additional Th2 immune 
phenotypes o f eosinophil counts and eotaxin levels.
4.2 Methods
An unselected population o f 1614 adults aged 18-30 years was recruited according to 
the Methodology outlined in Chapter 2. Genotyping results are reported on the 
Caucasian group (n=1445). Serum total IgE (klU/L) was measured by ELISA-type 
sandwich assay and plasma eotaxin (pg/ml) was measured using ELISA (BD OptEIA™, 
BD Biosciences) as outlined in Chapter 2. Eosinophil counts were measured by 
automated analyzer, providing a five part differential o f  the white cell count, as outlined 
in Chapter 2. Genotyping was performed for a total o f 22 polymorphisms at the IL13, 
IL4RA and STAT6 loci (see Chapter 2 for further detail). The analysis o f the association 
between genotype/phenotype took the form o f a series o f standard linear regression 
models, with adjustment made for relevant covariates (age, sex, smoking, height etc). 
Linear regression analysis was performed using SPSS 13.0. Since IgE, eosinophil 
counts and eotaxin were not normally distributed, statistical analysis was performed on 
log-transformed values. The phenotype data were analysed as continuous variables on a 
logarithmic scale, as ln(x+l) to overcome errors when levels were undetectable and thus 
counted as zero. Analysis o f continuous data was chosen, rather than choose a widely 
used arbitrary cutoff such as 100 klU/L for IgE, because continuous data may much 
better resemble the distribution o f immune markers in the population.
4.3 Results
4.3.1 Population characteristics
The Caucasian group for this analysis consisted o f 1445 subjects. O f the Caucasians, 
subjects reporting “smoking for as long as a year” represented 27.7% o f the population 
(n=399) with 17.6% reporting current smoking (n=253). Current asthmatics had
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significantly higher total IgE and eosinophil counts, after adjusting for relevant 
covariates (p<.001) but not higher levels o f eotaxin (Table 4.1).
Table 4.1 Baseline characteristics o f study participants.
Current asthma1 “Never asthma”
IgE (klU/L) 113 (91-141)2 41 (38-45)
Eosinophil count (cells x l0 9/L) 0.24 (0.22-0.27)2 0.17(0.16-0.18)
Eotaxin (pg/ml) 11.5 (8.9-13.9) 2 12.5(11.6-13.5)
“Asthma” refers to a subjective report o f physician diagnosed asthma. 
2 Geometric mean (95% confidence interval, Cl).
Males had higher total IgE, eotaxin levels and eosinophil counts (p<.001). Current 
smokers had higher eosinophil counts (p=.001) but not significantly higher total IgE nor 
eotaxin (Table 4.2). However smoker pack years were related to eotaxin (p=.036). A 
small increase in total IgE levels with increasing age was observed (p=.004, beta=.04) 
per year but not between age and eosinophil count and o f borderline significance for 
eotaxin (p=.052). Height was not associated with total IgE nor eosinophil count but was 
associated with eotaxin (p<.001) where it is likely to act as a marker for sex. Relevant 
covariates were included in the linear regression models and interactions examined.
Table 4.2 Mean total IgE, eotaxin and eosinophil count according to sex and smoking 
status.
Males
Females
Geometric mean total IgE (klU/L)
55
37
95% Cl
49-62
33-42
P value 
<.001
Geometric mean eotaxin (pg/ml) 95% Cl P value
Males 15.0 13.7-16.4 <.001
Females 9.9 8.9-11.0
Geometric mean eosinophil count 
(cells x109/L)
95% Cl P value
Males 0.20 0.19-0.21 <.001
Females 0.17 0.16-0.18
Smokers 0.21 0.19-0.22 .001
Non-smokers 0.18 0.17-0.18
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4.3.2 Linear regression analyses
Genetic associations with total IgE 
IL13
After adjusting for sex, age and height, the association between the 3’UTR SNP 6 and 
IgE just reached significance (p=.048), due largely to the difference between the G/T 
and G/G group (p=.014) (Figure 4.1). The heterozygotes had the highest IgE levels: T/T 
(42, 95% Cl 28-67), G/T (54, 95% Cl 47-64), G/G (42, 95% Cl 40-48). Data are 
presented in two categories since the number in the T/T group was small (n=44). Due to 
associations in other populations, SNP 10, SNP 1 and SNP 5 were examined in more 
detail. No significant association with IgE was seen for SNPs 1 (-1024C/T) and 5 
(Argl lOGln). For SNP 10 (-1512A/C), there was a trend towards a higher IgE level for 
heterozygotes A/C compared to A/A homozygotes, with p=.048 before adjustment and 
p=.064 after adjustment for sex, height and age.
T/T and G/T G/G
Figure 4.1 Mean IgE at 3’UTR SNP 6 o f IL13.
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IL4RA
Three of the IL4RA variants showed strongly significant associations with IgE. These 
were intronic SNP 8, Arg551Gln (SNP13) (Figure 4.2) and the 3’UTR SNP 16, shown 
in Table 4.3. A codominant mode o f inheritance was observed, with heterozygotes 
having intermediate levels compared with both homozygote groups.
A/A G/A G/G
Figure 4.2 Mean IgE at Arg551Gln SNP 13 o f IL4RA.
STAT6
Significant associations with IgE were seen at the 3‘UTR SNP 3 and intronic SNP 8, 
shown in Figure 4.3 and Table 4.3.
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C/C CAT T/T
Figure 4.3 Mean IgE at STAT6 intronic SNP 8 (C2892T).
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Table 4.3 Mean IgE level at IL13, IL4RA and STAT6 loci.
Location Genotype Mean IgE 
(klU/L)
95% Cl P
value1
IL13
SNP 6 3’UTR T/T 42 28-67 .048
rs848 G/T 54 47-64
G/G 43 40-48
IL4RA
SNP 8 Intron 8 A/A 50 46-55 .011
rs2891058 A/G 37 32-45
G/G 33 19-60
SNP 13 Exon 12 A/A 51 47-57 .001
rsl801275 A/G 42 37-49
Arg551Gln G/G 26 18-40
SNP 16 3’UTR T/T 50 45-56 .006
rs1049631 C/T 38 34-46
C/C 30 17-55
STAT6
SNP 8 Intron 2 T/T 61 50-75 .007
rs324011 C/T 45 41-51
C/C 41 37-49
SNP 3 3’UTR A/A 50 46-56 .001
rs 1059513 A/G 34 30-42
G/G 38 20-75
1 After adjusting for relevant covariates, see Table 4.4.
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Table 4.4 Final models o f genetic associations for total IgE after considering relevant 
covariates (sex, smoking, age, height if  significant at 5% level)1_____________________
Location Outcome P value
IL13
SNP 6 3’UTR IgE .0561
SNP 6 + sex + age + height .0482
IL4RA
SNP 8 Intron 8 IgE .007
SNP 8 + sex + age + height .011
SNP 13 Exon 12 IgE .001
SNP 13 + sex + age + height Arg551Gln .001
SNP 16 3’UTR IgE .005
SNP 16 + sex + age + height .006
STAT6
SNP 8 Intron 2 IgE .009
SNP 8 + sex + age + height .007
SNP 3 3’UTR IgE .001
SNP 3 + sex + age + height .001
Overall p value at this locus before considering relevant covariates. 
2 p value after adjusting for relevant covariates.
Genetic associations w ith eosinophil count
Associations with eosinophil count for the IL4RA variants are summarised in Tables 
4.5-4.6. There were no significant genetic associations with eosinophil count for IL13 
and STAT6 variants.
Table 4.5 Genetic associations with eosinophil count.
Location Outcome P value
IL4RA
SNP 3 Promoter Eosinophil count .035
SNP 3 + sex + smoking .030
SNP 5 Exon 5 Eosinophil count .024
SNP 5 + sex + smoking Ile50Val .020
SNP 12 Exon 12 Eosinophil count .031
SNP 12 + sex + smoking Ser478Pro .032
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Table 4.6 Geometric mean eosinophil count for IL4RA genotypes.
Location Genotype Geometric mean 
eosinophil count 
(cells x 109/L)
95% Cl P value1
IL4RA
SNP 3 Promoter G/G 0.19 0.17-0.21 .030
A/G 0.18 0.16-0.21
A/A 0.17 0.15-0.18
SNP 5 Exon 5 V/V 0.20 0.18-0.21 .020
Ile50Val V/I 0.18 0.17-0.20
I/I 0.17 0.16-0.19
SNP 12 Exon 12 A/A 0.17 0.15-0.19 .032
Ser478Pro A/G 0.18 0.17-0.20
it : ,
G/G 0.19 0.18-0.21
P value after adjusting for relevant covariates.
Genetic associations w ith plasm a eotaxin
Genetic associations with eotaxin are illustrated in Table 4.7. For IL13, there was an 
association between intronic SNP 7 and eotaxin (p<.05). An association was 
demonstrated between STAT6 3 ’UTR SNP 1 and eotaxin levels (p<.05). These 
associations were adjusted for sex.
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Table 4.7 Geometric mean eotaxin for genotypes of IL13 and STAT6 variants.
Location Genotype Geometric 
mean eotaxin 
(pg/ml)
95% Cl P value1
IL13
SNP 7 Intron 1 C/C 12.9 11.9-13.9 .048
A/C 10.7 9.0-12.7
A/A 7.0 3.0-15.1
STAT6
SNP 1 3’UTR A/A 14.8 10.8-20.2 .047
A/G 11.0 9.7-12.3
G/G 13.1 11.9-14.4
P value after adjusting for relevant covariates.
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Table 4.8 Summary o f significant associations o f IL13 signalling variants with 
immune phenotypes.
Location IgE 
P value1
Eosinophil count 
P value1
Eotaxin 
P value1
IL13
SNP 7 
rs2066960
Intron 1 .048
SNP 6 
rs848
3’UTR .048
IL4RA
SNP 3 
rs2283563
5’UTR .030
SNP 5 
rs1805010
Exon 5 
Ile50Val
.020
SNP 8 
rs2891058
Intron 8 .007
SNP 12 
rs1805015
Exon 12 
Ser478Pro
.032
SNP 13 
rsl81275
Exon 12 
Arg551Gln
.001
SNP 16 
rs 1049631
3’UTR .005
STAT6
SNP 8 
rs324011
Intron 2 
C2892T
.009
SNP 1 
rs324015 
SNP 3 
rsl059513
3’UTR
3’UTR .001
.047
1 P value after adjusting for relevant covariates.
4.4 Discussion
Highly significant associations (p<.01) with total IgE levels were seen at the IL4RA and 
STAT6 loci, rather than at IL13. A significant association was demonstrated between
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Gln551 and higher IgE levels, having been observed previously in a German case- 
control study [121], but with many case-control reports o f negative findings (see Table 
1.3). A gene-dosage effect was observed, with increasing IgE levels for each A allele. 
Our study has replicated findings from the only other unselected population study to 
examine this association, where Gln551 was associated with higher IgE in the British 
1958 Birth Cohort, with stronger associations and higher IgE levels observed in our 
population [132].
Associations were demonstrated for 1L4RA intron and 3’UTR variants which do not 
appear to have been previously examined in genetic association studies and whilst these 
variants were not in strong LD with the Arg551 variant, it is possible that these 
associations might be due to LD between these variants and alternative variants which 
were not examined. On individual SNP analysis, Ile50Val and Ser478Pro variants do 
not appear to be important in IgE regulation, which confirms findings from large 
unselected [12, 132] and smaller (partially unselected) studies [137]. Haplotype analysis 
indicated that associations with IgE focus on Arg551Gln but also suggested that 
Ile50Val may have a contributory role and these data are presented in Chapter 6.
This thesis provides the largest unselected study to date o f the association between IL- 
13 signalling variants and asthma and atopy phenotypes. Confirmation was found for 
the association between STAT6 cis-regulatory element and 3’UTR variants (rs324011 
and rs 1059513) with IgE levels, previously documented in German populations [127- 
129]. Although these are non-coding variants, they are likely to be o f functional 
importance. The function o f the 3’UTR o f eukaryotic genes is not yet fully understood. 
Human diseases such as myotonic dystrophy arise as a result o f 3’UTR variation. 
Variants in the 3’UTR region have been shown to affect gene expression by influencing 
translation, coding capacity, mRNA stability and localisation o f RNA in the cytoplasm 
and therefore may have biological relevance [272, 273]. The 3 ’UTR affects protein 
binding but may also exert its effects in its binding with short RNA [274].
Schedel et al proposed that carriers o f  the T allele for the 3 ’UTR variant would have
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larger amounts o f STAT6 mRNA available for translation due to increased stability, and 
thus increased STAT6 availability for intracellular signalling and induction o f IgE 
[128]. Variant rs324011 is located in the cis-regulatory element o f intron 2, where it is 
positioned within the matrix o f one o f two transcription binding sites which are in close 
proximity. Thus a SNP here may alter the binding o f NF-kB and therefore have 
important effects on STAT6 transcription. Moreover, although STAT6 is central in 
controlling the IgE germline gene promoter, NF-kB has synergistic effects, and the 
presence o f two NF-kB sites within intron 2 suggests feedback regulation between these 
two transcription factors [275]. Schedel et al found that this SNP was much less well- 
preserved in human DNA compared with primates, suggesting a functional role for this 
polymorphism [128]. Since both STAT6 SNPs are in strong LD, it is proposed that it is 
the cis-regulatory SNP which is o f  primary functional importance although further 
expression analysis studies are needed for confirmation.
Given the strong associations o f STAT6 3 ’UTR variant G2964A with clinical atopic 
disease in this study, it was unexpected that an association was not seen with IgE levels, 
although it is o f note that no investigators have found a positive association with IgE for 
this variant. This suggests that total IgE levels are controlled by different sets o f 
polymorphisms than clinical atopy per se, which will be influenced to a greater degree 
by environmental factors including allergen exposure and early sensitisation. Previous 
work points to IgE levels being under greater genetic control than clinical 
manifestations o f atopy [255, 256]. Total IgE and eosinophil counts are likely to 
represent the most useful immunophenotypes in this random population since eotaxin 
levels may be more dependent on clinical status at the time o f testing, being induced 
early in the allergic response [270].
This thesis does not confirm some previously documented associations between 1L13 
variants and IgE levels in British and German populations o f adults and children 
respectively [12, 132]. The only IL13 variant showing an association with IgE in our 
study was the 3 ’UTR variant rs848, which was in strong LD with ArgllOGln. 
Heterozygotes had the highest IgE levels, mirroring the highest odds o f asthma for the
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heterozygotes also, and this is discussed further in Chapter 6. For promoter 
polymorphism -1512A/C, there was a trend towards A/C heterozygotes having higher 
IgE than A/A homozygotes which may have been significant in an even larger study. 
The main explanation for the inconsistency with the German data was that the German 
study only examined very high IgE levels i.e. a more extreme phenotype (IgE >90* 
centile; 457 klU/ml), whereas in our study IgE was examined as a continuous variable.
We did not replicate associations between 1L13 SNPs and total IgE levels reported in 
the 1958 British Birth Cohort [132]. Explanations for the non-replication o f genetic 
association include differential exposure to environmental factors, heterogeneity in 
allele frequencies, true differences in IgE associations between populations, 
ascertainment bias, different methodology and classification o f  outcome and the use of 
inadequate sample size to detect a true effect. The study population was a similar British 
Caucasian population to the British Birth Cohort. However environmental factors may 
differ between the populations, and for the Birth Cohort, IgE was measured at the ages 
o f 45/46 years rather than an average age o f  21 years in our study. This is a possible 
explanation since in our study, a small increase in IgE levels with increasing age was 
observed, and environmental factors are also likely to be important since twin studies 
report 40% o f the variance in IgE to be due to environmental factors [276]. Whilst 
genotype is unchanged, differential gene expression will be influenced by 
environmental factors. It is also possible that our study o f 1445 Caucasians was 
insufficiently large to detect a modest effect o f IL13 on IgE levels. Although no 
significant associations were observed when IL13 variants were examined in isolation, 
highly significant associations were demonstrated for a risk haplotype containing the 
previously described promoter and coding IL13 risk variants and these data are 
presented in Chapter 6.
Our data are in concordance with the findings o f  Heinzmann et al who found A rgl30 to 
be associated with asthma rather than IgE in British and Japanese case-control 
populations [117]. Furthermore, Arima et al found that a recombinant G lnl30 variant 
did not alter STAT6 activation, induction o f germline transcripts, or IgE synthesis,
114
although there was a lower affinity with a decoy receptor IL-13RA2, leading to reduced 
clearance [25]. Moreover, our data are consistent with the emerging paradigm whereby 
IL-13 has been shown to induce allergic responses via resident airway cells rather than 
through traditional effector pathways involving eosinophils and IgE-mediated events 
[9].
Eosinophils have been measured in few studies examining the IL-13 signalling pathway 
[110, 134, 159]. In this thesis, weak associations were observed for IL4RA variants -  a 
promoter variant and two coding variants. The positive associations for Ile50Val and 
Ser478Pro and lack o f association for Arg551Gln are in contrast to findings from a 
Korean case-control study [159]. The association with the promoter variant rs2283563 
may have been due to the strong LD between this SNP and Ile50Val but it is not 
possible to exclude an individual biological effect for this variant. It should be noted 
that although the results reported are statistically significant, the magnitude o f the 
difference between mean eosinophil counts by genotype was small. We found no 
associations for IL13 variants with eosinophil count. For IL13, Japanese and American 
investigators have reported associations for promoter variants -1512A/C and 
A rgllOGln, with negative findings for promoter variant -1024C/T and ArgllO G ln (in 
the Japanese) [110, 134]. STAT6 variants have not previously been examined in relation 
to eosinophils in an unselected population study. Only one published study has 
examined STAT6 in relation to eosinophils, in a sib-pair design, and similarly to our 
unselected population, found no positive associations with the STAT6 locus [127].
The Th2 cytokines EL-13 and IL-4 are potent inducers o f epithelial cell expression o f the 
chemokine eotaxin. Eotaxin can be regarded as an effector molecule for the IL-13 
signalling pathway and this study examined whether genetic variants o f IL-13 signalling 
had effects on plasma eotaxin levels. This is the first time IL13, IL4RA and STAT6 
variants have been examined with respect to eotaxin. Associations observed for an 
intronic IL13 SNP and STAT6 3 ’UTR G2964A variant with eotaxin levels were o f 
borderline significance and must be interpreted with caution, but serve as hypothesis- 
generating observations. O f particular interest was the association with G2964A in
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STAT6 since this SNP showed a significant association with asthma, eczema and 
hayfever, although not with total IgE levels. Thus it may be speculated that the clinical 
effects o f this STAT6 variant may be mediated by mechanisms other than IgE induction.
In conclusion, these data indicate that Th2 immune phenotypes (IgE, eosinophils and 
eotaxin) are under the genetic influence o f variants in IL-13 signalling, with different 
patterns o f variants influencing specific phenotypes. The data presented here indicate 
that genetic variations in IL4RA and STAT6 contribute significantly to the regulation o f 
total IgE levels in British adults, which have been shown to be under strong genetic 
control in segregation analysis. O f the immune phenotypes examined, total IgE levels 
appear to be under the strongest genetic influence. Novel associations were 
demonstrated and robust confirmation o f previously documented associations between 
STAT6 SNPs and IgE was provided. The study provides new evidence for the effect of 
Ile50Val on eosinophil count.
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CHAPTER 5
Genetic association of single nucleotide 
polymorphisms with physiological phenotype
and asthma severity
117
5.1 Introduction
Few genetic association studies have attempted to examine lung function, and in 
particular, there is a paucity o f data testing the physiological effects o f genetic variants 
at the population level. A small number o f studies have examined the role o f IL-13 
signalling variants in asthma severity [164, 165, 277] but there are no published studies 
on the effects o f  these variants on more detailed measures o f lung function, nor on the 
predictive effects o f these variants in an unselected population. Pulmonary function may 
be used to categorise the severity o f asthma, in terms o f percentage predicted FEV1 and 
PEF. Asthma severity may be categorised as “mild”, “moderate” or “severe” by FEV1 
(or PEF) o f >80%, 60-80% and <60% respectively.
The first study to examine the association between a genetic marker and asthma severity 
found that Caucasians with the IL4 589T/T genotype had a 4.5% lower predicted FEV1 
than C/C individuals [278]. Two studies have demonstrated a correlation between the 
R576 coding variant o f IL4RA and asthma severity in terms o f baseline FEV1 [165], 
although numbers o f asthmatic subjects were small in one study (n=60) [164]. A 
Swedish study found IL4RA haplotypes to be associated with asthma severity in terms 
o f % predicted PEFR [277].
Smokers with the IL4RA 576R/R genotype have been shown to have a more rapid 
decline in lung function (FEV1) (odds ratio, 2.24; P = 0.043) and this decline was more 
significant in subjects who also had either the IL13 110R/R or -1024T/T genotypes 
[140].
This thesis examined the effects o f IL-13 signalling variants on lung function in an 
unselected population and a subgroup analysis was undertaken to examine whether 
these genetic variants had an impact on asthma severity in terms o f  lung function.
5.2 Methods
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Morning spirometry (before noon) was performed by standardised protocol [239], using 
a dry spirometer (Vitalograph, Buckingham, UK). Spirometry was undertaken by one 
researcher for the majority o f cases and supervised by the same researcher for the 
remainder (GD) in order to minimise inter-observer variation. Measurements included 
Forced Expiratory Volume in 1 second (FEV1), Forced Expiratory Flow at 25-75% of 
expired vital capacity (FEF 25-75), Forced Vital Capacity (FVC), FEV1/FVC ratio and 
Peak Expiratory Flow (PEF). The best value o f three manoeuvres was expressed as an 
absolute and percentage o f the age-gender-stature predicted value. If  on inhaler 
treatment for asthma, measurements were taken before the morning dose. Genotyping 
was completed as outlined in Chapter 2.
A subgroup analysis was undertaken on subjects with a current physician diagnosis of 
asthma to examine the effect o f genotype on physiological and clinical severity. Asthma 
severity was quantified by the following measures:
1. Clinically categorised into “intermittent”, “mild persistent”, “moderate 
persistent” and “severe persistent” asthma according to GINA criteria, shown in Table 
5.10. Current therapy was accounted for e.g. a subject having intermittent symptoms but 
on “mild persistent” therapy o f low-dose inhaled corticosteroids would be classified as 
having “mild persistent” asthma [50].
2. Lung function: % predicted FEV1; % predicted PEF.
Ordinal regression was applied to identify genotype associations with clinical severity 
categories. Linear regression was applied for continuous lung function data. SPSS 13.0 
was used for statistical analysis. In all cases, adjustments were undertaken for relevant 
covariates.
5.3 Results
5.3.1 Effect of genotype on lung function in an unselected population 
IL13
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There was an association between promoter SNP 1 (-1024C/T) and % predicted FEV1: 
after adjusting for relevant covariates (smoking, BMI), mean %FEV1 was 
approximately 2% lower in the C/C compared with the C/T and T/T group (p=.002) 
(Figure 5.1). This is o f uncertain clinical relevance, but it is worth noting that there was 
no overlap in the 95% confidence intervals here. There was also an association between 
promoter SNP 10 (-1512A/C) and %FEV1 (Figure 5.2). As seen with SNP 1, after 
adjusting for relevant covariates, mean %FEV1 was lower in the C/C compared with the 
C/T and T/T group (p=.007). As noted previously, SNP 10 was in strong linkage 
disequilibrium with SNP 1 in the promoter region (D’=0.93).
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Figure 5.1 Mean % FEV1 by genotype at IL13 -1024 promoter (SNP 1).
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Figure 5.2 Mean % FEV1 by genotype at IL13 -1512 promoter (SNP 10).
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An association was seen between SNP 5 (ArgllOGln) and % predicted FVC such that 
the mean value was lowest in the R/R (Arg/Arg) group (p=.036) (Table 5.1). SNP 13 
was in almost complete LD with SNP 5 (D’=0.99). As expected, a similar association 
was seen between SNP 13 and %FVC (p=.028) (Table 5.2).
Table 5.1 Mean % FVC by genotype at IL13 R11OQ (SNP 5).
Mean %FVC N 95% Cl p value1
R/R 100.4 973 99.7-101.1 .036
R/Q 102.1 399 100.9-103.0
Q/Q 103.0 43 99.7-105.6
Total 101.0 1415
* After adjusting for relevant covariates.
Table 5.2 Mean % FVC by genotype at IL13 3’UTR SNP 13.
Mean %FVC N 95% Cl p value1
C/C 100.4 981 99.7-101.1 .028
C/T 102.1 396 99.5-104.5
T/T 102.9 42 100.0-105.9
Total 101.1 1419
After adjusting for relevant covariates.
IL4RA
There was an association between SNP 12 (Ser478Pro) and PEF with an additive effect 
seen with A/A having the lowest mean PEF (p=.033) (Figure 5.2). A similar association 
was seen for % predicted PEF (p=.026) (Table 5.3).
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Figure 5.3 Mean PEFR by genotype at IL4RA S478P (SNP 12).
Table 5.3 Mean % PEFR by genotype at IL4RA S478P (SNP 12).
Mean 
% PEFR
N 95% Cl p value1
S/S 90.5 413 89.0-92.1 .026
S/P 91.7 687 90.5-92.9
p/p 93.8 323 92.1-95.5
Total
' T  A A ' "  _ . . . . . . . .  A.
91.8 1423
1 After adjusting for relevant covariates.
The 3 ’UTR SNP 16 showed an association with FEF 25-75 such that genotypes C/T and 
T/T had a significantly lower mean value than the C/C group (Figure 5.4). Although 
numbers in the homozygote C/C group were small (n=39), this difference remained 
statistically significant after adjusting for relevant covariates (sex, height, age) (p=.004). 
A similar association was seen with % predicted FEF 25-75, which remained significant 
after adjusting for smoking (p=.004) (Figure 5.5).
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Figure 5.4 Mean FEF 25-75 by genotype at IL4RA 3’UTR SNP 16.
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Figure 5.5 Mean % FEF 25-75 by genotype at IL4RA 3’UTR SNP 16.
There was an association between the intronic SNP 8 and FVC after adjusting for 
relevant covariates (p=.024) (Figure 5.6). There was also an association between this 
locus and FEV1/FVC before adjusting for covariates (p=.036). However, after 
appropriate adjustment for relevant covariates -  which proved to be sex, current 
smoking, BMI, height, age -  the association did not quite reach significance at the 5% 
level (p=.068). The main reason for this was a difference in the distribution o f 
genotypes between males and females: males represented 53.2% o f the A/A group and 
46.9% o f the G/G group. The effect o f sex is described in further detail in the STAT6 
section, where differences were more significant. There was also an association between 
the 3’UTR SNP 16 and FEV1/FVC (p=.026). However this was o f borderline 
significance after adjusting for relevant covariates (p=.051) -  sex, current smoking, age, 
height and BMI - and is described in Appendix VII.
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Figure 5.6 Mean FVC by genotype at IL4RA intron SNP 8.
S T  A T 6
Intronic SNP 11 showed an association with FVC, FEV1, PEF, FEF 25-75 (p<.05 for 
all) before adjusting for relevant covariates. However, sex showed an unexpected non- 
random distribution at this locus which meant that the associations between SNP 11 and 
these lung function parameters were not significant after adjusting for sex. 
Crosstabulation by sex at this locus is shown in Table 5.4. There were approximately 
equal proportions o f males and females in the C/C group but on examining the 
combined C/T and T/T group, 42.3% were female and 57.7% were male.
Table 5.4 Crosstabulation for STAT6 SNP 11 and sex.
C/C C/T T/T
Male 605 (50.9) 135 (59.7) 3 (23.1)
Female 583 (49.1) 91 (40.3) 10 (76.9)
Total 1188 (100) 226 (100) 13 (100)
Data are number (percentage) o f  subjects.
Percentages for combined C/T+T/T group are given in text since only 13 subjects 
in T/T group.
Chi2=.006.
SNP 11 showed an association with % predicted FEF 25-75, after adjusting for smoking 
(p= 036) (Figure 5.7). Mean % FEF 25-75 was 13.8% lower in the T/T group compared 
to the C/C group. Although numbers in the T/T group are small (n=13), the individual 
difference between the T/T and C/C groups remains significant after adjustment for 
smoking (p=.013) and there is a clear difference between confidence intervals.
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Figure 5.7 Mean % FEF 25-75 by genotype at STAT6 intron SNP 11.
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Table 5.5 Summary o f significant physiological phenotype-genotype associations at 
IL13, IL4RA and STAT6 loci in an unselected population.
Location Phenotype p value
IL13
SNP 10 (-1512A/C) Promoter % FEV1 .031'
SNP 10 + smoking3 + BMI .0082
SNP 1 (-1024C/T) Promoter % FEV1 .009
SNP 1 + smoking + BMI .008
SNP 5 (R110Q) Exon 4 % FVC .038
SNP 5 + BMI .036
SNP 13 3’UTR % FVC .028
SNP 13 + BMI .028
IL4RA
SNP 8 Intron 8 FVC .0234
SNP 8 + sex + height + BMI .027
SNP 12 (S478P) Exon 12 PEF .0124
SNP 12 + sex + height + age +BMI .010
SNP 12 % PEF .0064
SNP 12 + smoking + BMI .010
SNP 16 3’UTR FEF 25-75 .0134
SNP 16 + sex + height + age .006
SNP 16 % FEF 25-75 .0064
SNP 16 + smoking .008
STAT6
SNP 11 Intron 18 % FEF 25-75 .034
SNP 11 + smoking .036
2 p value after adjusting for relevant covariates
3 Current smoking.
4 p value for overall association with SNP modelled as a continuous variable 
clear additive effect observed).
(when
5.3.2 Effect of genotype on pulmonary function and clinical severity in asthma
Subjects with current physician diagnosed asthma represented 10.9% o f our population 
(n=176) with a further 12.3% (n=198) having had asthma which had remitted. Subgroup 
analysis o f the “current asthma” group was undertaken to ascertain whether certain 
genotypes were associated with asthma severity. Firstly, lung function, including 
physiological severity criteria (%FEV1, %PEF) was considered. Secondly, GINA 
severity categories were considered [50].
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The majority o f  asthma subjects had mild disease, since this was an unselected 
population sample. Tables 5.6, 5.7 and 5.10 show asthma subjects categorised by 
severity, by %FEV1, %PEF and by GINA criteria whereby severity is categorised by 
symptom frequency and medication usage is taken into account. It can be seen that there 
were few subjects categorised as “severe” in terms o f %FEV1 alone; a greater number 
when categorised by %PEF; and the greatest number when categorised by GINA 
criteria. This is because the GINA criteria takes into account medication usage, so that 
an individual with “mild” disease according to symptoms (or FEV1) would be classified 
as having more severe disease if  taking high dose inhaled steroids to achieve asthma 
control.
5.3.3 Effect o f genotype on lung function and  physiological severity in asthm a 
Baseline characteristics
Tables 5.6-5.7 illustrate asthma severity when classified according to %FEV1 and 
%PEF: the majority o f subjects fall into the “mild” category when using a purely 
physiological definition o f severity (and it should be noted that this does not take into 
account medication usage, in contrast to the GINA severity criteria).
Table 5.6 Asthma severity by % FEV1 in current asthmatics.
Number o f  subjects Percentage
“Mild” 154 (95.7)
FEV11 >80% predicted
“Moderate” 5 (3.1)
FEV1 60-80% predicted
“Severe” 2 (1.2)
FEV1 <60% predicted
Total 161 (100)
Pre-bronchodilator FEV1 taken before morning dose o f inhalers, if  on 
inhalers.
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Table 5.7 Asthma severity by % PEF in current asthmatics.
Number o f  subjects Percentage
“Mild” 130 (80.7)
P E F 1 >80% predicted
“Moderate” 25 (15.5)
PEF 60-80% predicted
“Severe” 6 (3.7)
PEF <60% predicted
Total 161 (100)
Pre-bronchodilator PEF taken before morning dose o f inhalers, if on
inhalers.
5.3.4 G enotype associations w ith severity of airflow obstruction in asthm a
IL13 promoter SNP 10 (-1512A/C) associated with percentage FEV1 in subjects with 
asthma, with an approximately 4% difference between groups, after adjusting for BMI 
(p=.04) (Figure 5.8). BMI was adjusted for since, although percentage FEV1 is height- 
adjusted, BMI acted as a significant covariate (p=.011) above the effects o f height 
alone. The same SNP was also associated with % FEF 25-75, after adjusting for relevant 
covariates (current smoking) (p=.027) (Figure 5.9).
IL4RA intronic SNP 8 was associated with FEF 25-75 and FEV1/FVC after adjusting 
for relevant covariates (sex, height, smoking) (p=.030, p=.034) (Figures 5.10, 5.12). An 
association o f borderline significance was observed for the same SNP with % FEF 25- 
75 (p=.045) (Figure 5.11). The relationship between genotype and FEV1/FVC appeared 
additive, with a decrease in FEV1/FVC o f 3% for each A allele when genotype was 
modelled as a continuous variable (p=.019 after adjusting for relevant covariates). A 
summary o f  genotype associations with severity o f airflow obstruction is shown in 
Table 5.8.
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Figure 5.8 Mean % FEV1 by genotype at IL13 -1512 promoter (SNP 10) in asthma.
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Figure 5.9 Mean % FEF 25-75 by genotype at IL13 -1512 promoter (SNP 10) in 
asthma.
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Figure 5.10 Mean FEF 25-75 by genotype at IL4RA intron SNP 8 in asthma.
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Figure 5.11 Mean % FEF 25-75 by genotype at IL4RA intron SNP 8 in asthma.
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Figure 5.12 Mean FEV1/FVC by genotype at IL4RA intron SNP 8 in asthma.
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Table 5.8 Summary of significant genotype associations with lung function severity in
asthma.
Location Phenotype p value1
IL13
SNP 10 Promoter % FEV1 .037
-1512A/C % FEF 25-75 .027
IL4RA
SNP 8 Intron FEV1/FVC .034
FEF 25-75 .030
1 7 n
% FEF 25-75 .045
After adjusting for relevant covariates.
5.3.5 Effects o f genotypes on clinical asthm a severity
Baseline characteristics
Table 5.9 summarises the clinical characteristics o f the group and Table 5.10 illustrates 
the number o f subjects with asthma o f various clinical severity by GINA criteria. Only 
one subject was taking inhaled cromoglycate, anti-muscarinic, oral methyl xanthine or 
an oral leukotriene antagonist respectively. Only one subject had spent nights in hospital 
over the last 12 months and no subjects had been admitted to ITU in the last 12 months. 
Forty subjects had had to give up days o f work or other activities over the last 12 
months: o f these, the number o f  days lost per month was 1.01 ± 1.30.
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Table 5.9 Summary of clinical characteristics of current asthmatics.
Number o f  
subjects
(Percentage)
Using inhaled short acting beta-2 agonist in last 12 
months
159 (90.3)
Using inhaled long acting beta-2 agonist in last 12 
months
29 (16.5)
Using regular inhaled corticosteroid in last 3 
months
56 (31.8)
Using oral corticosteroids in last 12 months 8 (4.5)
Visiting hospital casualty department because o f 
asthma, shortness o f breath or wheezing in last 12 
months
7 (4.0)
Seen by a general practitioner because o f asthma, 
shortness o f breath or wheezing in last 12 months
99 (56.3)
Seen by specialist because o f asthma, shortness o f 
breath or wheezing in last 12 months
5 (2.8)
Had to give up days o f work/other activities 
because o f asthma, shortness o f breath or 
wheezing in last 12 months
40 (22.7)
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Table 5,10 GINA classification of asthma severity in current asthmatics [50].
Number o f  
subjects
(Percentage)
In term itten t
Symptoms less than once a week 
Nocturnal symptoms not more than twice a 
month
74 (46.0)
M ild Persistent
Symptoms more than once a week but less than 
once a day
Nocturnal symptoms more than twice a month
38 (23.6)
M oderate Persistent
Symptoms daily
Nocturnal symptoms more than once a week 
Daily use o f inhaled short-acting beta2-agonist
29 (18.0)
Severe Persistent
Symptoms daily
Frequent nocturnal asthma symptoms 
Limitation o f physical activities
20 (12.4)
G enotype associations w ith clinical asthm a severity
Associations were seen for two IL4RA variants and clinical severity. These were 
Ile50Val (SNP 5) and promoter SNP 3 (rs2283563) which were in strong linkage 
disequilibrium. Promoter SNP 3 showed an association with clinical severity, after 
adjusting for relevant covariates (sex, height) (p=.011). The OR for being in a higher 
severity group was 3.14 for the G/G and G/A group versus the A/A homozygotes. For 
Ile50Val, the OR was 2.46 for the Ile/Val heterozygotes versus the Ile/Ile homozygotes 
(p=.012), suggesting that Val50 (which was associated with asthma) may have an effect 
on disease severity. However interpretation is limited by the small number in the 
Val/Val group (n=36).
133
5.4 Discussion
This is the first study to examine the association o f variants o f IL13 signalling with lung 
function in an unselected population. Strongest effects were seen between IL13 and 
IL4RA variants with markers o f airflow obstruction. Interestingly, both promoter SNPs 
o f IL13 were associated with %FEV1 (p<.01) with an approximately 2% difference 
between genotype groups. Although a relatively small difference, this may reflect a 
biologically important difference in an epidemiological study o f this size, and may be 
compared to small blood pressure changes demonstrated in large Cardiology trials 
which are accepted as being clinically important [279]. It is worth noting that recent 
evidence points to lung function being a more important predictor o f mortality than 
previously thought, with a recent study showing that moderately impaired lung function 
was associated with higher mortality, after appropriate adjustments [280].
It is o f note that the 1L13 promoter variants were solely associated with %FEV1 rather 
than the clinical or immune phenotypes examined. A summary o f phenotype 
associations for clinical, immune and physiological phenotypes from Chapters 3-5 is 
included in Table 5.11. The -1512C/T promoter SNP was also associated with asthma 
severity in terms o f %FEV 1 with an over 4% difference between genotype groups, and 
with % FEF 25-75 with an over 6% difference shown. This suggests that it may be the - 
1512 promoter SNP which is o f primary importance, with the associations for -1024 
being a result o f the strong linkage disequilibrium between these variants. The - 
1024C/T variant has been more widely studied, with gene expression studies and 
transcription factor binding analysis by electrophoretic mobility shift assay with this site 
supporting a functional role o f this variant altering IL13 gene expression [281]. The 
promoter SNPs are located within the extended matrix o f  a STAT binding site and 
phylogenetic shadowing has shown a high degree o f conservation in this area, indicating 
a potential functional role. Given their location, these SNPs may be involved in a 
STAT6-dependent regulatory loop in the signalling pathway [12].
Taken together, these findings suggest that the promoter region o f IL13 may have a
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specific effect on lung physiology, influencing this particular asthma phenotype, and 
may be particularly important in airway remodelling. A possible underlying mechanism 
is demonstrated by the effects o f IL-13 on remodelling shown in functional studies 
[282]. Experimental work has show prominent effects o f IL-13 on airway smooth 
muscle, suggesting that gene modulation by IL-13 in these cells may be an essential 
event leading to the development o f allergic asthma [283]. O f special interest is the 
observation o f an association between the -1024 variant with chronic obstructive 
pulmonary disease (COPD) in comparison to healthy controls and smokers with normal 
lung function [284]. A recent study has found this variant to enhance the adverse effect 
o f smoking on % FEV1 [285]. O f further note is the observation o f an association 
between the -1024 variant and severe RSV infection in children [96]. Whereas the -1024 
promoter variant has been associated with airway hyper-responsiveness (AHR) in one 
study [114], the -1512A/C variant has been associated with IgE levels [132] rather than 
AHR, and an association with AHR warrants examination.
The potential biological role o f non-coding variants is discussed further in Chapter 3 
and 8. Variation in the 5’UTR may have regulatory effects on mRNA translation or 
RNA processing. Several studies suggest that this type o f non-coding variant causes 
changes in the stability and splicing o f the encoded mRNAs and therefore has a 
biological effect [286, 287]. Cameron et al have shown that the 7Z/3-1024T allele 
enhances IL 13 promoter activity in primary human and murine CD4(+) Th2 
lymphocytes, and attenuates STAT6-mediated repression o f IL13 transcription [116]. 
The gain-of-function associated with the 7Z73-1024T allele was evident only in 
differentiated Th2 cells suggesting that 7Z73-1024C>T is likely to influence risk o f 
asthma and related phenotypes in the context o f an established Th2 response. Thus it 
may be postulated that this polymorphism may contribute to the maintenance and/or 
exacerbation o f airway pathology (such as remodelling) rather than to its inception, in 
the context o f an established Th2 immune response. Functional studies are lacking for 
the -1512 promoter and further investigation is needed.
In our unselected population, weak associations were demonstrated for IL13 A rgl lOGln
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and 3’UTR variants with %FVC. The 3 ’UTR association is likely to arise as a 
consequence o f the almost complete linkage disequilibrium between these two variants. 
The small additive effect seen for A rgl lOGln -  with a 1% decrease with each G allele -  
is o f uncertain clinical significance. It should be noted that no associations were seen for 
this variant with lung function in the asthmatic population, consistent with findings 
from other studies [147, 248] and the association observed with asthma (Chapter 3) was 
in the opposite direction i.e. the A  allele (resulting in Arg—►Gin) conferred asthma risk. 
Our study was consistent with other populations with only a low level o f LD between 
the coding variant and -1024 (and -1512) promoter variants [249], although high LD has 
been observed in some populations [118]. Since these SNPs have been identified as 
htSNPs belonging to different haploblocks, both should be included in disease 
association studies. It has been postulated that the modest transcriptional enhancement 
conferred by -1024C/T may act in synergy with that conferred by A rgl lOGln to amplify 
IL- 13-dependent events [118].
For IL4RA, the strongest association was between a 3 ’UTR variant and absolute and % 
FEF 25-75 (p<.01) with an almost 10% difference in % FEF 25-75. A weaker 
association was seen for Ser478 and absolute and %PEF (p=.01), with an additive effect 
seen and a reduction o f  over 3% for S/S compared to P/P subjects. The data also 
suggested that Val50 may be associated with clinical severity in addition to the 
previously demonstrated association with asthma, but these findings are to be 
interpreted with caution given the small number o f Valine homozygotes, and warrant 
replication in a further population.
In contrast to other studies examining genotype association with asthma severity [164, 
165, 277], our study included not only a definition o f asthma severity by symptom 
frequency, but a correction for medication usage. Other studies have tended not to 
correct for medication usage, which is likely to be a strong confounder for severity since 
a subject requiring high dose inhaled steroid to maintain a good %FEV1 would be 
incorrectly classified as having mild disease.
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A strength o f this study was that lung function was examined as a continuous variable 
rather than simply a categorical marker o f severity. This enabled the use o f a 
quantitative marker for asthma severity. Since this was primarily an unselected 
population study o f young adults, the asthma population within the study largely 
consisted o f milder asthma by lung function criteria, reflecting asthma in the general 
population rather than asthma in a hospital setting. This contrasts with other studies 
examining genotype associations with asthma severity, where subjects were recruited 
from hospital outpatients [164, 165, 277, 278]. Thus our effect sizes may be 
considerably more marked in a more severe asthma population. The main finding was 
that the IL13 promoter variant -1512A/C associated with asthma severity, with >4% 
difference in %FEV1. This variant was also associated with small airflow obstruction 
(%FEF 25-75) as discussed above.
The other findings o f note for the group with asthma, were the unexpected associations 
between IL4RA intronic SNP 8 and airflow obstruction (FEV1/FVC; absolute and % 
FEF 25-75). It is possible that this does not represent a true association but that this 
variant is in linkage disequilibrium with another marker which affects airflow 
obstruction in asthmatics and this requires further study in a separate population. The 
previously observed association for IL4RA R576 [164, 165] was not replicated in our 
population and this may be due to the small number o f subjects with severe airflow 
obstruction in our population.
In conclusion, IL-13 signalling variants were found to have identifiable predictive 
effects on lung function in an unselected population. The most interesting findings were 
the associations oiIL13  promoter polymorphisms with % FEV1. It is striking that these 
effects were demonstrable in an unselected population o f young adults and adds to 
emerging evidence supporting a role for these promoter variants in influencing 
physiological outcomes, perhaps via airway remodelling. Replication is needed in other 
populations, including examination o f airway hyperresponsiveness, and functional work 
is needed to explore the mechanistic basis o f  these associations.
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CHAPTER 6
Epistatic and haplotype effects of IL-13 
signalling variants on asthma and associated 
Th2 immune phenotypes
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6.1 Introduction
Recent studies have demonstrated the importance o f examining loci in the same 
biological pathway in combination, since small individual effects on phenotype may 
combine to produce much larger synergistic effects. Examining combinations o f 
multiple alleles, in haplotypes or combinations o f haplotypes, has proved more fruitful 
than examining individual SNPs, because the significance o f  a SNP may only be 
apparent in the context o f an additional SNP in the same or other genes in the same 
pathway [12, 14, 133]. The body o f literature on association studies points to the 
existence o f genetic effects via complex networks involving gene-gene and gene- 
environment interactions in complex disease, and it is thus important to model epistatic 
interactions simultaneously with single polymorphism associations.
Howard et al examined the interaction between IL13 and IL4RA genes. In their 
population, the IL13 locus was most significantly associated with bronchial hyper­
responsiveness and the 1L4RA locus with IgE but the combined effects o f the two 
susceptibility loci conferred an increased asthma risk [13]. Risma et al. found that two 
variants o f IL4RA, when occurring together, were more strongly associated with asthma 
than either allele alone [14]. In a recent study, Hytonen et al demonstrated that 
haplotypes o f IL4RA (but not individual SNPs) were associated with asthma 
susceptibility and to severity o f disease [277]. Thus the combination o f IL4RA 
polymorphisms - and the coexistence o f polymorphisms in IL4RA and IL13 - are more 
strongly associated with asthma [12-14, 133, 277].
Kabesch et al combined one functional polymorphism in 1L13, IL4, IL4RA and STAT6, 
and found that this increased the risk for high serum IgE levels 10.8-fold (p = .02) and 
the risk for the development o f asthma by a factor o f 16.8 (p = .005) compared with the 
maximum effect o f any single polymorphism. They observed significant interactions in 
a model with additive and dominant effects, for both pair and triplet combinations for 
asthma (lowest p = .005), and for pairs o f  polymorphisms in IgE regulation (lowest p = 
.054) [12].
140
The functional impact o f SNP/SNP interactions within the same gene could be further 
amplified by gene/gene interactions along the same pathway [8]. Chen et al 
demonstrated functional synergistic effects o f  1L13 and IL4RA polymorphisms on IL- 
13-dependent gene induction, when both variants occurred in combination. The G lnllO  
variant o f IL13 and the Val50Arg551 variant o f IL4RA act in a concerted fashion to 
enhance IL-13 responsiveness in mouse cell lines [133].
Similarly, it has been suggested that haplotype analyses may be more informative for 
drawing associations between phenotypes and genetic variation than SNPs, especially 
when considering common variants which have small individual effects on disease risk 
[288, 289]. Haplotype analysis may be considered as representing c/s-interactions, with 
epistatic interactions representing fnms-interactions. Recent German and Swedish 
population studies support the approach o f studying the effect o f  combinations o f 
multiple alleles, in haplotypes or in combinations o f haplotypes, on complex phenotypes 
within a biological pathway [12, 128, 168].
In this study, the combined effects o f  1L13, 1L4RA and STAT6 polymorphisms, 
including epistatic interactions and haplotype effects, were examined in relation to 
asthma and atopy phenotypes for the first time in a large population based cross 
sectional cohort o f adults.
6.2 M ethods
Physician-diagnosed asthma and clinical atopy (eczema, hayfever) were defined by 
validated bronchial symptoms questionnaire (IUATLD) as outlined in section 2.6.1. 
Spirometry was measured as previously described (2.6.2). Total IgE, eosinophil counts 
and eotaxin levels were measured as previously described (2.6.3). Quantitative variables 
(IgE, eosinophil counts, eotaxin levels) were analysed as continuous data (on a 
logarithmic scale) rather than choose a widely used arbitrary cutoff such as 100 klU/L 
for IgE, to increase the power o f the analysis.
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To guard against multiple-testing, we examined only those SNPs for which a main 
effect had been documented in chapters 3-5. Using the basic linear and logistic 
regression models, we then examined all possible 2-way interactions involving the 
significant factors, and retained them in the final model if  the interaction coefficients 
were significant at the 5% level.
To assess the effects o f haplotypes in our cross-sectional study population o f unrelated 
subjects, haplotypes were estimated from genotype data, at the IL13, IL4RA and STAT6 
loci, according to recently derived methods using the Expectation Maximisation (EM) 
algorithm [244, 245] and R statistical environment package [246], When linkage phase 
is unknown, for each individual there will be a set o f haplotypes that are consistent with 
the genotype data. In essence, the method assigns probabilities to the potential 
haplotypes for each individual by using the available information on unambiguous 
haplotypes and by assuming that there is random mating in the population. The code 
was written by Dr Mike Gravenor in the R statistical language. The relationship 
between haplotypes and traits is then assessed by a range o f regression models that take 
into account the estimated haplotype probabilities.
All haplotype analyses were carried out using the haplo.stats 1.3.0 package, and the 
haplo.glm function. Haplotype analysis was run for the following binary outcomes: 
asthma, eczema, hayfever, and the following quantitative outcomes: absolute lung 
function parameters, total IgE, eosinophil count and eotaxin levels. For most o f the 
quantitative traits (IgE, eosinophil counts, eotaxin) a log transformation was applied as 
necessary. For all haplo.glm analyses, all the key algorithm parameters were explored to 
check for consistent results. Problems were encountered with algorithm conversion for 
age-gender-stature adjusted lung function, PEFR and FEV1/FVC ratio, with different 
starting conditions for the haplo.glm generating different results, and so these were 
omitted. Significant associations are reported after adjusting for relevant covariates 
(such as age, sex, smoking).
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6.3 Results
6.3.1 Two locus interaction effects on asthma and immune phenotypes 
Epistatic interactions for asthma
IL13 Argl lOGln and IL4RA Ile50Val interaction in asthma
The interaction between IL13 A rgl lOGln (R110Q, SNP 5) and IL4RA Ile50Val (I50V, 
SNP 5) was examined. Individually, these loci associated with physician “asthma ever” 
as follows:
• IL13 A rgl lOGln (SNP 5): OR 1.37 for Gln/Gln + Gln/Arg vs Arg/Arg (95% Cl 
1.06-1.77, p=.016). Previous studies have shown that Gin is the risk allele for asthma at 
this locus. This SNP was considered as a categorical (binary) variable since there was 
no evidence o f a clear additive effect in the initial logistic regression.
•  IL4RA SNP 5 (Ile50Val): for OR 1.25 for Val/Val vs Ile/Val and Ile/Val vs 
Ile/Ile (p=.013, 95% Cl 1.05-1.49). A clear additive effect was demonstrated and this 
SNP was considered as a continuous variable in subsequent logistic regression analysis.
Logistic regression analysis o f 1L13 SNP 5 (Argl lOGln)* IL4RA SNP 5 (Ile50VaD in 
asthma
Although 5% statistical significance was not quite reached for the interaction term 
(p=.082), the trends seen were o f interest and were as follows. The probability o f 
asthma associated with different genotype combinations is shown in Figure 6.1.
Odds for IL4RA Ile50Val genotypes stratified by IL13 A rgl lOGln
1) For Gln/Gln individuals, Ile/Ile is highest risk genotype to have in combination: OR 
16.09 compared to Val/Val.
2) For Gln/Arg individuals, Ile/Ile confers protection: OR 0.71 for Ile/Ile compared to
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Val/Val. Thus conversely for these individuals, Val/Val has an OR o f 1.40 compared to 
Ile/Ile.
3) For Arg/Arg individuals, as for Gln/Arg, Ile/Ile confers protection: (OR 0.55 for 
Ile/Ile compared to Val/Val. Conversely, Val/Val has an OR o f 1.81 compared to Ile/Ile 
for Arg/Arg individuals.
4) Therefore lie may only act as a risk allele in the presence o f a Gln/Gln “risk” variant 
o f  IL13.
Odds for IL13 genotypes stratified by IL4RA
1) For Ile/Ile individuals, Gln/Gln confers higher risk than Arg/Arg: OR 2.39 
compared to Arg/Arg.
2) For Ile/Val individuals, Gln/Gln is protective: OR 0.44 compared to Arg/Arg. 
Conversely, OR 2.26 for Arg/Arg vs Gln/Gln.
3) For Val/Val individuals, Gln/Gln also appears protective: OR 0.08 compared to 
Arg/Arg. Thus OR 12.17 for Arg/Arg vs Gln/Gln.
4) Therefore, Gin may only act as a risk allele in the presence o f an Ile/Ile genotype at 
the 1L4RA locus.
Table 6.1 shows crosstabulations for the presence or absence o f physician-diagnosed 
asthma according to different combinations o f genotypes for these two variants at IL13 
and IL4RA. Figure 6.1 shows the probability o f asthma, according to different genotype 
combinations derived from Table 6.1. It can be seen that individuals having both 
Gln/Gln and Ile/Ile have the highest probability o f  asthma, having an OR o f 1.36 
compared with Arg/Arg Val/Val individuals. However, it can be seen that the Arg/Arg 
Val/Val individuals do not have the lowest probability o f asthma; individuals having 
either a Val/Val or Ile/Val genotype in combination with Gln/Gln have the lowest 
probability o f asthma. The OR cannot be calculated for Val/Val Gln/Gln since n=4 only 
in this group with none having this genotype and asthma. The OR for the highest risk 
Gln/Gln Ile/Ile individuals compared to Gln/Gln Ile/Val individuals is 3.5.
The interaction between this functional variant A rgl lOGln o f  IL13 with the functional
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variant Ile50Val o f IL4RA has been presented here. As previously noted, IL13 3’UTR 
SNPs 6, 9 and 13 were in strong linkage disequilibrium with the functional variant 
A rgl lOGln (SNP 5). On examining the interaction between Ile50Val with these three 
IL13 SNPs, the interaction terms more closely approximated statistical significance for 
SNP 9 and 13, with a p value o f .054 and .067 respectively. Figure 6.2 shows the 
probability o f  asthma for different combinations o f genotypes for SNP 9 in IL13 and 
Ile50Val in IL4RA: the probabilities shown are virtually identical to those for
combinations o f genotypes for A rgl lOGln and Ile50Val (Figure 6.1).
Table 6.1 Crosstabulation for IL13 Argl lOGln and IL4RA Ile50Val by asthma.
He50Val
Ile/Ile Ile/Val Val/Val Total
Asthma1 A rgl lOGln Arg/Arg 50 115 50 215
Arg/Gln 34 54 26 114
Gln/Gln 5 3 0 8
Total 89 172 76 337
No asthma Arg/Arg 244 372 136 752
Arg/Gln 97 130 53 280
Gln/Gln 10 21 4 35
Total 351 523 193 1067
“Physican diagnosis o f asthma ever” .
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Ile/Ile || i% / *
lle/Val Val/Val
IL4RA lle50Val
Figure 6.1 Probability of asthma for different combinations o f genotypes 
for IL13 Argl lOGln and 1L4RA Ile50Val.
Probability of 0 4 
asthma n 3
Ile/Val
Val/Val
IL4RA lleSOVal
Figure 6.2 Probability of asthma for different combinations of genotypes 
for IL13 SNP 9 and IL4RA Ile50Val.
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Epistatic interactions for total IgE levels
Interaction between IL13 SNP 6 and STAT6 SNP 8 with IgE
The individual loci associated with IgE as follows:
• IL13 3’UTR SNP 6: T/T+G/T group had a geometric mean IgE o f 52 (95% Cl 
45-61), G/G group had a geometric mean IgE of 43 (95% Cl 39-47) (p=.027).
• STAT6 intronic SNP 8: T/T group had a geometric mean IgE o f 61 (95% Cl 49- 
74), C/C+C/T group had a geometric mean IgE of 43 (95% Cl 39-47) (p=.003).
When examining these two loci in a general linear model, there was a significant 
interaction between them in the association with IgE. For individuals with both 
genotypes associated with higher IgE levels -  T/T at STAT6 locus and either T/T or G/T 
at IL-13 locus -  the geometric mean IgE was raised to 102 klU/L (interaction effect 59, 
95% Cl 19-181, p=.003) (Figure 6.3).
3  110
1 100
in 90 -O)
Z  80 
3
o 70
ra 60 a)
E 50
0
S  40a>
E 30
1  20
Figure 6.3 Graph showing the interaction effects of high risk genotypes o f IL13 and 
STAT6 on total IgE level. A significant effect is only seen when both high risk 
genotypes are present in combination.
IL13 high risk genotype 
IL13 low risk genotype
low risk high risk
STAT6 genotype
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Genetic interactions for eosinophil count
Interaction between Ile50Val and Ser478Pro variants of IL4RA and eosinophil 
count
The individual variants associated with eosinophil count as follows:
•  IL4RA SNP 5 Ile50Val: Ile/Ile, Ile/Val and Val/Val groups had a geometric 
mean eosinophil count o f  0.20, 0.18 and 0.17 respectively (p=.020).
•  IL4RA SNP 12 Ser478Pro: Pro/Pro, Pro/Ser and Ser/Ser groups had a geometric 
mean eosinophil count o f 0.19, 0.18 and 0.17 respectively (p=.032).
When examining these two variants in a general linear model, there was a significant 
interaction between them in the association with eosinophil count (interaction effect 
0.10, 95% Cl 0.01-0.17, p=.016). Table 6.2 shows the effects o f individual genotypes 
and different genotype combinations for these two variants on eosinophil count. The 
highest mean eosinophil count was observed for individuals with Val/Val Ser/Ser 
genotypes. The effects o f these genotypes were interdependent in that significant effects 
were only seen when both high risk genotypes were present (Figure 6.4). In fact, when 
examined in combination, mean eosinophil count is actually lower (though not 
significantly) for the Ser/Ser group -  which is associated with higher eosinophil count 
when examined in isolation - when in the presence o f  the Ile/Ile low risk IL13 genotype.
148
Table 6.2 Geometric mean eosinophil count by individual genotype and genotype 
combinations for 1L4RA SNP 5 and SNP 12
Genotype Geometric mean 
eosinophil count 
(cellsxl09/L)
95% Cl P value
IL4RA
SNP 5 G/G 0.20 0.18-0.21 .020
Ile50Val A/G 0.18 0 .17-0 .20
A/A 0.17 0 .16-0 .19
SNP 12 G/G 0.19 0.18-0.21 .032
Ser478Pro A/G 0.18 0 .17-0 .20
A/A 0.17 0 .15-0 .19
Genotype
combinations
SNP 5 G/G 0.29 .016
SNP 12 A/A
SNP 5 G/G 0.19
SNP 12 A/G or G/G
SNP 5 A/G or A/A 0.18
SNP 12 A/G or G/G
SNP 5 A/G or A/A 0.17
SNP 12 A/A
c  0.33
8  0.28
0.26CL O -j.
.5 ^  0.24
O ©
<W S  0.22
c  v>
8 a> 0 .2
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o
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E
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0.18
0.16
0.14
IL4RA lle50Val high risk 
IL4RA lle50Val low risk
low risk high risk
IL4RA Ser478Pro genotype
Figure 6.4 Graph showing the interaction effects of Ile50Val and Ser478Pro on 
eosinophil count. There is no effect by Val/Val (high risk genotype) unless in the 
presence of Ser/Ser and vice versa i.e. the effects of each genotype on eosinophil 
count are interdependent.
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6.3.2 Haplotype analysis
IL13
When maximum-likelihood haplotype frequencies were estimated using the EM method 
in the 1445 Caucasian samples for which complete genotyping information was 
available, seven (out o f a possible 28 = 256) exceeded a frequency o f  1%, with a 
cumulative frequency o f over 95% (Table 6.3).
The most common or ‘baseline’ haplotype was estimated to have a frequency o f 67.8%, 
and this was used as the baseline for calculation o f  odds ratios.
Table 6.3 IL13 haplotypes based on total genotyped polymorphisms and haplotype 
frequencies (haplotypes with frequencies<l% were not considered).______________
Haplotype number Haplotypes Frequencies
IL13*01 11121121 0.678
IL13*02 22211212 0.087
IL13*03 21121111 0.055
IL13*04 11122121 0.052
IL13*05 12211222 0.037
IL13*06 12212222 0.028
IL13*07 22212212 0.014
Haplotype associations are summarised in Table 6.4. Haplotype analysis revealed the 
existence o f  two IL13 haplotypes associated with asthma: IL 13*03 (OR 1.42, p=.003) 
and IL13*06 (OR 1.59, p=.03). Smoking was identified as a potential confounding 
factor and only IL13*03 was shown to be a risk haplotype for asthma after adjusting for 
smoking (TGGGCGCC, from consecutive IL13 SNP 1, 2, 5, 6, 7, 9, 10, 13). This 
haplotype contains the A allele for A rgl lOGln (which was protective in single analysis), 
in combination with the T allele o f -1024C/T which has been identified as a risk allele 
for asthma by others [12, 114, 135, 141] but not in SNP analysis in this study. IL13*06 
was found to confer borderline increased risk for eczema (OR 1.36, p=.055). In this 
case, the risk haplotype contained both risk alleles found to also confer borderline risk
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when examined individually (Chapter 3).
Two haplotypes, IL13*07 and IL13*02, comprised -1024T, -1512C and +2044A 
(Gin 110), and these haplotypes were both associated with higher IgE levels and 
IL13*07 with additional Th2 phenotypes. IL13*07 was identified as a risk haplotype 
for hayfever, with OR 1.15 (95% Cl, 1.04-1.29, p=.009). IL13*07 was also associated 
with higher IgE levels, with a borderline association shown for IL13*02. This was 
consistent with individual risk effects seen for IgE levels for intron SNP 6 and -1512 
promoter SNP 10 (section 4.3). Highly significant associations were also shown for 
IL13*07 and eotaxin levels and eosinophil counts, whereas only weak associations had 
been demonstrated for the individual SNPs, with no individual associations with 
eosinophil counts. In addition, IL13*07 was associated with FEV1, in concordance with 
the individual effects o f  the promoter alleles contained within this haplotype on % 
FEV1. IL13*04 associated with higher FEV1 and FVC levels which was consistent 
with individual protective effects for Q110R with % FVC within the haplotype, but also 
contained the -1024 promoter allele associated with lower % FEV1 when examined 
individually.
Table 6.4 Summary o f  IL13 haplotype-phenotype associations.
Haplotype Phenotype OR p value
IL 13*03 Asthma 1.42 .003
IL13*07 Hayfever 1.15 .009
IgE <.0001
Eotaxin <.0001
Eosinophil count <.0001
FEV1 <.001
IL13*02 IgE .046
IL13*04 FVC .044
1 . . . .
FEV1 .035
r  1 ..........  ..................... ...........
After adjusting for relevant covariates. 
2 “Physician diagnosed asthma ever”.
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IL4RA
When maximum-likelihood haplotype frequencies were estimated using the EM  method 
in the 1445 Caucasian samples for which complete genotyping information was 
available, fourteen (out o f a possible 27 =128) exceeded a frequency o f  1%, with a 
cumulative frequency o f  over 94% (Table 6.5). Three haplotypes covered 56% o f all 
chromosomes, differing in 4 o f  7 alleles. IL4RA *01 was the most common haplotype, 
accounting for 23% o f the haplotypes.
Table 6.5 IL4RA haplotypes based on total genotyped polymorphisms and haplotype 
frequencies (haplotypes with frequencies<l% were not considered).________________
Haplotype number Haplotypes Frequencies
IL4RA *01 1121111 0.226
IL4RA *02 2111112 0.199
IL4RA *03 2111122 0.138
IL4RA *04 2121122 0.091
IL4RA *05 1122211 0.062
IL4RA *06 2212222 0.050
IL4RA*07 1222212 0.041
1L4RA*08 1211112 0.031
IL4RA*09 2112121 0.030
IL4RA*10 1111112 0.023
IL4RA*11 1111111 0.018
1L4RA *12 2121112 0.016
IL4RA *13 1121112 0.013
IL4RA *14 1112111 0.011
There were no significant associations between IL4RA haplotypes and asthma. 
However, for IL4RA*06 (AAAGCAC, from consecutive IL4RA SNP 5, 8, 16, 13, 12, 3, 
7) a borderline protective effect was seen, with OR 0.62 (p=.058). This haplotype 
contained the Ile50 allele, found to be protective in previous individual SNP analysis 
(section 3.3). For hayfever, IL4RA*05 and IL4RA*11 confer risk (p<.001) and 
IL4RA*06 is protective (p=.02). In this case, the risk haplotypes contained the Val50 
risk allele and conversely, the protective haplotype contained the Ile50 protective allele
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(SNP 5). There were no associations with eczema.
Haplotype associations are summarised in Table 6.6. Three haplotypes showed highly 
significant associations with IgE levels: IL4RA *14 and IL4RA *06 were associated with 
lower IgE levels and IL4RA*11 with higher IgE levels. The strongest contribution to the 
haplotype effects observed was made by Q551R (SNP 13), where the T allele also 
associated with higher IgE levels when examined individually. 1L4RA *06, which was 
protective for IgE levels, contained all protective alleles associated individually with 
lower IgE: GGA for intron SNP 8, Q551R (SNP 13) and 3’UTR SNP 16 respectively. 
IL4RA*14 also exerted a protective effect for eotaxin levels and IL4RA*06 was 
identified as a risk haplotype for higher eotaxin levels. When examined individually, no 
IL4RA variants were associated with eotaxin levels but it is worth noting that the 
protective haplotype for both IgE and eotaxin levels contained the T allele o f Q551R 
SNP 13. IL4RA*11 was shown to be associated with higher eosinophil counts in 
addition to IgE levels. IL4RA*11 comprised both “risk” alleles for the coding variants 
150V and Q551R. Consistent effects were observed for haplotypes IL4RA*06 
(protective) and IL4RA*12 (risk) in their effects on Th2 immune marker levels. In 
contrast, IL4RA *14 (protective haplotype for IgE) was associated with higher eosinophil 
counts but effects were small. Three IL4RA haplotypes were associated with risk o f 
higher eosinophil counts and IL4RA*06 was found to be protective. When haplotype 
effects for eosinophil counts were compared with individual allele effects, the strongest 
contributions to the observed haplotype effects on total IgE were made by promoter 
SNP 3 and I50V SNP 5, rather than S478P SNP 12, with effects for the former two 
variants largely concordant with the effects seen in single analysis. IL4RA*05 
comprised all three risk alleles that were individually associated with higher eosinophil 
counts.
1L4RA*14 was associated with higher FVC but lower FEF 25-75. IL4RA*11 was 
associated with lower FVC and higher FEF 25-75. IL4RA*12 was associated with 
higher FEV1 and FEF 25-75. This suggests that IL4R A*llm d IL4RA*12 may be 
protective against airflow obstruction, whereas IL4RA*14 may confer increased risk.
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Table 6.6 Summary of IL4RA haplotype-phenotype associations.
Haplotype Phenotype p value1
IL4RA *14 IgE <.0001
Eotaxin <.0001
Eosinophil count <.0001
FVC <.0001
FEF 25-75 .003
IL4RA*11 IgE <.0001
Eosinophil count <.001
FVC .003
FEF 25-75 <.001
IL4RA *06 IgE <.001
Eosinophil count .028
IL4RA *12 Eotaxin <.0001
Eosinophil count .007
FEV1 <.001
FEF 25-75 <.0001
IL4RA *05 Eosinophil count .011
After adjusting for relevant covariates.
STAT6
When maximum-likelihood haplotype frequencies were estimated using the EM method 
in the 1445 Caucasian samples for which complete genotyping information was 
available, eight (out o f a possible 27 =128) exceeded a frequency o f 1%, with a 
cumulative frequency o f  over 98% (Table 6.7). Two haplotypes covered 63% o f all 
chromosomes, differing in 5 o f  7 alleles. STAT6*01 was the most common haplotype, 
accounting for 39% o f the haplotypes.
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Table 6.7 STAT6 haplotypes based on total genotyped polymorphisms and haplotype 
frequencies (haplotypes with frequencies<l% were not considered).________________
Haplotype number Haplotypes Frequencies
STAT6*01 1222212 0.393
STAT6*02 2121111 0.237
STAT6*03 1222112 0.096
STAT6*04 1121121 0.090
STAT6*05 1112112 0.081
STAT6*06 1122111 0.041
STAT6*07 1112111 0.032
STAT6*08 1121112 0.014
Haplotype STAT6*08 (GGAGCCT, from consecutive STAT6 SNP 1, 2, 3, 4, 8, 11, 12) 
was observed to be a risk haplotype for asthma, with OR 1.99 (95% Cl, 1.06-3.74, 
p=.03). Smoking was identified as a potential confounding factor since a high 
proportion o f subjects with this haplotype were smokers, and the association therefore 
became non-significant after adjusting for smoking. The same haplotype was also 
associated with hayfever, with OR 1.05 (95% Cl, 1.01-1.09, p=.01). Haplotype 
STAT6*07 was associated with eczema, with OR 1.73 (95% Cl, 1.11-2.67, p=.01). Both 
these haplotypes contain the G2964 allele o f SNP 1, whereas it was the A/A 
homozygotes that had an increased risk o f  asthma and clinical atopy when this SNP was 
examined in isolation.
Haplotype analysis revealed the existence o f  a protective STAT6 haplotype for total IgE 
levels. STAT6*05 was associated with lower IgE levels (p<.0001), with a geometric 
mean o f 34 klU/L compared to 57 klU/L for baseline STAT6*01. The strongest 
contribution to the observed haplotype effects on total IgE was made by 3’UTR SNP 3 
(rs 1059513) and intron SNP 8 (rs324011) variants, which were also significant in the 
single analysis (section 4.3). STAT6*08 was associated with lower eosinophil counts 
although these effects are unlikely to be o f clinical relevance with negligible differences 
between mean absolute counts despite p<.05. No associations were demonstrated with 
eotaxin levels.
155
STAT6*08 paradoxically associated with a small increment in FEV1 and FVC, after 
adjusting for relevant covariates: differences were small, with FEV1 0.05 litres greater 
than baseline haplotype STAT6*01 (p<.0001). STAT6*02, STAT6*06 and STAT6*08 
were associated with higher FEF 25-75 suggesting a protective effect against small 
airflow obstruction, although the association was o f borderline significance for 
STAT6*06. The association demonstrated for STAT6*02 was concordant with the 
individual variant association o f intron SNP 11 with % FEF 25-75 and it is worthy of 
note since this haplotype with potential protective effects for airflow obstruction has a 
relatively high frequency in our population with a prevalence o f 23.7%.
Table 6.8 Summary o f STAT6 haplotype-phenotype associations.
Haplotype Phenotype OR p value
STAT6*08 Hayfever 1.05 .009
Eosinophil count <.0001
FVC <.0001
FEV1 <.0001
FEF 25-75 <.0001
STAT6*07 Eczema 1.73 .015
STAT6*05 IgE <.0001
STAT6*02 FEF 25-75 .033
STAT6*06 FEF 25-75 .049
After adjusting for relevant covariates.
6.4 Discussion
Interesting trends were noted for IL13-IL4RA epistatic interactions for ArgllO Gln and 
Ile50Val with asthma, but differences did not reach statistical significance. These trends 
were worthy o f note since they may suggest one possible explanation for non­
replication o f findings by previous investigators regarding Ile50Val, whereby in some 
populations it is the Val50 which confers asthma risk, whilst others have observed the
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Ile50 allele to confer risk [119, 155]. In our population, trends were observed for Val50 
conferring risk only in those with a low risk IL13 genotype whereas elevated risk o f 
asthma in Ile50 carriers was in those with a high risk genotype o f  IL13. A case-control 
study o f Chinese children showed similar effects which were significant with an OR of 
high risk to low risk group o f 3.9 for asthma [153]. It is possible that statistically 
significant differences would be seen in our study if  groups were stratified according to 
environmental exposures. A recent study by Bernstein et al found a significant epistatic 
interaction between these two variants and diisocyanate asthma, but only in a subgroup 
stratified by a specific diisocyanate exposure (OR 4.13, p=.01) [290]. Further analysis 
in groups stratified for example by atopy or smoking exposure may yield interesting 
results.
As previously discussed (Chapter 3), it was the heterozygote Arg/Glnl 10 group that had 
the highest odds o f  asthma. This may have been due to small numbers in the 
homozygote group but another explanation is that the presence o f both alleles has 
biological relevance and increases the chance o f  a functional interaction with Ile50Val 
(or with another locus). Two different protein copies, given that there is bi-alleleic 
expression, give greater opportunity for interaction with variants proteins from other 
loci in promoting asthma. IL13 heterozygotes for other SNPs (promoter and 3’UTR, 
Chapter 4) were also noted to have the highest IgE levels.
There are several points to be made regarding Figure 6.1. The most striking trends of 
interest are that the probability o f asthma increases in a dose-response manner in the 
presence o f Val50, for the Arg/Gln and Arg/Arg group. However the trend is reversed 
for the Gin homozygotes, with probability o f  asthma increasing in the presence o f Ile50. 
Secondly, Gin may only act as a risk allele in the presence o f the Ile/Ile genotype and lie 
may only act as a risk allele in the presence o f the Gln/Gln genotype. Lastly, the 
Arg/Gln heterozygotes would appear to have a relatively high probability o f asthma 
with the two groups having the highest (and almost identical) probability o f asthma 
being Arg/Gln Val/Val and Gln/Gln Ile/Ile at 0.49 and 0.50 respectively. As pointed 
out, these trends did not reach significance, probably due to the rarity o f  the joint variant
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homozygotes. However, taken together, these epistatic effects could provide an 
explanation o f disease susceptibility in heterozygotes and suggest that the “risk” 
conferred by a particular allele is likely to be determined by the genetic milieu in which 
it exists. This may contribute to the non-replication o f genetic associations in different 
populations where allele frequencies, and thus the strength o f epistatic effects, may 
differ. Therefore, this may provide one explanation o f why the Val50 variant o f IL4RA 
and A2964 variant o f STAT6 were found to confer risk o f asthma/atopy in our 
population, whereas these were found to be protective variants in other populations. The 
observations presented here hint at the potential complexity o f genetic interactions and 
suggest that effects are unlikely to be straightforward and additive.
Epistatic interactions were observed between 1L13 and STAT6 genes in their effects on 
total IgE levels. The effects o f a variant o f one gene were dependent on the presence o f 
a high risk genotype related to an entirely separate gene, that is, a true epistatic effect. In 
the examination o f the isolated effects o f  IL-13 signalling polymorphisms, these two 
IL13 and STAT6 variants had minor effects on IgE levels. However, in this combined 
analysis, each polymorphism amplifies the effects o f  the other polymorphism in the 
signalling pathway. This is all the more striking since these loci are located on different 
chromosomes, emphasising the importance o f examining the co-effects o f genes coding 
for molecules which signal and interact in a particular biological pathway. This is 
especially intriguing since both polymorphisms are non-coding variants, suggesting yet 
again the potential functional role o f non-coding variants, which awaits further 
clarification in functional work, and which is discussed further in section 4.4. Another 
possibility is that the observed association is due to strong LD with coding variants: in 
the case o f the IL13 polymorphism, there was strong LD with a coding variant but it 
should be noted that an interaction was not seen when examining the coding variant 
itself. Other investigators have found a gene-gene interaction between risk alleles o f 
each IL13 promoter polymorphism and an IL13RA1 polymorphism in predicting higher 
total IgE in children with atopic asthma [148].
Similarly, interactive effects were seen for eosinophil counts, in this case between two
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coding variants o f IL4RA. Both high risk genotypes needed to be present for a 
significant effect to be seen, with the effect o f one again dependent on the combined 
presence o f the other high risk genotype. In the analysis o f the isolated effects o f IL4RA 
polymorphisms, Ile50Val and Ser478Pro had minor effects on eosinophil counts. 
However, in combination, each polymorphism amplifies the effects o f the other.
Haplotype analysis revealed much stronger associations when alleles were examined in 
combination rather than in isolation. A high risk IL13*03 haplotype was identified for 
asthma, which contained -1024C/T, which has been identified as a risk allele for asthma 
by others [12, 114, 135, 141] but not in single analysis in this study. Haplotypes 
containing multiple risk alleles - for instance IL13 haplotypes comprising -1024T, - 
1512C and +2044A (Gin 110) - showed strong associations with Th2 phenotypes 
including IgE levels. This is concordant with a Korean study which showed a three 
locus haplotype for IL13 (comprising the described high risk alleles) to be associated 
with higher IgE levels in children with atopic asthma [148]. We have thus replicated 
these findings at the population level and found an identifiable haplotype effect in an 
unselected population rather than the findings being limited to subjects with asthma.
A high risk atopy haplotype was identified for 7Z/3, comprising three high risk alleles, 
which associated with risk o f hayfever and higher levels o f all Th2 immune markers 
(IgE, eotaxin and eosinophil counts), whereas individually, only weak effects were seen 
for IL13 variants and IgE levels. The Val50 allele o f IL4RA showed only a trend 
towards risk o f hayfever in isolation, but a very significant association was observed 
when examined in combination with other variants as part o f a haplotype (p<.00001). 
Similarly, associations with IgE levels became much stronger when SNPs were 
examined in haplotype combinations, with IL4RA haplotypes associated with p values 
as low as 1.75 x 10"14.
This is the first study to examine the influence o f IL13, IL4RA and STAT6 
polymorphisms and haplotypes on IgE regulation in a large population based cross- 
sectional cohort o f adults. The data indicate that IL13, IL4RA and STAT6 haplotypes
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contribute significantly to the genetic determination o f total IgE levels in a British 
population o f adults, although when taking these results together with data from the 
individual SNP analysis, it would seem that IL4RA and STAT6 have stronger regulatory 
effects on total IgE than IL13. These data are concordant with recent findings by Moller 
et al, who showed that STAT6 haplotypes relate to IgE levels, allergy and worm burden, 
in a comparison o f Chinese and British populations [82].
When considering IL13 risk haplotypes, the promoter variant -1512A/C seemed to be 
mainly responsible for the detected alterations in total serum IgE regulation, and a non­
significant trend towards higher IgE levels had been detected for this variant in 
isolation. Associations for IL4RA with elevated serum IgE clearly focus on the Q551R 
variant, with consistent protective/risk haplotype effects determined at this locus for 
each o f  the significant haplotypes examined. This variant showed significant 
association in single analysis and these findings are concordant with findings from the 
British 1958 Birth Cohort [132], with higher total IgE levels found in our population.
For STAT6, the effects on IgE were focused on two polymorphisms located in intron 2 
and the 3' UTR region, identical to findings from a large German population o f children 
[128]. Although in strong linkage disequilibrium, alleles at these loci were not 
invariably inherited in identical haplotype combination. On examining the relative 
contribution o f each variant to the direction o f risk/protection for each haplotype, it 
would appear that intron SNP 8 (rs324011, C2892T) had the strongest effects. A 
functional role for this intron 2 variant is suggested by sequence analysis showing this 
variant to alter a NF-kB transcription binding site [128]. However it remains possible 
that the 3’UTR variant, or another variant in linkage disequilibrium with rs324011, is 
functionally important in the regulation o f IgE production.
Risk haplotypes did not invariably contain individual “risk” alleles. For example, 
STAT6*08 which associated with asthma contained the G2964 allele (3’UTR SNP 1) 
which was found to be protective against asthma when examined individually. This
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demonstrates that asthma results from a complex interaction between multiple 
polymorphisms and that risk is not conferred by a single variant. The epistatic 
interactions described demonstrate the potential complexity o f interactions between 
individual SNPs: in some cases an allele found to confer risk when examined in 
isolation, was actually found to be protective when its interaction in combination with 
another risk allele was examined. Also, these findings may suggest that an asthma 
susceptibility variant is on STAT6*08 but is not any o f the individual SNPs comprising 
this haplotype but rather that the true susceptibility SNP(s) are in linkage disequilibrium 
with one or more o f these. It is worth noting that STAT6 is a highly conserved gene, 
with strong linkage disequilibrium found between the examined SNPs. Only one STAT6 
haplotype (STAT6*02) contained the A2964 “risk” allele: this was the second 
commonest haplotype (with a trend towards a risk o f asthma but not reaching 
significance) suggesting that alleles conferring asthma risk may confer another survival 
advantage and are thus conserved. This may be explained by Peisong et al’s observation 
that the STAT6 3’UTR variant that conferred asthma risk was protective against ascaris 
worm infection in a population o f Chinese children [84].
The protective effect o f IL13*07 on FEV1 was compatible with the observed individual 
effects o f the promoter alleles contained within this haplotype on % FEV1. Two IL4RA 
haplotypes were found to be protective against airflow obstruction (IL4RA*11 and 
IL4RA*12) with one haplotype associating with lower FEF 25-75 (IL4RA*14). A 
common STAT6*02 haplotype was associated with higher FEF 25-75. Associations with 
lung function, although adjusted for relevant covariates, are difficult to interpret in 
isolation; unfortunately problems encountered with algorithm conversion for percentage 
predicted values and FEV1/FVC did not allow further clarification o f these associations.
For IL13, genetic variability is characterized by a high level o f nucleotide diversity and 
haplotype structure and linkage disequilibrium (LD) has been shown to differ across 
ethnic and geographical groups, emphasising the importance o f determining haplotype 
structure in a particular population for gene association studies. Since the identification 
o f single causal variants is hampered by the extended LD haploblock spanning intron 3,
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exon 4 and the 3’UTR, haplotype analysis may be o f greater utility than single 
nucleotide analysis alone. The HapMap initiative is likely to provide important 
information which should be applicable to the investigation o f common disease 
aetiology across a range o f populations, with its remit o f identifying common patterns o f 
haplotype structure (and htSNPs) for use in association studies across geographical 
regions [258].
In this thesis, we have employed a standard, step-wise, approach to detecting 
interactions (epistatic effects). This is partly to guard against false positives deriving 
from multiple testing, and also partly a pragmatic approach given the vast numbers o f 
interactions that could be tested in the limited time frame. Our results, however, have 
highlighted an interesting potential drawback with this approach. In several instances 
we have found the effect o f two interacting SNPs to be fully dependent on each other. 
That is, the increased risk allele at one locus is only manifest if  a certain other risk allele 
is present at another locus. The effect o f this situation is to dilute the impact o f any 
particular locus, when it is examined individually, and its marginal effect ‘averaged’ 
over the alleles at the other locus. Here, the standard approach runs the risk o f not 
selecting out the key loci in the first set o f analyses, in which case their epistatic effects 
would not be tested. Therefore this conservative approach to haplotype and interaction 
modeling may mean that some true interactions were not identified. To extend our work 
further, we propose the exhaustive testing o f all possible interaction terms (a 
combinatorially large process if  more than 2-way interactions are also considered) and 
this is outlined in Chapter 8. Although one would have to tackle the issues o f multiple 
testing, it would be very interesting to use this method as a means o f identifying 
combinations o f  risk loci. Given available flexible software (the R  language) and the 
availability o f supercomputing, this task is not as daunting as it once appeared, and is 
likely to become a standard component o f analyses o f  genome scans for complex 
diseases.
This thesis shows that analysis o f epistatic and haplotype effects, in addition to 
individual SNP analysis, provides a more complete picture o f how variants along the IL-
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13 signalling pathway may interact to produce measurable asthma and atopy 
phenotypes. These findings may have practical clinical utility in the development o f a 
diagnostic or predictive genetic test which could be used in infancy. The identification 
o f an isolated high risk SNP is unlikely to be highly predictive o f the development of 
asthma, whereas a combined analysis o f SNPs in the IL-13 pathway may prove useful 
as a predictor o f atopy and asthma in children. Even though the prevalence o f high risk 
haplotypes was low, the highly significant associations demonstrated mean that the 
identification o f these haplotypes in selected children (e.g. with a strong family history 
o f atopy) may predict those with the highest risk. Epistatic and haplotype analysis 
suggests that the identification o f combinations o f multiple alleles in haplotypes is 
likely to advance towards differentiating the child with high genetic risk for the 
development o f asthma and atopy from the child at low risk. Further assessment o f these 
variants is required, with further replication studies in other populations to evaluate their 
utility as predictive markers for asthma and atopy.
The observations presented here support the approach o f studying the effect o f 
combinations o f multiple alleles, in haplotypes or in combinations o f haplotypes, on 
complex phenotypes within a biological pathway. Whilst the data are supportive o f a 
biological interaction between polymorphisms along the IL-13 signalling pathway, this 
requires confirmation in functional assays in vitro and in vivo. One such study has been 
undertaken by Faffe et al who have shown that expression o f the Val50/Pro478/Arg551 
haplotype o f IL4RA in human airway smooth muscle cells is associated with greater IL- 
13-stimulated TARC (thymus and activation regulated chemokine) production by these 
cells. Since TARC has an important role in recruiting Th2 cells, expression o f  the 
variant IL4RA haplotype results in a positive feedback loop promoting the recruitment 
o f Th2 cells and IL-13 production in the asthmatic airway [291]. Since complex 
diseases are likely to result from combinations of, and complex interactions between, 
variants with moderate effects (in contrast with monogenic disorders), interpreting the 
contribution o f these variants to the pathogenesis o f allergic inflammation requires 
advancing beyond the one SNP by one SNP approach taken so far, and interrogating 
multiple genes within a biological pathway.
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CHAPTER 7
The impact of obesity on asthma, lung 
function and Th2 immune phenotypes
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7.1 Introduction
The concomitant rise in the prevalence o f both asthma and obesity has led to speculation 
on a causal link between these conditions. Obesity has reached epidemic proportions in 
affluent societies with the adult prevalence o f obesity in the UK almost trebling since 
1980. In 2002, 23% o f British men and 25% o f women were obese [292]. Worldwide 
obesity prevalence has risen from 200 million obese adults in 1995 to 300 million in 
2000 [293]. There is an inherent difficulty in proving a causal link between obesity and 
asthma since both are common conditions and may be rising in parallel with no 
association between them. However, evidence o f an association comes from cross- 
sectional and prospective studies in addition to weight loss studies in asthmatics which 
show an improvement in lung function and asthma symptoms [5, 17]. The studies used 
body mass index (BMI), calculated as weight/height2, as the predominant measure o f 
obesity. Adult obesity is represented by a BMI o f at least 30 kg/m2 and overweight by a 
BMI o f  25-29.9 kg/m2. In UK centile charts for children, overweight and obesity are 
defined as a BMI greater or equal to the age and sex specific 91st and 98th percentiles o f 
the population distribution in 1990 [294]. Evidence on the role o f obesity in asthma is 
summarised below, in addition to an account o f the available evidence on the 
relationship between obesity and atopy.
7.1.1 Cross-sectional studies
Cross-sectional studies in different countries have found adult asthmatics to have a 
higher prevalence o f obesity than non-asthmatics, although this is not universally the 
case [5]. Self-reported asthma was used in the majority, with or without a physician’s 
diagnosis. Several studies have reported obesity to be more strongly associated with 
wheeze and asthma diagnosis in females [190, 295, 296] but other studies have not 
shown a significant modification by sex [297,298] or have shown a stronger association 
between obesity and airway hyperresponsiveness (AHR) in males [299, 300],
A large Chinese study o f families o f asthmatics found a U-shaped relationship between
165
obesity and AHR with both extremes o f BMI being associated with symptomatic AHR 
in men and women [301]. This was also the case for the association between obesity and 
asthma in women, but in men, asthma was associated only with being underweight 
rather than overweight. Conversely, a US study demonstrated this U-shaped relationship 
in men but in women, asthma was associated with overweight and obesity only [298]. 
The Humbolt study showed both BMI and waist circumference to be significantly 
associated with asthma in women but not in men and a Swedish study showed these 
associations without sex-specific effects [302, 303]. These associations were also 
observed in Hispanic women but not men [304].
Studies in adolescents and children show a less consistent association between obesity 
and asthma. BMI is the most widely used measure, but other anthropometric measures 
have also been used. Again, some studies showed an association with females only 
[305] with other studies showing no sex difference [306].
7.1.2 Prospective studies
Cross-sectional studies have demonstrated an association between obesity and asthma. 
Prospective studies allow exploration o f  the causal nature o f this association. A recent 
meta-analysis o f  cohort studies concluded that children with high body weight were at 
increased risk o f developing future asthma. Combined results from four studies 
examining the effect o f high body weight during middle childhood on the outcome o f 
future asthma showed a 50 percent increase in relative risk (RR 1.5, 95% confidence 
interval [Cl], 1.2-1.8). Combined results from nine studies examining the effect o f  high 
birth weight on subsequent asthma had a pooled RR o f 1.2 [307]. Seven o f eight adult 
prospective studies have shown an association between baseline BMI and subsequent 
development o f asthma [203, 297, 308-313]. A recent meta-analysis o f adult studies 
concluded that overweight and obesity are associated with a dose-dependent increase in 
the odds o f incident asthma in both men and women [314]. Thus strong evidence for 
causality is provided, since overweight and obesity antecede the development o f 
asthma, with relative risk ranging from 1.6 to 3, with several studies showing a dose-
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response relationship. Prospective studies showing obesity to antecede the development 
o f asthma refute the suggestion that obesity is related either to corticosteroid use or 
reduced physical activity in asthmatics.
Some (but not all) studies showed sex-specific effects which may reflect differences in 
the shape o f the relationship in men and women, as seen in some o f the cross-sectional 
studies. A study including only men demonstrated a U-shaped relationship between 
AHR and both extremes o f weight [315], whereas a study including only women 
detected a monophasic relationship between asthma and overweight development [203]. 
In the Coronary Artery Risk Development in Young Adults study, 4547 adults from the 
same age range as our own study (18-30 years) were followed for 10 years. An 
association between asthma and obesity was seen for females but not males. However 
the definition o f asthma was less strict, not requiring a physician diagnosis [311]. A 
similar association in females has been noted in other studies [310, 313]. A Norwegian 
study o f  135,000 found an association in both sexes: for each unit o f increased BMI 
between 25 and 30, the risk o f asthma increased by 10% and 7% for men and women 
respectively [316]. The European Community Respiratory Health Survey found that the 
association between asthma symptoms and obesity was similar in both men and women 
[317].
In children and adolescents, two US studies showed conflicting results on obesity and 
risk o f asthma development according to sex, one showing an association in females 
(population aged 6-14) and the other in males (population aged 7-18) and it may be that 
the effects were modified by the slightly different ages in the study populations [318, 
319]. A  recent birth cohort followed for up to 14 years, showed an association for boys 
only [320]. In a British cohort o f 5-6 year olds followed for 12 years, obese children had 
an increased risk o f asthma development after 4 years. However the investigators 
concluded that obesity was not causing increased asthma prevalence but that lifestyle 
changes common to obesity and asthma were responsible for the associations 
demonstrated [321]. A New Zealand birth cohort study showed an association between 
BMI and asthma in females only and estimated a population attributable fraction o f 28%
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(95% confidence interval 7-45) o f asthma developing in females after age 9 to be due to 
overweight [322].
7.1.3 Effects of weight change
In two prospective studies, weight gain was associated with an increased incidence of 
asthma, with a non-significant trend seen in another study [203, 311, 312]. The National 
Population Health Surveys did not find an increase in weight or BMI to be associated 
with increased asthma incidence over a 2 year follow-up [313]. In children, an 
association was seen between an increase in BMI and asthma incidence or asthma 
symptoms and bronchial responsiveness in females only [319, 323].
Conversely, weight loss in obese asthmatic patients has been shown to improve 
symptoms. Bariatric surgery in morbidly obese asthmatics led to resolution o f asthma in 
up to half of patients with an improvement in symptoms, exacerbations, hospitalisations 
and medication use in up to 90% of cases [324, 325]. A limitation o f bariatric studies is 
the difficulty in generalisability to obese asthmatics in the general population, since 
bariatric surgery is only offered to the morbidly obese (BMI >40kg/m2) or those with 
comorbidities and BMI >35kg/m2. An alternative explanation to weight loss improving 
asthma per se is that symptoms are improved rather than the condition itself and bariatric 
studies have provided no objective measures o f lung function or bronchial 
hyperreactivity. Other explanations are that the change in diet or improvement in gastro- 
oesophageal reflux following surgery may be important.
Low calorie diets in obese asthmatics have been found to improve FEV1, FVC, 
variation in peak expiratory flow, ratio o f  forced midexpiratory flow rate to FVC; 
number o f exacerbations and use o f rescue medications [64, 176]. An uncontrolled 
study which combined a low calorie diet with an exercise programme demonstrated an 
improvement in FEV1 and FVC but no significant improvement in bronchial 
hyperreactivity [65]. The obvious problem with a weight loss intervention is that this 
either involves dietary change, increased exercise or a combination o f these factors,
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both o f which may act as confounders beyond the effects o f weight loss alone. This has 
led to the suggestion that obesity may be an epiphenomenon related to the effects o f diet 
and/or physical activity on asthma. It is difficult to measure physical activity accurately 
but three o f the prospective studies attempted to adjust for it [203, 308, 309]. A t least 
one study found physical activity to be inversely related to asthma (in men only) [312] 
but no significant association was seen in two other studies [203, 311] and population 
studies have not shown that asthmatics are significantly less physically active [308, 
313]. The potential role o f diet in asthma aetiology has been reviewed in Chapter 1.
7.1.4 Evidence o f the effects of obesity on atopy
Whereas several studies have examined the association between obesity and asthma, 
there is a paucity o f data on the relationship between obesity and atopy, and the 
reported data are conflicting. Positive associations between body mass index (BMI) and 
atopy have been reported in cross-sectional surveys o f children/adolescents [326-328]. 
Any association with atopy is likely to be age-dependent and influenced by the 
developmental stage o f the immune system with modifying effects by gender. For 
instance, Schachter et al found no association between BMI and atopy when examining 
Australian adults, but an association was seen for girls, but not boys, aged 7-12 years 
[326, 329]. A similar association was seen for girls in the Dunedin cohort study, with a 
higher frequency o f  atopy in those who became both asthmatic and obese after puberty, 
and BMI was positively associated with total IgE [322]. Likewise for Taiwanese girls, 
obesity was related to atopy, including an association with rhinitis [327]. Obesity was 
reported in association with atopy in a longitudinal Finnish study from birth to 31 years 
[330].
In contrast, several studies have also reported negative findings. In a study o f 9000 
German schoolchildren aged 5-6  years, physician-diagnosed asthma, but not hayfever 
and eczema, was associated with overweight in girls [331]. In the NHANES-III study, 
no association was found between BMI and atopy or eosinophilia in over 7500 children 
aged 4-17 years, although a positive association was seen for asthma [332], with a New
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Zealand study reporting similar negative findings for atopy [333]. Moreover, the 
Children Health Study, found that overweight/obese children had an increased risk o f 
incident asthma during about 4 years after recruitm ent, but that this effect was limited 
to non-allergic children [334]. The European Community Health Survey (ECRHS) 
found that BMI was related to airway hyperresponsiveness but not to atopy in a cross- 
sectional survey o f  adults [317].
It is difficult to draw any definitive conclusions from these conflicting data. It is 
important to clearly define the atopic phenotype to be examined, since recent data show 
that BMI was associated with skin sensitisation but not with corresponding serum IgE 
antibodies among South African schoolchildren with exercise-induced bronchospasm, 
as well as in age-matched controls [335]. Moreover, most studies have defined atopy by 
objective measures (skin test reactivity, IgE) in addition to self-reported allergic 
symptoms, including asthma symptoms, and have made no attempt to adjust for asthma. 
Thus the effect o f obesity on atopy, independent o f asthma, has been difficult to assess. 
Clearly more research is needed to explore the association between obesity, asthma and 
atopy, and in particular to define effects by gender and in different age groups and to 
clarify other environmental effects which may impact upon this relationship.
7.2 Study design
The majority o f studies used BMI as the only measure o f obesity, which takes no 
account o f body frame and muscle mass, and BMI may be an unreliable indicator o f 
adiposity in men in particular [336]. Potential misclassification o f  adiposity might 
explain why the association with asthma appears weaker in men. Other measures o f 
obesity might clarify the associations, possible modification by sex and provide new 
insights into the mechanisms behind the relationship. Measuring waist circumference 
(WC) and waist/hip ratio (WHR) advances our understanding o f  the role o f abdominal 
obesity specifically. In Europids, central obesity relates to a waist circumference > 
94cm and 80cm in males and females respectively, whereas in the Chinese, the cut-off 
for males only is reduced to 90cm [337]. Cut-off points for waist/hip ratios are 0.9 and
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0.85 for males and females respectively [338]. It is also important to provide an 
assessment o f body fat to clarify the role o f the adipose tissue itself in the development 
o f asthma. In this way, new light may be shed on molecular interactions at the adipocyte 
level. Here for the first time we examine percentage body fat in addition to BMI, WC 
and WHR.
In order to explore whether obesity was associated with atopy and an upregulation o f 
Th2 pro-inflammatory markers, multiple Th2 immune phenotypes were included, in 
additional to clinical data on the presence o f asthma, hayfever and eczema. The Th2 
immune phenotypes examined included total IgE levels, eosinophil counts and plasma 
eotaxin, a Th2 chemokine which acts as a chemoattractant for eosinophils.
7.3 Methods
Methods have been outlined in detail in the main Methodology section (Chapter 2). 
Here I will focus on the particular methods relevant to examining the association 
between obesity, asthma and atopy and lung function.
Subjects comprised 1614 unselected volunteers (aged 18-30) from students and staff at 
Swansea University, Swansea Institute and Singleton Hospital, Swansea. Subjects were 
studied when free o f acute lower respiratory infection which would be likely to result in 
transient reduced lung function.
7.3.1 A nthropom etric measurements
The following measurements were recorded on a data sheet (Appendix III)
1. H eight measured by staediometer to 0.1 cm (Leicester; Chasmors, UK)
2, W aist and hip circumference to 0.1cm (D loop non-stretch fibreglass tape; 
Chasmors, UK). Waist was measured at the smallest circumference between the ribs and 
iliac crest, with the participant standing with abdomen relaxed at the end o f a normal
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expiration. Hip circumference was measured at the point o f maximum circumference 
over the buttocks [339].
3. W eight to 0.1kg (Seca 873 digital scales; Cranlea, Birmingham, UK).
4. Percentage body fat to 0.1% (Biolelectrical impedance; Tanita digital scales, 
Tanita UK Ltd, Yiewsley, UK)
The following were then calculated:
1. W aist/hip ratio
2. Body mass index (BMI) = weight (kg)/ [height (m)]2 
7.3.2 Clinical variables
Demographic data were collected and subjects completed a validated bronchial 
symptoms questionnaire which included questions on symptoms (e.g. wheeze) and 
presence o f  asthma, hayfever and eczema [236]. Smoking status (pack-years) was 
recorded. Those who answered positively to "doctor-diagnosed asthma" completed a 
further validated asthma and allergy symptom questionnaire, based on the European 
Community Respiratory Health Survey [237]. Asthma severity was graded as mild 
intermittent, moderate persistent or severe persistent according to GINA criteria [50]. 
Quantification o f severity included recording symptom frequency, volume o f 
medication and number o f  doctor visits over the previous 12 months.
73 .3  Spirom etry
Forced Expiratory Volume in 1 second (FEV1), Forced Expiratory Flow at 25-75% of 
expired vital capacity (FEF 25-75), Forced Vital Capacity (FVC), FEV1/FVC ratio and 
Peak Expiratory Flow (PEF) were measured by standardised protocol [239], using a dry 
spirometer (Vitalograph, UK). The best value o f three manoeuvres was expressed as an 
absolute and percentage o f the age-gender-stature predicted value. Spirometry was 
performed in the morning (before noon) in order to capitalise on the diurnal variation in 
asthma thus maximising the discriminatory value o f  this test in subjects with airflow
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obstruction. If  on inhaler treatment for asthma, measurements were taken before the 
morning dose.
7.3.4 Severity criteria
A subgroup analysis was undertaken on subjects with a current physician diagnosis o f 
asthma to examine the effect o f obesity on physiological and clinical severity. Asthma 
severity was quantified by the following measures:
1. Clinically categorised into “intermittent”, “mild persistent”, “moderate persistent” 
and “severe persistent” asthma according to GINA criteria (shown previously in Table 
5.10), ascertained by validated questionnaire (ECRHS, Appendix V). Current therapy 
was accounted for e.g. a subject having intermittent symptoms but on “mild persistent” 
therapy o f low-dose inhaled glucocorticoids would be classified as having “mild 
persistent” asthma [50].
2. Number o f asthma attacks in last 3 months.
3. Frequency o f waking because o f asthma in last 3 months.
4. Frequency o f problems with breathing because o f asthma in last 3 months.
5. Volume o f  daily inhaled beta-2 agonist therapy in last 3 months.
A daily equivalent dose o f  Salbutamol was estimated, taking long-acting beta agonist 
usage into account e.g. if  on Salmeterol 50mcg daily, this was considered equivalent to 
800mcg Salbutamol.
6. Volume o f daily inhaled corticosteroid therapy in last 3 months.
7. Lung function: % predicted FEV1; % predicted PEF.
7.3.5 Th2 immune phenotypes 
Total IgE
Whole blood was collected in vacutainers (serum separator clotted tube) and centrifuged 
for serum separation. Serum total IgE (klU/L) was measured using an ELISA-type
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sandwich assay (Roche Diagnostics, Lewes, UK) at Morriston Hospital Chemical 
Pathology, as outlined in Methodology section 2.6.3.
Eotaxin
Whole blood was collected in EDTA vacutainers and centrifuged for plasma separation. 
Plasma eotaxin (pg/ml) was measured using enzyme-linked immunosorbent assays 
(ELISA) (BD OptEIA™, BD Biosciences), under the supervision o f Dr Cathy 
Thornton, Senior Lecturer in Newborn Immunity, as outlined in Methodology section
2.6.3.
Eosinophil counts
Whole blood was collected in EDTA vacutainers and full blood count with white cell 
differentials including eosinophil count was measured on a Sysmex XE-2100 automated 
analyser, as outlined in Methodology section 2.6.3. Analysis was performed by 
Haematology staff at Singleton Hospital, Swansea NHS Trust, under the supervision o f 
Dr Ann Benton, Consultant Haematologist.
73 .6  Data analysis
The analysis o f the association between obesity measures -  BMI, waist circumference, 
waist/hip ratio, % body fat - and risk of asthma took the form o f a series o f standard 
logistic regression models, with adjustment made for relevant covariates (sex, smoking 
etc). Since smoking is directly associated with asthma and inversely associated with 
weight, it acts as a potential confounder for which adjustment must be made [5]. The 
analysis was expanded upon to include the quantitative outcomes -  e.g. lung function, 
IgE, eosinophil count, eotaxin - using general linear models. A quadratic model was 
chosen as the best model for the data when the quadratic form o f the covariate showed a 
significant association with the dependent variable at the 5% level.
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Th2 immune markers were analysed on a logarithmic scale since they were non- 
normally distributed. All were analysed as ln(x+l) in order to overcome an error 
occurring when x was undetectable and counted as zero.
A subgroup analysis was undertaken on subjects with a current physician diagnosis o f 
asthma to examine the effect o f obesity on physiological and clinical severity. Ordinal 
regression was applied to identify associations o f obesity with clinical severity 
categories. Linear regression was applied for continuous lung function data.
Our model building approach has been outlined in section 2.8 and will be briefly 
reiterated. Initially the relationship between the primary predictor and outcome was 
explored in a univariate analysis. The effect o f adjustment for relevant covariates was 
explored by adding the variables to the model in a stepwise manner and (at each step) 
retaining the covariates if there was either 1) a significant (p<.05) improvement in the 
likelihood of the fit o f the new model, or 2) the covariate caused a substantial alteration 
o f the coefficients representing the effect o f the primary predictor. Lastly, when the 
above process had settled on a ‘final model’, all pairwise interactions involving the 
primary covariate were tested.
7.4 Results
7.4.1 Population characteristics
There were 1614 participants in our cross-sectional sample. O f these, 829 (51.4%) were 
men, 1445 (90%) were white, 53 (3.3%) were Chinese and 24 (1.5%) were Indian. The 
mean ± SD age o f the participants was 21 ± 2.89 years. Twenty-six percent o f the 
population were either overweight or obese (n=420): 21% were overweight and a 
further 5% were obese (Figure 7.1). Self-reported subjects with “doctor confirmed 
diagnosis of asthma ever” represented 23.3% of the study population (n=374) with 
“current doctor diagnosed asthma” represented by 10.9% (n=176). Bronchodilators 
were taken by 10.8% (n=175) and 3.5% (n=56) were taking regular inhaled
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corticosteroids. Subjects reporting “smoking for as long as a year” represented 26.8% of 
the population (n=433) with 16.9% reporting current smoking (n=271). Population 
characteristics are shown in Figure 7.1 and Tables 7.1-7.3 with correlations between the 
adiposity indices shown in Table 7.4.
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Figure 7.1 Baseline characteristics o f the population by weight 
category, subdivided by gender. Males are slightly over-represented in 
the overweight group.
Table 7.1 Baseline characteristics o f study participants, by adiposity 
indices.
Males Females
BMI 23.8 ± 3 .5 ' 23.1 ±3 .6
Waist circumference 82.8 ± 8.6 74.0 ±8.1
Waist/hip ratio 0.82 ± 0.05 0.75 ±0.05
Percentage body fat 17 ± 6.0 28 ± 7 .0
x ± SD (all such variables).
underweight to noi inal 18.5 to overweight 25 to obese 30 and
18 499 24 999 29 999 above
Weight group
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Table 7.2 Baseline characteristics o f study participants in relation to 
asthma and adiposity indices.___________________________________
Current asthma “Never asthma”
BMI 24.5 ± 4.21 23.3 ± 3 .4
Waist circumference 80.4 ± 11.1 78.1 ±9.1
Waist/hip ratio 0.79 ± 0.07 0.78 ± 0.06
Percentage body fat 24.3 ± 9.3 22.0 ± 8.4
x ± SD (all such variables).
Table 7.3 Baseline characteristics o f asthmatics vs. non-asthmatics, 
according to weight category.___________________________________
Current asthma “Never asthma”
Underweight 4 (2.3) 52 (4.3)
Normal weight 110 (62.5) 856 (70.7)
Overweight 49 (27.8) 243 (20.1)
Obese 13 (7,4) 59 (4.9)
Data are number (percentage) o f subjects.
Table 7.4 Correlations between adiposity indices.
BMI Waist
circumference
Waist/hip
ratio
Percentage 
body fat
BMI .8231 .462 .876
Waist circumference .776 .575 .834
Waist/hip ratio .180 .578 .509
Percentage body fat .794 .782 .460
Data are R
1 Model included sex in all cases except analysis o f waist/hip ratio dependent on 
waist circumference where sex interaction was non-significant.
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7.4.2 Logistic regression analysis of adiposity and clinical outcomes
Logistic regression analysis was performed for the clinical outcomes o f asthma, 
hayfever and eczema and the results are outlined in this section. Analysis o f  the 
association between adiposity and asthma severity then follows: severity was analysed 
by a combination o f logistic and linear regression. Lastly, the linear regression results 
are presented, examining the association between adiposity and lung function, IgE, 
eosinophils and eotaxin. The outcomes o f “current asthma”, “asthma ever” and “asthma 
attack in last 12 months” all refer to a physician diagnosis o f asthma.
BMI was a highly significant predictor o f current asthma (p<.001); “asthma ever” 
(p<.001); “attack of asthma in last 12 months” (p<.01) and “wheeze in last 12 months” 
(p<.001). The odds ratio for the association with current asthma was 1.083 for a unit 
change in BMI (95% Cl, 1.04-1.13). Thus a clinically meaningful change in BMI would 
be associated with increased risk o f asthma as follows:
• a BMI o f 29 (overweight range) compared to BMI 24 (normal range) equates to 
a 41.5% increased risk o f asthma
• a BMI o f 34 (obese range) compared to BMI 24 (normal range) equates to a 
83% increased risk o f asthma
When comparing the odds o f asthma in the obese versus the non-obese categories, the 
odds ratio was 1.6 (95% Cl 0.98-2.22): this is just non-significant at the 5% level due to 
the small number o f obese subjects, and examining BMI as a continuous variable is 
more informative. When the overweight and obese are grouped together, the odds ratio 
is almost identical at 1.61 (95% Cl 1.28-1.94), which is a significant difference, with 
p=.005.
The prevalence o f asthma according to weight group is shown in Figure 7.2 and the 
estimated probabilities derived from the logistic regression model are shown in Figure
7.3. It can be seen that prevalence rises across weight groups for the group as a whole,
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with a dose-response effect o f elevated BMI on asthma, with much more striking effects 
seen for females. For the males, prevalence drops slightly between the overweight and 
obese groups but this is not a significant difference, and as stated, numbers of obese 
subjects were relatively small. For both sexes, there was a significant and positive 
association between BMI and asthma, with larger effects for females: OR 1.093 (95% 
Cl 1.04-1.14) for females; OR 1.076 (95% Cl 1.02-1.13) for males.
There was a sex modifying effect in the association with “asthma ever” such that there 
was only a significant association for females (p<.001; OR 1.094, 95% Cl, 1.05-1.14). 
The association with “attack of asthma in last 12 months” did not remain significant 
after adjusting for body fat.
■ male
□  female
□  all
Underweight Normal weight Overweight O b ese
Figure 7.2 Prevalence of asthma according to weight group. The 
prevalence o f asthma increases with weight, with the effects being more 
marked in the females. A dose-response effect o f elevated BMI on 
asthma is seen across the group as a whole.
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Figure 7.3 Estimated relationship between probability of asthma and 
BMI, as obtained from fit of logistic regression model.
Waist circumference was significantly associated with current asthma (p<.01; OR 
1.022, 95% Cl, 1.01-1.04; Figure 7.4) and “wheeze in last 12 months” (p<.001). Putting 
this into clinical context, a 10cm increase in girth would equate to a 22% increase in 
risk of asthma. These associations were not significant after adjusting for BMI. The 
association with wheeze (but not current asthma) remained significant after adjusting 
for body fat. Again the association with “physician-diagnosed asthma ever” was only 
significant in females (p<.001; OR 1.039, 95% Cl, 1.02-1.06).
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Figure 7.4 Estimated relationship between probability o f asthma and 
waist circumference (WC), as obtained from fit of logistic regression 
model.
Waist/hip ratio showed no significant associations with any o f the binary asthma 
outcomes described. There was a significant association with ‘"wheeze in last 12 
months” with a high OR of 8.25 (p=.02, 95% Cl, 1.50-45.39). There was an inverse 
association with “eczema ever” (p=.03, OR 0.12, 95% Cl, 0.05-0.32) but this is of 
questionable relevance since no significant association was seen for males or females 
when analysed as separate subgroups, and there was no association with “current 
eczema”.
Percentage body fat was significantly associated with current asthma (p=.001; OR for 
unit increase o f 1.032, 95% Cl, 1.01-1.05) (Figure 7.5) after adjusting for waist 
circumference but not after adjusting for BMI. However the association with “asthma 
attack in last 12 months” (p=.001; OR 1.04) remained significant after adjusting for 
BMI and WC indicating an effect over and above these factors. The association with 
“wheeze in last 12 months” did not quite reach significance. Body fat significantly 
predicted current eczema (p=.001; OR for unit increase o f 1.031, 95% Cl, 1.01-1.05). 
Thus to extrapolate to a clinical context, if we consider a male with low-normal BF of
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12% compared to male with BF 22% which is just beyond normal range, this 10% 
increase in body fat would equate to:
• 32% increase in risk of current asthma
• 31% increase in risk of current eczema
A summary of the associations between adiposity indices and clinical outcomes is 
shown in Table 7.5. None of the obesity measures showed significant associations with 
hayfever.
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Figure 7.5 Estimated relationship between probability of asthma and 
body fat (BF), as obtained from fit of logistic regression model.
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Table 7.5 Associations between adiposity indices and clinical outcomes.
Current doctor- 
diagnosed asthma
Wheeze last 
12 months
Current eczema
BMI Positive association 
p c .0 0 1  
OR 1.08
95% Cl 1.04-1.13
Positive association 
p c .0 0 1  
OR 1.06
95% Cl 1.03 to 1.09
No association
W C Positive association 
p < .0 1
OR 1.02
95% Cl 1.01- 1.04
Positive association
p < .001
OR 1.02
95% Cl 1.01-1.03
No association
W H R No association Positive association 
p c .0 0 1  
OR 8.25
No association
%  BF Positive association 
P =. 001 
OR 1.03
95% Cl 1.01-1.05
Association N S1 
P = .055
Positive association 
P = .001 
OR 1.03 
Cl 1.01-1.05
NS, non-significant
7.4.3 A sthm a severity
Subjects with current asthma represented 10.9% of our population (n=176) with a 
further 12.3% (n=198) having had asthma which had remitted. Subgroup analysis o f the 
“current asthma” group was undertaken to ascertain whether adiposity indices were 
associated with asthma severity. The characteristics o f the asthma group have 
previously been shown in Table 5.9. Only one subject was taking inhaled cromoglycate, 
anti-muscarinic, oral methyl xanthine or an oral leukotriene antagonist respectively. 
Only one subject had spent nights in hospital over the last 12 months and no subjects
183
had been admitted to ITU in the last 12 months. Forty subjects had had to give up days 
o f work or other activities over the last 12 months: o f these, the number o f days lost per 
month was 1.01 ± 1.30.
A subgroup analysis was undertaken on subjects with a current physician diagnosis of 
asthma to examine the effect o f obesity on physiological and clinical severity. BMI 
predicted frequency o f symptoms over the last 3 months, after adjusting for sex and 
smoking (p<.05, OR 1.086). Therefore for each unit change in BMI, there was an 8.7% 
increased risk o f having a higher frequency o f symptoms e.g. “continuous” compared 
with “daily” symptoms. BMI also predicted daily inhaled bronchodilator volume 
(p<.05). There was a significant sex modifying effect such that the association was only 
significant in men (p<.01) (Figure 7.6). There was also a smoking interaction (p=.048) 
such that a positive linear association was seen for the current smokers or those who had 
smoked for up to one year (p<.001), whereas a quadratic relationship provided the best 
fit for the data for the non-smokers, where a J-shaped curve shows volume of 
medication to be increased at both weight extremes, with a rise also for the underweight 
group (Figure 7.7).
BMI did not predict any other o f the severity criteria, including classification by GINA 
criteria (shown previously in Table 5.10) nor daily volume o f  inhaled corticosteroid. 
None o f the other adiposity measures predicted asthma severity. None o f  the adiposity 
indices were associated with worse lung function severity (% predicted FEV1 and PEF) 
in the current asthmatics. In fact, BMI was positively associated with % predicted FEV1 
and PEF; and waist circumference and body fat were positively associated with % PEF. 
These data are difficult to interpret and the main reason for the positive association is 
likely to be that the quadratic variable (BMI2, WC2, BF2) failed to reach significance for 
this subgroup compared to the population as a whole, probably because o f the much 
smaller number in the current asthma subgroup (n=176). However, waist circumference 
and waist/hip ratio were inversely associated with FEV1/FVC ratio (p<.05, p<.01) with 
the association only significant at the 10% level for body fat, in the asthma group 
(p=.09).
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Figure 7.6 Estimated relationship between daily beta-agonist usage and 
BMI according to gender. Volume of medication rises sharply in males 
with increasing levels of obesity. No association is seen for females. Plot 
lines are obtained from linear regression. Data points are omitted for 
reasons of clarity here, since the large number of data points obscures the 
intersect.
Current sm okers 
Non-smokers
Figure 7.7 Estimated relationship between daily beta-agonist usage and 
BMI according to smoking status. For smokers, a linear association is 
seen, with volume of medication rising steadily with increasing levels of 
obesity. For non-smokers, a J-shaped curve is seen, with volume of 
medication increased at both weight extremes, with a rise also for the 
underweight group. Data points are omitted for reasons o f clarity here, 
since the large number of data points obscures the intersect.
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7.4.4 Linear regression analysis of adiposity and lung function in an unselected 
population
Although there is considerable scatter about the regression lines, the large population 
makes it possible to detect significant relationships. The obesity measures showed non­
linear associations with lung function parameters. For the majority o f associations, a 
quadratic curve provided the best fit for the data in regression analysis. That is, lung 
function increased as anthropometric measurements increased over normal ranges but as 
higher values were reached, lung function then decreased. A quadratic model was 
chosen as the best model for the data when the quadratic form o f the covariate showed a 
significant association with the dependent variable at the 5% level.
A summary o f the associations between adiposity indices, asthma and lung function is 
shown in Table 7.6.
BMI
BMI was significantly associated with absolute and percentage o f age-gender-stature 
predicted values of FVC, FEV1 and PEF (pc.001) (Figure 7.8 & 7.9). BMI was 
inversely associated with FEV1/FVC ratio which indicates degree o f airflow obstruction 
(p<.001) (Figure 7.10). Smoking (history o f “smoking for as long as a year”) modified 
the effects on FVC and FEV1. There was no significant association between BMI and 
flow rates at 25-75% of expired vital capacity (FEF 25-75). BMI remained a significant 
predictor of lung function after adjusting for WC and body fat, but was not an 
independent predictor o f FVC, FEV1 and PEF once waist/hip ratio was adjusted for.
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Figure 7.8 The association between FVC and BMI. A quadratic 
relationship is seen, with FVC increasing across normal anthropometric 
ranges of BMI, with an inverse association seen as BMI approaches 
obese levels.
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Figure 7.9 The association between % FEV1 and BMI. A quadratic 
relationship is seen, with % FEV1 increasing across normal 
anthropometric ranges of BMI, with an inverse association seen as BMI 
approaches obese levels. An almost identical association is seen as for 
FVC in Figure 7.8 above: similar quadratic associations were seen for 
both absolute and age-gender-stature predicted values.
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Figure 7.10 Estimated association between FEV1/FVC and BMI. A 
decline in FEV1/FVC, indicating increased airflow obstruction, is seen 
with increasing BMI. As for other variables, there is considerable scatter 
about the curve. Data points are omitted here because they obscure the 
inflexion point at around BMI=30.
W aist circumference
Waist circumference (WC) was significantly associated with FVC, FEV1, PEF and also 
FEF 25-75 (unlike BMI) (p<.001) (Figures 7.11-7.13). Similarly to BMI, smoking 
modified the effects of WC on FVC, FEV1 and also showed an interaction with PEF. 
Sex also modified the effects on PEF such that the relationship was more marked in the 
males (p<.05) (Figure 7.12). Like BMI, WC was inversely associated with FEV1/FVC 
ratio (p<.001) (Figure 7.14). The associations between WC and absolute lung function 
and FEV1/FVC ratio remained significant after adjusting for BMI but the associations 
observed for % predicted values for FVC and PEF did not remain significant after 
adjusting for BMI.
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Figure 7.11 The association between FEV1 and waist circumference 
(WC). A quadratic relationship is seen, with FEV1 increasing across 
normal anthropometric ranges of WC, with an inverse association seen at 
higher levels of adiposity.
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Figure 7.12 The association between PEF and waist circumference 
(WC), according to gender. A quadratic relationship is seen for both 
sexes, with PEF increasing across normal anthropometric ranges o f WC, 
with an inverse association seen at higher levels of adiposity. The 
relationship is more marked in the males.
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Figure 7.13 The association between FEF 25-75 and waist 
circumference (WC). A quadratic relationship is seen, with FEF 25-75 
increasing across normal anthropometric ranges o f WC, with an inverse 
association seen at higher levels of adiposity.
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Figure 7.14 The association between FEVI/FVC and waist 
circumference (WC). A decline in FEVI/FVC, indicating increased 
airflow obstruction, is seen with increasing WC.
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Waist/hip ratio
Waist/hip ratio (WHR) was significantly associated with FVC, FEV1, PEF, FEF 25-75, 
FEVI/FVC and % predicted FVC (p<.001) (Figure 7.15-7.16). These associations 
remained significant after adjusting for BMI and body fat, except for the association 
with % predicted FVC which was not significant after adjusting for BMI . Interestingly 
WHR was an independent predictor of FVC, FEV1, PEF and FEF 25-75 whereas BMI 
was not an independent predictor once WHR was adjusted for. An inverse association 
was again seen for the relationship between WHR and FEVI/FVC ratio (p<.001) 
(Figure 7.16).
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Figure 7.15 The association between FEV1 and waist/hip ratio (WHR). 
A quadratic relationship is seen, with FEV1 increasing across normal 
anthropometric ranges of WHR, with an inverse association seen at 
higher levels of adiposity. Note that the quadratic parameter is not 
(strongly) determined by the outlying very high WHR individuals.
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Figure 7.16 Estimated association between FEVI/FVC and waist/hip 
ratio (WHR). A decline in FEVI/FVC, indicating increased airflow 
obstruction, is seen with increasing WHR. Data points are omitted here 
since they obscure the plot line, obtained from linear regression.
Body Fat
Body fat showed significant associations with FVC, FEV1, PEF, FEF 25-75 and % 
predicted FVC, FEV1 and PEF (p<.001 except for % FEV1 where p<.05) (Figures 7.17- 
7.20). Associations remained significant after adjusting for BMI, waist circumference or 
waist/hip ratio, except for the association with % predicted values which were not 
significant after adjusting for BMI. There were sex-modifying effects on the 
associations with absolute lung function, which was most significant for the interaction 
with FEV1 (pc.001). Of interest was the importance of analysing the data for male and 
female subgroups separately, since both absolute lung function and body fat ranges are 
different for males and females. Thus when analysing the group as a whole, the 
associations between body fat and absolute lung function were inverse i.e. lung function 
declined with increasing body fat across the entire range (Figure 7.17). However, 
analysis by sex subgroup clarified the association with the same quadratic relationship
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demonstrated as with other obesity measures (Figure 7.18). When analysing separate 
subgroups o f males and females, there was an inverse association o f body fat with 
FEVI/FVC, i.e. an increase in airflow obstruction with BF for both sexes (p<.001). 
Exploration o f quadratic terms clarified the association, with a linear inverse 
relationship for females and a quadratic relationship shown for males (Figure 7.21).
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Figure 7.17 The association between FEV1 and body fat (BF). A 
decline in FEV1 is seen with increasing BF, for the group as a whole.
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Figure 7.18 The association between FEV1 and body fat (BF), 
according to gender. A quadratic relationship is seen for both sexes, with 
FEV1 increasing across normal anthropometric ranges of BF, with an 
inverse association seen at higher levels of adiposity. The relationship is 
more marked in the males.
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Figure 7.19 The association between % FEV1 and body fat (BF). A 
weak quadratic relationship is seen, with % FEV1 increasing across 
normal anthropometric ranges o f BF, with an inverse association seen as 
BF reaches higher levels. Small effects are seen, individual data points 
are removed in Figure 7.20 to show the association more clearly.
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Figure 7.20 Estimate of relationship between % FEV1 and body fat 
(BF), obtained from regression fit in Figure 7.19. Note the difference in 
scale presented in the two graphs.
195
 Plot line for fem ales
 Plot line for m ales
>
W 80Li-
75
70
0 10 20 30
% B o d y  fa t
Figure 7.21 Estimated relationship between FEVI/FVC and body fat 
(BF) according to gender. For females, an inverse linear association is 
seen. For males, a quadratic relationship is seen. Data points are omitted 
for reasons of clarity here, since the large number o f data points obscures 
the plot lines.
7.4.5 Linear regression analysis of adiposity and Th2 immune m arkers in an 
unselected population
The geometric mean IgE was 49kIU/L (95% Cl 40-59). The highest IgE was 
18,802kIU/L from a male ex-asthmatic with moderately severe eczema (subsequently 
referred for investigation of hyper IgE syndrome). Males had significantly higher total 
IgE (p<.001), outlined in detail in Chapter 4.
IgE significantly predicted current asthma, after adjusting for sex (OR, on log scale, 
1.51, 95% Cl 1.35-1.67, p<.001). Thus for a 2.7 fold increase in IgE, there was a 51%
Total IgE
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increased risk of having current asthma. For current asthmatics, IgE was positively 
associated with an attack of asthma in the last 12 months, after adjusting for sex and 
height (OR, on log scale, 1.53, 95% Cl 1.20-1.94, pc.001). Thus a 2.7 fold increase in 
IgE was associated with a 53% increased risk of having an attack of asthma in the last 
12 months. IgE was not associated with other severity indices, including severity score, 
symptom frequency, % predicted FEV1 and PEF.
BMI
The association between BMI and IgE was non-significant for the group as a whole 
(p=.09). However there was a significant sex interaction with BMI and IgE (p=.016) 
such that there was a significant positive association between BMI and IgE in the 
female subgroup only (Figure 7.22). For the entire range of BMI (15-51), this equates to 
an increase from IgE 29 to 120kU/L. The positive association for females remained 
significant after adjusting for current asthma (p= 04).
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Figure 7.22 The association between total IgE and BMI for the females. 
A positive association was seen for the females but not the males.
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Waist circumference
For the group as a whole, there was an association between waist circumference and 
IgE, after adjusting for age (p=.012). There was a sex interaction (p=.044) such that 
there was a positive association for females but no significant association for males, 
with a small positive effect seen with increasing age (Figure 7.23). The association 
remained significant after further adjustment for current asthma, in addition to age- 
adjustment (p=.04).
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Figure 7.23 The association between total IgE and waist circumference 
(WC) for the females. A positive association was seen for the females 
but not the males.
Waist/hip ratio
There was a similar pattern for waist/hip ratio as for waist circumference, with a small 
positive effect seen with increasing age (p<.001 after adjusting for age). A positive
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association was seen in females (Figure 7.24) but the sex interaction did not quite reach 
significance (p=.053). The association was of borderline significance for females when 
further adjustment for current asthma in addition to age was applied (p=.052).
When examining the group with current asthma (n=176), the only significant 
association was between waist/hip ratio and IgE (p=.024).
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Figure 7.24 The association between between total IgE and and waist/hip 
ratio (WHR) for the females. A positive association was seen for the females 
but not the males. Note that the fit obtained from linear regression is not 
dependent on the outlying very high WHR individuals.
Body fa t
There was no relationship between body fat and IgE except for sex being associated 
with body fat which is expected since normal body fat ranges are different for males and 
females.
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Eotaxin
BMI
BMI showed a significant association with eotaxin, after adjusting for sex, age and 
number of pack years (p<.01). There was a sex-modifying effect such that the 
association was only significant for males. The relationship was also modified by age 
and number of pack years such that the relationship was more marked with increasing 
age and pack years. A quadratic model provided the best fit for the data, with 
improvement in the fit o f the model being significant at the 5% level (likelihood ratio 
test). Figure 7.25 shows the relationship for males, with a comparison of the different 
shaped relationship for those aged 30 years versus those aged 18 years. An adjustment 
for asthma was not undertaken since there was no significant correlation between 
asthma and eotaxin levels (in contrast to correlations for asthma with IgE and eosinophil 
count, presented previously in Table 4.1).
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Figure 7.25 The relationship between eotaxin and BMI for males, with plot 
lines derived from linear regression showing the shape o f the relationship at age 
30 years in comparison to age 18 years. An essentially U-shaped curve is seen 
for those aged 18 years, with an increase in eotaxin at both extremes o f BMI, 
whereas the relationship approximates linearity for those aged 30 years. 
Individual data points are not shown by age since the majority o f the population 
fell between the ages of 18-30 years. No significant associations were seen for 
females.
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Waist circumference
Waist circumference showed a positive linear association with eotaxin, after adjusting 
for number of pack years (p<.05), for both males and females. The relationship was 
more marked with increasing pack years. However the effects were small: across the 
range of WC (57.8-128.4cm), geometric mean eotaxin increased from 10.2-17.3 pg/ml. 
Figure 7.26 shows ln(eotaxin+l) plotted against WC.
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Figure 7.26 The association between between eotaxin and waist 
circumference (WC). Given the sample size, the undetectable eotaxin levels 
(counted as zero) did not affect the analysis since ln(eotaxin+l) closely 
approximated normal distribution. Moreover, since the sample size is large, 
the regressions are robust to departures from normal assumptions.
Waist/hip ratio
Waist/hip ratio (WHR) showed a similar positive linear association with eotaxin as WC, 
after adjustment for pack years (p<.001), with a more marked relationship with 
increasing pack years. The effects were larger than for WC: across the range of WHR 
(0.63-1.25), geometric mean eotaxin increased from 8.7-30.8 pg/ml (Figure 7.27).
2 0 1
10 n
9 1 8 -
7
6
5
4
3
2
1
0
0.80.6 1 1.2
Waist/hip ratio
Figure 7.27 The association between between eotaxin and waist/hip ratio 
(WHR). Given the sample size, the undetectable eotaxin levels (counted as 
zero) did not affect the analysis since ln(eotaxin+l) closely approximated 
normal distribution. Moreover, since the sample size is large, the regressions 
are robust to departures from normal assumptions.
Body fa t
Body fat showed a significant association with eotaxin, after adjusting for age and 
number of pack years (p<.001). A quadratic model provided the best fit for the data. 
There was a sex-modifying effect such that the association was only significant for 
males. The relationship was also modified by age and number o f pack years such that 
the relationship was more marked with increasing age and pack years (Figure 7.28). For 
example, when comparing males with a body fat beyond the normal range at 33% with 
no pack years versus 15 pack years, the geometric mean eotaxin is 14.8 vs 48.3 pg/ml 
respectively, with greater differences at the extreme upper end o f the range.
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Figure 7.28 The relationship between eotaxin and body fat (BF) for males, with 
plot lines derived from linear regression. The curves become steeper with 
increasing smoking history (pack years) indicating a more marked increase in 
eotaxin with BMI with increased smoking. Associations were not significant for
females.
Eosinophil count
Waist circumference showed a significant positive association with eosinophil count 
(p<.001 after adjusting for current smoking) and there was a smoking interaction such 
that the association was more marked in the current smokers (p<.05) (Figure 7.29). 
Waist/hip ratio showed similar associations (p<.001, smoking interaction p<.05) (Figure 
7.30). The associations for central adiposity measures and eosinophil count remained 
highly significant after adjustment for current asthma, with adjusted p values o f .001 
and <.001 for waist circumference and waist/hip ratio respectively. It was noted that 
smoking pack years predicted eosinophil count such that an increase of 10 pack years 
equated to a 0.07 increase in eosinophil count (p<.001). For BMI, there was a smoking- 
modifying effect such that a positive association with eosinophil count was only seen in 
current smokers, although the interaction with current smoking just failed to reach 
statistical significance (p=.054). The associations for smokers remained significant after 
adjustment for current asthma (p =.027). For body fat, the only significant association 
was between sex and body fat, with no direct relationship with eosinophil count.
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A summary of the associations between adiposity indices and immune phenotypes is 
shown in Figure 7.7.
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Figure 7.29 The relationship between eosinophil count and waist 
circumference (WC), with plot lines derived from linear regression. The 
gradient is steeper for the smokers indicating a more marked increase in 
eosinophils with WC for smokers.
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Figure 7.30 The relationship between eosinophil count and waist/hip ratio 
(WHR), with plot lines derived from linear regression. The gradient is steeper 
for the smokers indicating a more marked increase in eosinophils with WHR for 
smokers.
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Quadratic relationships were seen: see section 7.4.4.
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Table 7.7 Summary of associations between adiposity indices and immune
phenotypes.
Adiposity measures Immune phenotype P value1
BMI, WC, WHR Total IgE <.05 for females
BMI, %BF Eotaxin <.01 for males
WC, WHR Eotaxin <.05 for whole group
WC, WHR Eosinophil count <.001 for whole group
BMI
"i 1 ^
Eosinophil count <.05 for current smokers
After adjusting for relevant covariates.
7.5 Discussion
General adiposity measures (BMI, BF) were associated with increased odds o f asthma. 
Waist circumference, as a measure o f central adiposity, was also associated with 
increased odds of asthma but WHR was not. Several studies have shown the association 
between BMI and asthma is exclusively or predominantly seen in females. Our study 
showed adiposity indices to be associated with increased risk o f asthma in both sexes, 
but with more marked effects in females.
Due to the more marked effects in females, a smaller sample size is likely to result in 
significant association being seen only in females; this is supported by our analysis o f 
the first 1000 subjects initially, where significant associations were seen only for the 
female group, with smaller but significant effects seen for males on analysis o f the total 
dataset. This highlights the importance o f sample size in such studies. As expected from 
diseases with complex aetiology, there tends to be large scatter around the average trend 
lines for individual factors, and adiposity measures are not expected to explain a high 
percentage o f the variance in asthma risk. However, within this large study we were 
able to demonstrate the significant involvement o f adiposity in a range o f asthma 
outcomes.
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The age of our population may have had some bearing regarding differential sex effects 
also since this was a young adult population; sex differences may become apparent in 
older age groups and this may skew results unless analysis o f subgroup according to age 
is undertaken.
Relatively few studies have examined the association between central adiposity and 
asthma. Studies in Canadian and Hispanic populations demonstrated an association 
between waist circumference and asthma, but only in women [302, 304], Our study 
demonstrated an association in both sexes, corroborated by a Swedish study [303]. The 
relationship with WHR has only been examined in one other study, which found no 
association with asthma, as did our own study [304]. A study o f  morbidly obese 
subjects found WHR to be associated with increased odds o f asthma [340].
The examination of body fat as a predictor of asthma is relatively novel, having been 
examined in few other studies. Body fat has the advantage o f  being the most direct 
marker o f adiposity and significantly predicted current asthma in our study. A recent 
Dunedin study, which examined a similar age group to our own population, found body 
fat to associate with asthma and airflow obstruction in females only [341]. However, it 
is o f note that this study used an identical sample size as included in our preliminary 
analysis (n=1000), with additional effects only apparent in our male population when 
the total subset was analysed. Body fat was associated with rhinoconjunctivitis but not 
asthma in a study o f  1185 Vietnamese adolescents [342]. Our findings o f an association 
between body fat and asthma further clarifies the role o f adiposity in asthma, suggesting 
that an increase in adipocytes themselves may contribute to asthma -  possibly via pro- 
inflammatory effects - beyond the mechanical effects o f  increased body mass alone. 
Ideally, the gold standard of dual-energy X-ray absorptiometry would have been used to 
measure body fat. However, this was not practical in a field study and for large 
epidemiological studies, body impedance analysis is regarded as a simple and valid 
measure of determining body composition [343]. Moreover, differences between fat 
measurement using these techniques are small [344] and other investigators have used 
bioelectrical impedance with reproducible results [345, 346].
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There are methodological weaknesses to several studies reporting an association 
between obesity and asthma (e.g. use o f self-reported asthma, weight and height) and 
there is a possibility o f bias in that the obese may be more likely to present to the 
healthcare system and so asthma may be diagnosed more often. Also, it is difficult to 
assess the extent o f publication bias for studies showing a positive association. A 
strength o f our study was that we used exact anthropometric measurements rather than 
self-reported measurements; the majority o f measurements being done by the same 
operator and the remainder supervised by that same operator (myself), minimising inter- 
operator variation. Furthermore, the use o f the outcome o f current doctor-diagnosed 
asthma in addition to “doctor-diagnosed asthma ever”, is likely to strengthen our 
findings. Many studies used only the latter definition which may lack specificity by 
including uncertain cases diagnosed during childhood (where asthma has now remitted) 
and o f dubious relevance to the relationship between obesity and asthma, in particular 
when examined in a cross-sectional study in adulthood. A weakness is that we did not 
confirm the diagnosis o f asthma by objective measures (PEF variability, AHR). 
However only cases o f “physician-confirmed asthma” were included which is accepted 
as a relatively robust measure for epidemiological purposes [234, 235]. Furthermore, 
intermediate phenotypes were quantified (IgE, eosinophils, eotaxin, lung function).
Our study had the advantage o f  examining BMI (in addition to other adiposity indices) 
as a continuous variable rather than simply as weight group categorical variables, which 
is likely to lead to more informative results. For comparison purposes, odds ratio by 
weight category was also reported: compared with normal weight, overweight/obesity 
conferred increased odds o f asthma, with an odds ratio o f 1.61 (95% Cl 1.28-1.94), 
which is comparable to other studies, but with smaller effect sizes seen than in some 
[297, 298]. A dose-response effect o f elevated BMI on asthma was observed. The 
effects are especially striking since stricter definitions o f  physician-diagnosed asthma 
were used in the study, as outlined above, and also since a narrow age range o f  young 
adults were examined, and the effects o f  obesity may be more marked in older groups. 
Publication bias is likely to lead to the reporting o f striking positive associations in
208
smaller studies, whereas effects tend to be more modest when studied in larger 
populations [347], Since obesity may be a more specific phenomenon to certain subsets 
- and this was true for females in our study -  dilutional effects are likely to be relevant 
when examining the group as a whole, emphasising the importance o f examining effects 
by gender [328].
Adiposity had few discernible effects on asthma severity in terms o f GINA criteria or 
lung function, on subgroup analysis. This is not surprising since this was an unselected 
population with few subjects having severe disease, and the majority having mild 
asthma, as expected in a community sample. However, BMI predicted frequency o f 
symptoms in the previous 3 months and an interesting positive correlation between BMI 
and daily bronchodilator volume was observed for a subset o f male smokers. It may be 
tentatively hypothesised that BMI may relate to airway hyperresponsiveness (AHR). It 
was not logistically feasible to measure AHR in this field study, but it is interesting to 
note that Chinn et al found BMI to associate with AHR only in men [299].
There are inherent difficulties in obtaining a truly random sample representative o f the 
general population, which apply to any epidemiological study. This study may 
underestimate the effects o f obesity on asthma since overweight/obese students may be 
less likely to volunteer for anthropometric measurements and lung testing. 
Overweight/obese females in particular may be reluctant for reasons o f  body image, 
supported by females being under-represented in the overweight group. However, the 
prevalence of overweight/obesity overall was comparable to national figures for this age 
range, at 26% of our population.
With regard to physiological measures, adiposity measures showed a non-linear positive 
association with lung function over normal ranges and negative association as adiposity 
measures increased beyond the normal range, suggesting extremes o f adiposity to be 
associated with lower lung function. A similar inverted U-shaped curve was 
demonstrated from the NHANES-III data (for BMI quintiles) and for children aged >12 
years in a recent Mexican study [348, 349]. However previous studies have in general
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shown solely an inverse association between BMI and lung function [294]. Our data are 
consistent with increasing muscle mass leading to improved ventilatory function but as 
subjects become more adipose, a detrimental effect on lung function is seen.
In addition to BMI, we examined the effects o f increasing body fat and central adiposity 
(WC, WHR) about which there is a relative paucity o f  data. We also examined the 
effects on other lung function parameters in addition to FEV1 and FVC, giving further 
information on expiratory flow rates (PEF, FEF 25-75) and airways obstruction 
(FEV1/FVC ratio). Additional adiposity measures (BF, WC, WHR) showed similar 
non-linear association with lung function as BMI. Unlike BMI, this association was also 
seen for mid-expiratory flow rates (FEF 25-75). Separate studies in children and elderly 
men have shown body fat to be inversely associated with ventilatory function but have 
not examined flow rates [345, 350].
In our study, both BMI and central adiposity measures were inversely associated with 
FEV1/FVC ratio. Inverse effects were also seen for body fat in male and female 
subgroups. This is interesting since several previous studies have shown adiposity to 
have no effect on this ratio, with similar reduction in FEV1 and FVC leading to a 
restrictive pattern of lung function [351-353]. The NHANES-III study found the 
prevalence o f significant airflow obstruction (FEV1/FVC<80%) to be lower in the 
obese, despite an increased prevalence o f self-reported asthma [348] and the Normative 
Ageing Study on 30-79 year olds found a positive association between BMI and 
FEV1/FVC ratio [354]. However data from children and adolescents have shown a 
tendency for FEV1/FVC to decline with BMI, supporting our findings, and it is possible 
that an inverse relationship exists in childhood and early adulthood rather than in later 
adulthood [332,349].
Decline in FEV1/FVC along with reduced PEF and FEF 25-75 suggest both central and 
peripheral airways obstruction with increasing adiposity. This is consistent with 
previous findings o f reduced flow rates with increasing BMI [355, 356]. O f interest are 
the findings of Mansell et al who report an increase o f  FEV1 with BMI in normal
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subjects (comparable with the first part o f our quadratic curve), but found opposing 
patterns in subjects with asthma, with decreased FEF 25-75 with BMI demonstrated 
[357]. In our study, body fat and central adiposity measures, but not BMI, predicted 
FEF 25-75 (showing a quadratic association). This suggests that central or visceral 
adiposity may have a greater effect on small airways function than the effect o f weight 
itself, which is corroborated by a weight loss study which found loss o f  truncal fat mass 
to be most strongly related to improvements in FEF 25-75 [358]. A proposed 
explanation is that obesity may lead to accelerated remodelling o f the asthmatic airway 
with each exacerbation. Supporting evidence comes from the observation that weight 
loss in obese asthmatics leads to improved lung function but has no effect on airway 
hyperresponsiveness (AHR) [65], which may be because o f  increased remodelling, 
which tends to be irreversible. Other investigators have examined AHR with conflicting 
results; some studies show no association with BMI [322, 329], and others show an 
association only for men [299].
Despite a decline in FEV1/FVC ratio with increasing adiposity in our study, it should be 
noted that clinically relevant reductions in FEV1/FVC ratio (<80%) were only seen at 
upper extremes o f adiposity e.g. WC > 100cm. The data support a relationship between 
obesity and baseline flow limitation. The well-documented reduction in end-expiratory 
lung volume in obesity could be a cause o f expiratory flow limitation.
The influence o f body weight on lung function is complex and is likely to be dependent 
on a combination o f muscularity effects (directly proportional to lung function) and 
adiposity effects (inversely associated with lung function). This explains the non-linear 
relationship demonstrated in our study whereby lung function increases initially with 
increasing muscle mass but then decreases above a certain threshold o f adiposity. Weak 
inspiratory and expiratory muscles decrease vital capacity [359] whereas stronger 
muscles tend to improve ventilatory function. The contrasting effects o f  muscularity and 
adiposity may well also explain the purely inverse association seen in older age groups 
(where an increased weight correlates more closely with increased adiposity rather than 
muscle mass) compared with our population o f young adults.
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There are some limitations to our study. Firstly, we did not measure pre and post- 
bronchodilator spirometry or serial peak flow rates and so did not document 
reversibility to any airways obstruction present. However, given recent evidence that 
airway remodelling is an early phenomenon in asthma [238], pre-bronchodilator 
spirometry is likely to provide useful information beyond peak flow variability alone, 
especially in cases of more fixed airways obstruction associated with remodelling and 
occurring in a more severe asthma phenotype. Secondly, some o f our asthmatic subjects 
were on bronchodilator and/or inhaled corticosteroid treatment which is likely to 
improve lung function. Participants on bronchodilators and inhaled corticosteroids 
represented 10.8% and 3.5% of our population respectively. This potential bias was 
minimised by asking asthmatics to avoid taking their inhalers prior to spirometry if  
possible and taking all measurements in the mornings to maximise the effects o f diurnal 
variation in spirometry in asthma, characterised by morning dipping o f flow rates. 
Grading of asthma severity also takes these medications into account. Moreover, this 
could only lead to a Type 1 error if our asthmatic population were leaner than our non­
asthmatic population which was not the case.
Potential underlying mechanisms linking adiposity and asthma are outlined in detail in 
section 1.3. A body o f evidence supports a role for the adipocyte as a pro-inflammatory 
cell [328]. For instance, microarray data have shown that eotaxin is expressed by 
adipocytes, with expression upregulated by TNF-alpha [360]. Whilst several studies 
have examined the association between obesity and asthma, only a minority have 
examined whether obesity may also associate with atopy, with BMI being almost 
exclusively the only adiposity measure used, and conflicting findings in different 
populations. In this study, clinical atopic states (hayfever, eczema) were examined in 
additional to quantitative Th2 immune markers.
Body fat was found to associate with current eczema. No other associations were 
demonstrated between adiposity indices and clinical atopy, in particular, no associations 
for BMI or between adiposity indices and hayfever were demonstrated, consistent with 
findings from a German study [331] but in contrast to those o f  a Taiwanese study who
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reported an association between BMI and rhinoconjunctivitis in girls [327]. The 
negative findings described for BMI do not exclude that adiposity may have pro-atopic 
effects, since BMI is a rather indirect measure o f adipose tissue, being influenced to a 
large extent by body build, and measuring adipose tissue by more direct methods (e.g. 
body fat, skin fold thickness) may provide the tools to answer questions on the effects of 
adiposity on allergic inflammation in a more informative way.
In this cross-sectional study o f young adults, adiposity measures (BMI, WC) were 
associated with IgE in females but not in males, suggesting differential pro- 
inflammatory or endocrine effects by gender. These data are concordant with the 
finding o f higher total IgE in females with higher BMI after puberty [322]. A possible 
mechanistic basis is provided by Shore and colleagues’ murine studies where leptin 
administration has been shown to increase IgE production, airway hyperresponsiveness 
and Th2 cytokine production in ovalbumin-sensitized mice [178, 194]. As discussed in 
Chapter 1, leptin is increased in obesity and is higher in women. Thus females in our 
study may have higher leptin levels with potential effects on IgE production, although 
this requires further exploration in functional experiments.
Most studies have examined atopy together with asthma, with no attempt to correct for 
the effects o f asthma. Thus the effects o f obesity on atopy, independent o f asthma, have 
tended not be examined. Although asthma and atopy are inextricably linked, we also 
made adjustments for asthma in our analysis and found that the associations described 
between adiposity and Th2 markers remained significant after adjusting for asthma. 
This suggests that adiposity has effects on Th2 inflammatory markers, over and above 
the effects on asthma alone. Recent evidence suggests that obesity may lead to a pre- 
allergic state. A study examining the relationship between obesity and serum IgE levels 
and the appetite-regulating peptides leptin and ghrelin, found that obese children had 
significantly higher IgE levels and that ghrelin levels inversely correlated with IgE 
levels [192].
Our study included an exploration o f the modifying effects o f gender and smoking on
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the associations between adiposity indices and markers o f Th2 immunity. Novel 
differential effects were seen, which included the observation o f an association between 
BMI and eosinophil count, which was confined to the subgroup o f current smokers, and 
WC was associated after adjusting for current smoking. The National Health and 
Nutrition Examination Survey found obesity to be associated with skin test reactivity 
but not eosinophils but did not look specifically at the smoking subgroup [332]. 
Elevated levels of eosinophils have previously been observed in a small group o f 
morbidly obese individuals [361].
Eotaxin has not been widely studied in obesity. Vasudevan et al examined 49 obese 
patients and found higher eotaxin levels, demonstrated in humans and mice, and adipose 
tissue explants were found to secrete eotaxin [21]. A small Japanese study showed 
eotaxin levels to correlate with BMI and WHR, in addition to raised eotaxin-2 and 
monocyte chemoattractant-4 in the obese [362]. In our much larger study, BMI and 
body fat associated with eotaxin for the males rather than the females, suggesting 
differential effects by sex according to the specific phenotype examined. Furthermore, 
smoking was observed to potentiate these effects, in addition to influencing the 
associations described for eosinophil counts. It can be postulated that smoking enhances 
the pro-inflammatory effects o f adiposity. Murine studies have shown that acute 
concurrent exposure to allergen and cigarette smoke enhances airway inflammation, 
with increased eotaxin levels in bronchoalveolar fluid and increased airway 
responsiveness in sensitized mice [363].
The data suggest that the mechanisms driving the adiposity-asthma association are 
complex. Differential effects by sex and smoking were seen and it is likely that other 
environmental factors will also have modifying influences on the underlying 
mechanisms responsible in different phenotypes. Thus future work should explore the 
mechanistic basis o f the association in different homogenous subsets, e.g. sex, smoking, 
allergy. Outcomes must be clearly identified, and if  examining sex-specific effects, then 
the age range o f subjects is relevant since associations by gender are likely to occur at 
specific stages o f development o f the immune and endocrine systems.
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This thesis provides an analysis of multiple adiposity phenotypes in relation to asthma, 
lung function and Th2 immune parameters. A significant association is found between 
adiposity measures and asthma with adverse effects demonstrated on lung function, 
including increased airflow obstruction with obesity. The positive associations between 
adiposity measures with IgE, eosinophils and eotaxin suggest that the association 
between obesity and asthma may in part be mediated via an upregulation o f  Th2 
immunity, with modifying effects by sex and smoking status.
Since this thesis only examined Th2 immune markers, it may be that obesity has a non­
specific pro-inflammatory effect, and that Thl markers may also be raised in certain 
subsets. However, the positive associations seen between adiposity and all three Th2 
immune markers would suggest that Th2 upregulation is certainly likely to have a 
contributory role. Analysis o f other pro-inflammatory molecules, including Thl subsets, 
warrants further examination.
Since this was a cross-sectional study, a causal relationship between obesity and asthma 
cannot be inferred. However, several prospective studies have shown that an initial 
raised BMI is associated with an increased odds o f developing asthma in the future 
[203, 297, 308-313]. The increased risk o f asthma in the obese has significant public 
health implications since the prevalence o f obesity has risen dramatically and is likely to 
continue to rise. Obesity has a particularly high prevalence in socially deprived areas 
where individuals already have an increased risk o f asthma [364]. As many as 70% of 
severe asthmatics are obese [365] and findings from this thesis are likely to be 
especially pertinent to this severe refractory asthma phenotype which is associated with 
female gender, obesity and smoking and which poses the greatest challenge in terms o f 
asthma management and resources [366]. Quantifying the impact o f obesity on asthma 
will be crucial in guiding public health strategies and emphasising weight loss as a 
central part of asthma prevention and treatment. Further work is needed to explore the 
mechanistic basis o f the relationship between obesity and asthma which may identify 
novel targets for treatment o f this susceptible population.
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CHAPTER 8 
Conclusions
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8.1 CONCLUSIONS (I)
8.1.1 Effects of genetic variants of IL-13 signalling molecules on asthma,
Th2 immunity and physiological phenotypes
This thesis describes the largest population study to date to examine how common 
variants of IL-13 signalling genes relate to asthma and atopy. The primary objective was 
to test genetic variants o f Th2 immune signalling at the population level, to clarify the 
strength of these effects and examine the interactions between different loci. Common 
variants, encompassing the span o f the IL13, IL4RA and STAT6 loci, were used and 
associations with a range of phenotypes (including the validated phenotype o f physician 
diagnosed asthma) were tested.
Use of a large population of young volunteers, representative o f the general population 
from the same ethnic group and geographical background, allowed the estimation o f the 
true population risks conferred by specific genetic variants. However, the population 
cannot be said to be wholly ‘unselected’ since there was an element o f self-selection 
inherent in the recruitment process. Since the population is predominantly formed o f 
university students, it cannot be said to be socioeconomically representative o f the 
general population as a whole. However, the assembled population o f 1614 young adult 
volunteers did prove to be representative o f a general population o f adults o f this age 
group, in terms of asthma, overweight and obesity prevalence.
Genetic effects were clearly seen in our population, with effects evident across a range 
o f continuous variable clinical, immune and physiological phenotypes. Given the 
polygenic nature o f asthma and atopy with gene-environment interactions, it is striking 
that we see these effects consistently in a population o f young volunteers, where only 
extremes o f phenotype will manifest (as actual disease) clinically in what we would 
label “asthma”. Recent reviews o f genetic association studies have emphasized the 
importance o f large sample size both to confirm previous findings and to uncover novel 
associations [242,243, 367].
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Asthma is a heterogenous disorder and is therefore difficult to define for research 
purposes. For this reason, the genetic basis o f complex diseases such as asthma has 
proved difficult to unravel. The clinical diagnosis o f asthma is based on a combination 
o f clinical features (wheeze, breathlessness, cough) and evidence o f lability/reversibility 
(variability in peak flow rate, bronchodilator reversibility). When there is diagnostic 
doubt, methacholine challenge testing may be employed. In this thesis, asthma was 
defined as ‘physician confirmed asthma’ using a validated bronchial symptoms 
questionnaire. This thesis describes a genetic epidemiology study, and the phenotype of 
‘physician diagnosed asthma’ has been validated and accepted as a robust tool for 
epidemiological purposes. Ideally, a quantifiable asthma phenotype such as AHR 
(defined by challenge testing) would have been used in addition. This was not feasible 
in this initial field study but would be incorporated in future work. Whilst it is likely 
that AHR would provide useful additional information and allow narrowing o f the 
asthma phenotype, it is an intermediate phenotype and does not provide sufficient 
diagnosis of asthma when examined in isolation. Another potentially useful measure 
would have been bronchodilator reversibility o f FEV1, although many volunteers with 
asthma had a normal FEV1 in their stable state, and FEV1 is also influenced by asthma 
medication, limiting the usefulness in this context.
Another limitation o f the study is that although total IgE provided an intermediate 
phenotype for atopy, no direct quantifiable measures o f atopy were used. ‘Atopy’ 
describes a tendency to mount specific IgE responses to allergens and sensitisation is 
defined by positive skin prick tests (SPT) or specific IgE directed against common 
allergens. Early sensitization is a major risk factor for the development o f asthma in 
genetically susceptible individuals and asthma is associated with atopy in around 80% 
o f childhood asthma and up to 50% of adult asthma. Measurement o f SPT or specific 
IgEs should have been included in the study but given the large sample size was omitted 
for logistic reasons and limited resources.
A striking distribution of phenotype associations was evident across the three genes
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examined. Whereas IL13 variants associated with asthma and lung function variables, it 
was variants of 1L4RA and STAT6 that predicted higher IgE levels. This is consistent 
with the lack of association between IL13 variants and IgE levels demonstrated in 
previous case-control work [117] but contrasts with recent findings in British and 
German unselected populations [12, 132]. Our findings are consistent with a large body 
of functional work which implicates IL-4 (interacting with IL-4RA) in the initiation of 
Th2 immune responses to allergenic peptides leading to IgE production, whereas IL-13 
mediates the main physiological consequences of disease (AHR, mucus hypersecretion, 
and subepithelial fibrosis leading to airway remodelling) [9]. Figure 8.1 illustrates the 
various functional roles of IL-13 in the pathophysiology o f asthma, with effects on 
residential effector cells in addition to circulating immune cells.
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Figure 8.1 A diagrammatic illustration of the complex interplay between IL-13 and 
residential effector cells and circulating immune cells in asthma. IL-13 acts on B cells in 
the circulation to cause isotype switching to IgE production. IL-13 recruits eosinophils 
from the circulation into the airway. The cytokine acts on goblet cells to increase mucus 
production and causes bronchial epithelial cells and fibroblasts to produce eotaxin, a 
chemokine which in turn acts as a chemoattractant for further eosinophil recruitment. 
IL-13 acts on fibroblasts and smooth muscle (SM) within the mesenchyme leading to 
airway remodelling, with resultant disease chronicity.
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The differential genetic associations with specific outcomes emphasise the importance 
o f a well-defined phenotype. This highlights asthma as a heterogenous composite o f 
different phenotypes rather than a single disease entity and illustrates the importance o f 
teasing out the individual phenotypes within this group. This has been exemplified by 
work on the ADAM33 susceptibility locus where examination o f a phenotype o f asthma 
and airways hyperresponsiveness markedly increased the linkage signal in comparison 
to the much weaker association with IgE levels [26].
This thesis demonstrated for the first time that the A rgl lOGln variant o f IL-13 may be a 
predictor of asthma at the population level. This is o f relevance since case-control 
studies have shown inconsistent results, with some but not all demonstrating this 
association. IL13 promoter variants were shown for the first time to predict %FEV1 and 
asthma severity. Genotype associations with lung function have not been widely 
studied, especially in unselected populations, and variants across the 3 loci were 
associated with airflow obstruction, the most marked findings being for IL13 and IL4RA 
variants. This is a striking and novel finding, since discernible genetic effects on lung 
function were evident in an healthy young adult population. IL13 promoter associations 
with airflow obstruction were also demonstrated in the group with asthma. This is 
consistent with a role for IL-13 in airway remodelling leading to chronicity o f disease, 
and IL-13 has been shown to induce o f a complex array o f  genes in resident airway cells 
(smooth muscle cells, fibroblasts, epithelial cells and monocyte/macrophages) 
independently o f  traditional effector cells such as mast cells and eosinophils [9].
Another coding variant o f interest, Ile50Val o f IL4RA, was also shown for the first time 
to predict asthma at a population level. Other findings o f note for IL4RA and STAT6 
were the strong associations seen with total IgE levels, confirming the role o f 
Arg551Gln in IgE regulation, observed in another unselected population [132]. Other 
associations for IL4RA variants with immune phenotypes including that o f Ile50Val and 
Ser478Pro with eosinophil counts, which showed significant interaction effects with 
each high risk genotype potentiating the effects o f the other.
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The main STAT6 SNP of interest proved to be the G2964A 3’UTR variant, which 
showed the strongest associations with asthma, with consistent associations seen for 
both clinical atopy phenotypes (hayfever, eczema). These data are concordant with 
emerging evidence of the potential functional importance o f non-coding regions. There 
is evidence that the 3’UTR affects gene expression by influencing translation, coding 
capacity, mRNA stability and localisation o f RNA in the cytoplasm [272]. This region 
affects protein binding but may also exert its effects in its binding with short RNA 
[368]. Non-coding regions may play an important role in mRNA expression or mRNA 
stability. Alternatively, the G2964A variant may be in LD with as yet unidentified but 
functional variants in regulatory or coding regions, or variants o f the immediately 
adjacent genes.
Epistatic interactions were observed for IL13 and STAT6 polymorphisms which in 
combination predicted higher IgE levels than for each genotype alone. The association 
o f each individual high risk allele with IgE was dependent on the coexistence o f the 
high risk allele for the other gene. The same was true for eosinophil counts for a 
combination o f two IL4RA coding genotypes (which were not in strong LD): Ile50Val 
and Ser478Pro, where each high risk genotype potentiated the effects o f  the other.
For asthma, whilst the interaction between A rgllOGln and Ile50Val was significant 
only at the 10% level, interesting trends were observed suggesting that the asthma risk 
attributable to one locus may be dependent on the genotype held in combination at a 
distant locus. This may provide an explanation for the genetic heterogeneity o f atopic 
disease, even within one locus in different ethnic groups, which is suggestive that 
interaction effects are important. Epistatic effects may also explain why heterozygotes 
for certain variants, rather than having an intermediate phenotype, have the highest risk 
phenotype, which is discussed in Chapter 6.
Haplotype analysis revealed stronger associations when alleles were examined in 
combination. Although no significant associations were observed for single IL13
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variants with total IgE, highly significant associations were demonstrated for a risk 
haplotype containing the promoter and coding IL13 risk variants. Haplotype analysis 
indicated that IL4RA and STAT6 haplotypes played an important role in IgE regulation 
and supported genetic associations for IL4RA Q551R and STAT6 C2892T identified on 
individual SNP analysis.
Caution must be exercised in the interpretation o f these findings, as emphasised in the 
General Methodology chapter. Correction for multiple testing was not applied since a 
candidate gene approach was used, and based on previous genetic and functional studies 
we would expect to find at least some true positive associations. In this context, and in 
particular for a large number o f variables tested that are clearly not independent, the use 
o f methods such as the Bonferroni correction would result in a large loss o f  power and 
inability to reject a global null hypothesis thus resulting in an unacceptable number o f 
false negatives. It should be emphasised that the findings must therefore be interpreted 
with caution and accepting there are likely to be some false positives. The findings 
which can be regarded with most confidence are those where there are consistent results 
and concordance with previous genetic association or functional studies. Clearly the 
findings require replication in another population. Then further clarification o f  the 
biological role o f these polymorphisms is required by functional studies to complement 
this epidemiological work.
This thesis did not examine all components of the IL-13 signalling pathway, but focused 
on IL-13, IL-4RA and STAT6. Important omissions were IL-4, which is currently being 
genotyped, and IL-13RA (1 and 2) which we will examine in future work. IL-13RA2 is 
likely to act as a decoy receptor and work emerging since completion o f this thesis 
suggests the presence o f an important feedback mechanism between IL-13 and IL- 
13RA2. The A rgl lOGln variant has been shown to lead to increased eotaxin production 
by human lung fibroblasts [369], but only from cells expressing low levels o f  IL- 
13RA2. This suggests that there may be important interactions with implications for 
asthma susceptibility here and it would be interesting to examine epistatic interactions 
initially in this context. Findings from this thesis, and across ethnically diverse
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populations, suggest that genetic variation at the IL13, IL4RA and STAT6 loci is 
implicated in asthma and atopy susceptibility. The data suggest that asthma is both a 
genetically heterogenous and polygenic disease, and individual variants may only cause 
disease when in combination with other variants, or in gene-environment interactions. 
This is supported by functional studies which have shown significant but modest 
differences in activity between variants and wild-type counterparts. IL-13 signalling 
polymorphisms and haplotype combinations are likely to contribute significantly to 
asthma and atopy phenotypes, including the regulation o f total IgE levels. This thesis 
supports the approach of studying the effect o f combinations o f multiple alleles, in 
haplotypes or in combinations o f haplotypes, on complex phenotypes within a 
biological pathway. The potential clinical utility o f these findings includes progress 
toward the development of diagnostic/predictive genetic testing for asthma in childhood 
and the development of new asthma therapies targeting specific ligands and receptors in 
the IL-13 signalling pathway.
8.1.2 Future directions
Storage of DNA, serum and plasma from this study provides an opportunity to use this 
biobank to explore further genotypes and phenotypes relating to Th2 immunity. The 
biobank can also be used as a resource to confirm findings o f  other asthma/atopy studies 
in a large well-phenotyped unselected population.
If  designing this study again, and with no resource limitation, I would include the 
following measures: challenge testing as a measure o f  AHR; bronchodilator 
reversibility; SPT and specific IgE to common allergens as a direct measure o f  atopy; 
extended genotyping of the IL-4/IL-13 signalling pathway, to include in particular, 
variants of IL-4, IL-13RA1 and IL-13RA2; and advanced statistical methods (with 
supercomputer analysis) o f all possible interactions.
Further genotyping is planned:
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1. At the IL13, IL4RA and STAT6 loci, to examine further variants o f interest, 
including STAT6 GT dinucleotide repeats (in particular the GT repeat in the first exon of 
STAT6, shown to be associated with elevated eosinophil levels among Caucasians and 
with allergic phenotypes and childhood asthma in Japanese case-control studies [126, 
127, 130,131] in addition to examining new non-synonymous STAT6 SNPs.
2. At related loci, such as IL4, which is part o f the same biological pathway, 
signalling via the IL-4R alpha chain. Another important locus is IL-13RA2 as outlined 
previously. Further analysis o f  epistatic interactions and haplotype associations will be 
undertaken.
3. At distant loci, such as the eotaxin genes, ADAM33. IL-13 signalling, whilst 
central to bronchial inflammation, is clearly not the only biological pathway relevant in 
asthma. Variation in other independent pathways is important to asthma pathogenesis 
e.g. ADAM33 has been shown to have a key role in remodelling, and the phenotype o f 
AHR. Phenotypes can be considered in relation to other loci which shape disease.
Functional studies are needed to unravel the underlying molecular mechanisms and 
clarify which o f the variants confer the greater functional effects. Much o f the evidence- 
base for the role o f the IL-13 signalling pathway in asthma comes from murine models 
rather than studies in humans. Problems with murine models include the absence o f 
naturally occurring asthma-like syndromes in mice and important anatomical 
differences between the mouse and human lung such as the absence o f smooth muscle 
bundles in most mouse airways [370]. Studies on human cells (including leukocytes, 
fibroblasts, bronchial epithelial cells) are now needed to better understand the effects o f 
specific genetic variants on human airways and systemically. Immunological studies 
have been initiated in order to explore and clarify whether the variants found to 
associate with asthma/atopy phenotypes at the population level have a biological role, or 
act merely as markers for unidentified variants in linkage disequilibrium with the 
examined polymorphisms. Initial functional studies will focus on the C2892T intron 
variant of STAT6 (rs324011, SNP 8) located in a transcription factor binding site and 
found to have effects on IgE regulation in single polymorphism and haplotype analysis. 
Selection by genotype will allow functional comparison o f four groups: C/C and T/T
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homozvgotes, having high/low IgE levels (90th centile). Th2-trophic activity will be 
examined by measuring outputs such as upregulation o f  the low affinity IgE receptor 
(CD23) by flow cytometry and phosphorylation o f STAT6 (ELISA based method 
measuring total and phospho-specific STAT6), using B cells and monocytes stimulated 
by IL-4/IL-13. For further studies, selection by genotype will allow examination of 
genetic associations with other Th2 immune phenotypes. Currently, the population is 
being phenotyped for serum IL-13 levels, and measurement o f  soluble IL-4RA is 
planned, thus direct associations between genetic variants and expressed proteins can be 
examined. Other phenotypes o f interest include specific IgE sensitisation to common 
allergens, since there is evidence that different genetic influences are responsible for the 
inheritance o f basal and allergen specific IgE regulation [138],
Individual genetic variants have modest functional effects in asthma. This thesis 
suggests that it is the combination o f modest effects at a number o f loci that confer 
susceptibility to disease. The very large amount o f  genetic information offers an 
opportunity for more detailed statistical analysis based on haplotype analysis and 
multivariate techniques. Where haplotypes need to be reconstructed and where a huge 
number o f potential genetic interactions are possible, considerable computing power is 
required to fit models to large data sets, and for testing large numbers o f potential 
models. To extend our work further, we propose to address the exhaustive testing o f all 
possible interaction terms (a combinatorially large process if  more than 2-way 
interactions are also considered), discussed in Chapter 6. This advanced analysis was 
beyond the scope o f  this thesis and future analysis will be provided by the Institute o f 
Life Sciences’ Blue-C supercomputer (maximum speed 2 teraflops), which can be used 
for visualization o f this complex dataset, and novel means o f data mining, in 
combination with available flexible software (the R  language). Future work to 
encompass a combination o f  functional genomics utilising microarray technology 
(allowing the simultaneous monitoring o f thousands o f genetic or expression data 
points) coupled with sufficiently powerful supercomputer analysis is likely to begin to 
tease out the complex networks o f gene-gene and gene-environment effects in asthma. 
This will involve a multidisciplinary approach involving collaboration between the
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overlapping fields of epidemiology, clinical medicine, genetics & bioinformatics.
The potential clinical utility o f identifying the most important genetic predictors o f 
asthma and associated phenotypes are twofold. Firstly, this will advance towards the 
development of genetic testing for asthma. Since there is no gold standard diagnostic 
test for asthma, a simple inexpensive test would be especially useful in childhood, to aid 
diagnosis or even to simply predict which children are at highest risk, thus identifying 
those in need o f asthma surveillance and ayoidance o f potential precipitants where 
appropriate. Secondly, unraveling the molecular basis o f asthma would allow drug 
development and targeting o f specific ligands and receptors involved in Th2 signalling, 
leading to novel asthma therapies. Preliminary studies o f antagonists targeting this 
pathway have shown promising results in animal models [371, 372] and it has recently 
been shown that inhaled IL-4RA antisense oligonucleotide has anti-inflammatory 
activity in mice, suggesting the potential utility o f a dual IL-4 and IL-13 oligonucleotide 
inhibitor in targeting asthma and allergy [373].
This biobank provides a well-phenotyped population with stored biological data which 
may be used as a resource, both in terms of replicating findings from association studies 
in other population and in investigating asthma pathogenesis in more diverse ways. We 
plan a collaboration with investigators o f the Isle o f White cohort (Arshad Hassan, 
Wilfried Karmaus, Marianne Huebner, Susan Ewart) which will involve investigating 
whether our findings are replicated in another population, and also using the PAPA 
population for replication work. Regarding use o f the biobank as a resource, future 
collaborations o f interest include using this population to undertake replication studies 
of genes involved in GPCR signalling pathways identified by SNP based association 
approaches in two other cohorts (Professor Ian Hall, University Hospital o f 
Nottingham). A current collaboration relates to the investigation o f the role o f CMV 
infection in the development o f atopy (Professor Paul Moss, University o f 
Birmingham).
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8.2 CONCLUSIONS (II)
8.2.1 Effects of adiposity on asthma, Th2 immunity and physiological phenotypes
The parallel rise in prevalence o f the complex traits o f obesity and asthma over recent 
decades has led to speculation on a possible causal role o f obesity in asthma 
pathogenesis. Prospective studies have tended to confirm that there is an association 
between BMI earlier in life and the development o f  later asthma, with varying 
differential effects by sex. Obesity, in common with asthma, is a complex trait with 
multiple phenotypes. For example, central adiposity associates with insulin resistance 
whereas centrifugal or gluteal adiposity does not. Investigators have focused on the 
effects o f obesity (BMI>30) on asthma but alternative adiposity phenotypes, such as 
central adiposity and body fat, have not been widely examined. This population study 
provided an opportunity to test the relationship between different measures o f obesity 
and the state o f asthma, in addition to atopy and putatively Th2 signalling. This thesis 
provides the first investigation o f how BMI, central adiposity and body fat relate to 
asthma and associated phenotypes.
This thesis confirmed the association between BMI and asthma in a cross-sectional 
population o f young adults. In contrast to some studies, showing an effect only in 
females, effects were seen for both sexes, although effects tended to be stronger for 
females. Observed effects for both sexes are likely to be due to the large sample size in 
this study, since when examining the first 1000 volunteers, significant associations were 
found only for females. Differential effects by sex were seen for specific outcomes such 
as ‘physician diagnosed asthma ever’, with the association for BMI seen only in females 
whereas this was observed in both sexes when considering ‘current physician diagnosed 
asthma’. Similar associations were seen for central adiposity (waist circumference) and 
body fat.
Interesting effects o f adiposity on lung function were observed in this cross-sectional 
unselected population of young adults. Lung function was observed to increase initially
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across more normal anthropometric ranges, presumably due to muscularity effects. 
However, when higher anthropometric ranges indicative o f adiposity were reached, lung 
function declined. A quadratic curve provided the best fit for the data in regression 
analysis.
Since this was a cross-sectional rather than a prospective study, it is not possible to 
conclude that there is a causal link between obesity and asthma, merely that there is an 
association between these two complex traits. To explore the possible mechanistic basis 
for this association, the association between adiposity and markers o f Th2 immunity 
was examined. This is the first study to examine a comprehensive range o f both 
adiposity and Th2 phenotypes.
Adiposity measures were found to be associated with higher levels o f Th2 immune 
markers, and these effects were significantly modified by both sex and smoking. 
Differential effects by sex were clearly seen for the association between BMI/central 
adiposity and total IgE levels, with a positive association for the females but not the 
males. Conversely, plasma eotaxin showed a positive association with BMI/body fat in 
the males, associating with central adiposity in both sexes, with a modifying effect by 
smoking which caused more marked effects. There was a similar smoking-modifying 
effect for the association between BMI/central adiposity and eosinophil count, with the 
association between BMI and eosinophil count confined to current smokers. Differential 
effects by sex and smoking were seen when examining different adiposity phenotypes. 
This illustrates the importance o f exploring separate and well-defined phenotypes for a 
complex trait such as the obese state.
Since sample size was large, it was possible to detect highly significant associations 
between adiposity with the phenotypes o f asthma, lung function and Th2 immunity, 
despite some of the effects being relatively small in comparison to some previous 
epidemiological studies. The reason for relatively small effects in some cases was likely 
to be the age of our population. A narrow age range o f  young adults (18-30 years) was 
examined, in comparison to other studies, where the age range is broader e.g. 18-80
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years. The advantage of our study is that using a narrow age range allows us to answer 
questions relating to adiposity associations in a specific and relatively homogenous 
young adult population, whereas the examination o f broader age ranges is more likely to 
introduce potential confounders. When analyzing a broad age range o f adults, subgroup 
analysis by age is important, since associations have been found to change with age. 
Analysis of too heterogenous an age group is likely to lead to masking o f  effects, for 
instance, an obstructive defect may be seen with increasing adiposity in the young, but 
with increasing age, it may be that restrictive effects predominate. We found lung 
function to increase initially with anthropometric measures due to muscularity effects, 
until higher levels o f adiposity were reached, but it may be hypothesized that the point 
at which lung function begins to decline becomes lower with age i.e. at lower levels o f 
adiposity than in the young. Larger effect sizes might be expected for the association 
between adiposity and asthma, if  we had also included volunteers over the age o f 30 
years.
It is difficult to unravel the potential confounding effects o f  factors such as diet and 
exercise, which may have effects on both obesity and asthma traits. In order to provide 
as comprehensive a picture as possible, in addition to the validated phenotype o f 
‘current physician diagnosed asthma’, associated/intermediate phenotypes were also 
quantified including lung function and markers o f Th2 immunity (total IgE, eotaxin 
levels, eosinophil count). In addition to a highly significant association with asthma, 
adiposity measures also impacted negatively on lung function at higher values. 
Moreover, positive association were observed between adiposity indices and markers o f 
Th2 immunity, as outlined, with modifying effects by sex and smoking.
The potential mechanistic basis o f an association between adiposity and asthma is 
explored in Chapter 1. One possible explanation is that both complex traits share 
common biological pathways, and rather than being causally linked, their prevalence 
may be rising in parallel. The data presented supports the hypothesis that adiposity and 
asthma may be linked by an upregulation o f Th2 immunity, given the positive 
correlation between adiposity indices and the Th2 immune markers examined. This is
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supported by animal models, in particular the work by Shore et al who have 
demonstrated an innate airway hyperresponsiveness in obese (ob/ob) mice, in addition 
to increased Th2 responses on allergen challenge [181]. Moreover, the effects o f  obesity 
are not merely mechanical, since experimental murine data has shown that when the 
mechanical load of obesity is removed (by opening the chest wall and applying artificial 
ventilation), the effects o f adiposity on airways resistance is unchanged [181]. Evidence 
is mounting for the role of the adipocyte as a pro-inflammatory cell, and leptin, which is 
elevated in the obese, has been found to act as a cytokine, and has been shown to be 
associated with higher IgE levels [188,192].
The biological pathways regulating obesity and asthma may not be mutually exclusive. 
It is possible that these complex traits have genetic pathways in common, with specific 
variation promoting both obesity and asthma. The overlap between these two complex 
traits and potential common pathways linking the two are shown in Figure 8.2. Data 
described in this thesis suggest that obesity and genetic factors have contributory roles 
in asthma. Examining common genetic pathways was beyond the scope o f  this thesis, 
but will be explored in future work. If  obesity and asthma have genetic pathways in 
common, then care must be taken when including BMI as a covariate in genetic studies 
of asthma, since it may act a true confounder to any relationships seen. However, in 
Chapter 3, BMI was only found to act as a confounding variable in one case, so the 
potential confounding effect o f BMI does not seem to be relevant to the genetic 
pathways studied in this thesis.
In conclusion, adiposity was found to associate with asthma, have a negative impact on 
lung function over the upper range, and showed a positive association with markers o f 
Th2 immunity. The effect o f adiposity on specific immune phenotypes suggests that 
pro-inflammatory Th2 signalling may provide one potential mechanistic basis for this 
association. This epidemiological study suggests that obesity contributes to the 
causation o f asthma and associated phenotypes and upregulation o f Th2 signalling may 
provide one common pathway. Much work is needed to address this hypothesis, with 
replication required in other populations including different age groups, in parallel with
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functional work to examine the mechanistic basis for the association between obesity 
and asthma.
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Figure 8.2 A diagrammatic representation of the overlap between the complex traits 
of asthma and obesity and the potential common pathways linking these conditions. 
The areas of potential overlap which are addressed in this thesis are highlighted.
8.2.2 Future directions
Exploratory functional studies are needed to investigate the mechanistic basis o f the 
obesity-asthma association and to test whether adiposity per se results in upregulation of 
Th2 pathways. To investigate this, a comparison o f leptin levels is being made in 4 
subject groups: normal weight/obese with/without asthma. In addition, leptin levels will 
be compared with levels of Th2 immune markers (total IgE, eotaxin, eosinophil count) 
and serum IL-13 levels, (in collaboration with Dr Sadaf Farooqi, Professor Steve
Asthma
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O’Rahilly, Addenbrooke’s Hospital, University o f Cambridge). Further work o f similar 
design will involve the analysis o f differential proteome and metabolome profiles in 
serum/urine in obesity and asthma (Dr Cathy Thornton, Swansea University, Dr Ruta 
Furmonaviciene, DeMontfort University, Leicester, Dr Egidijus Machtejevas, Johannes 
Gutenberg University, Mainz, Germany). Further exploration o f  the role o f adiposity in 
allergic phenotypes will include the measurement o f specific IgE levels in our 
population. Additional work in collaboration with the Cambridge group, will involve 
further genotyping o f our population, to investigate whether obesity and asthma may 
share common genetic pathways. In particular, the leptin receptor gene will be focused 
upon.
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APPENDIX IA Poster advertisem ent
How good are your lungs??
Want to find out?
Sm okers & N on-sm okers needed
SIMPLE LUNG FUNCTION TESTS 
Single blood test 
One session -1 5  minutes only 
£5 as reimbursement for time
To take part in this study, please contact Dr Gwyneth Davies on 602214 
mobile 07838 273863, email gwyneth.davies@swan.ac.uk
PAPA project: Dr G Davies, Prof Hopkin, Dr M Gravenor, Prof R Williams
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APPENDIX IB Em ail advertisem ent
Dear Student Colleague,
How good are your lungs ?
You are invited to take part in a simple study which will take only around 15 minutes of your time. The 
purpose of the study is to investigate whether certain genetic markers can predict lung function and 
other markers of asthma in a young adult population.
v We are offering simple lung function tests and can discuss the results with you i f  requested
v We will check basic screening tests o f weight and body mass index: we can discuss the results
with you and let you know your optimum weight if requested
v A single blood test is needed
v We are recruiting all students (aged 18-30), whether you have asthma or not, whether you smoke
or not
v All participants will be receive £5 as reimbursement for their time 
Interested?
Please contact Dr Gwyneth Davies to arrange a convenient time or for further information. Tel 01792 
602214 (or extension 2214 i f  phoning internally) or mobile 07838 273863 or email 
gwyneth.davies@swan.ac.uk.
We hope to hear from you soon!
Kind regards,
Dr G Davies Professor J Hopkin Dr M Sansbury Dr M Gravenor
PAPA, Poblogaeth Asthma Prijysgol Abertawe: School o f Medicine, Swansea University
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APPENDIX II
CONSENT FORM
Project Reference Number 04/WMW02/29 
Version (2)
Date: 06/06/2005
Participant Identification number for this trial...........
N.B. Two copies should be made: (1) participant (2) researcher
Title of Project: The Genetic Prediction o f Asthma
Name of Researchers: Dr Gwyneth Davies, Professor Julian Hopkin
Dr M  Sansbury, Dr Divya Gopalakrishnan,
Dr Silas Benjamin, Dr Mike Gravenor 
Professor Rhys Williams
Contact Telephone Number: 01792 602214
Please Initial
1. I confirm that I have read and understood the information sheet dated 06/06/05 
(version 2) for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected.
3 .1 agree that my blood samples can be analysed for possible genes relating to 
asthma.
4 .1 agree that my blood samples can be kept for 25 years for possible further 
analyses of genes, as more information becomes available. I understand that my 
samples are anonymous and I am not able to be identified from them.
5 .1 understand that I may be asked to give a further blood sample on one occasion.
6 .1 agree to take part in the above study.
Name of Participant Date Signature
Name of Person taking consent Date Signature
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APPENDIX III
DATA SHEET
Volunteer number
Height (to 0.1cm)
Waist circumference (to 0.1cm) 
Hip circumference (to 0.1cm)
Weight (to 0.1 kg)
% Body fat
cm
cm
cm
Kg
~%
MEASURED % PREDICTED
FVC
FEV1
FEV1/FVC
L %
L %
%
Please tick
BLOODS 1
QUESTIONNAIRE
ASTHMA INTERVIEW QUESTIONNAIRE, IF APPLICABLE
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APPENDIX IV
| MODIFIED IUATLD BRONCHIAL SYMPTOMS QUESTIONNAIRE
To answer the questions, please choose the appropriate box; IF YOU 
ARE UNSURE OF THE ANSWER, PLEASE CHOOSE ‘NO’
Wheeze and tightness in the chest
1. Have you, at any tim e in the last 12 m onths, had  w heezing or w histling  
in your chest? N o Y es
[ ] [ 1
If rio, go to question 2. If  yes to 1:
la. Have you been at all breathless when the wheezing noise was present?
N o  Y es 
[ ] [ 1
lb. Have you had this wheezing or whistling when you did not have a cold?
N o Y es 
[ ] 1 1
2. Have you, at any time in the last 12 months, woken up with a 
feeling of tightness in your chest first thing in the morning?
No Yes
[ ] [ 1
Shortness of breath
3. Have you, at any time in the last 12 months, had an attack of shortness 
of breath that came on during the day when you were not doing 
anything strenuous?
No Yes
[ ] [ 1
4. Have you, at any time in the last 12 months, had an attack of shortness
of breath that came on after you stopped exercising? No Yes
[ ] [ ]
5. Have you, at any time in the last 12 months, been woken at night by an
attack of shortness of breath?
No Yes
[ ] [ 1
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Cough and Phlegm from the chest
6. Have you, at any tim e in the last 12 m onths, been  w oken a t n ight by an 
attack o f  coughing?
No Yes 
[ ] [ ]
7. Do you usually cough first thing in the morning?
No Yes
[ ] [ 1
If yes to 7:
7a.Do you have a cough like this most mornings for as 
much as 3 months per year?
No Yes
[ ] [ ]
7b.How many years have you had this cough?
YEARS
8. Do you usually bring up phlegm from your chest first thing in the 
morning?
No Yes
[ ] [ ]
If yes to 8:
8a. Do you have phlegm like this most mornings for as much 
as 3 months per year?
No Yes
[ ] [ ]
8b. How many years have you had this phlegm?
YEARS
Breathing_________________________________________________________
9. Which of the following statements best check only one:
describes your breathing?
I never or only rarely get trouble with my breathing [ ]
I get repeated trouble with my breathing but it always 
gets completely better [ ]
My breathing is never quite right [ ]
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Hayfever and eczema
10. Do you have any nasal allergies including hayfever?
No Yes
[ ] [ ]
11. Have vou ever had eczema? No Yes
[ ] [ 1
If yes to 11:
11a) Do you still have it? No Yes
[ 1 [ ]
Asthma
12. Have you ever had asthma? No Yes
[ ] [ 1
PLEASE LET US KNOW IF  YOU ANSW ER YES TO TH IS Q UESTION  AS
W E W ILL NEED SOME FU R TH ER IN FORM ATION  FR O M  YOU
If no to 12, go to question 13. If yes to 12:
12a) Do you still have it? No Yes
[ ] [ ]
12b) Was it confirmed by a doctor? No Yes
[ 1 [ ]
12c) At what age did it start?  Age in years
12d. If you no longer have it, at what age did it stop?  Age in years
13. Have you had an attack of asthma at any time in the last 12 months?
No Yes
[ ] [ 1
14. Are you currently taking any medicines (including inhalers, aerosols 
or tablets) for asthma?
No Yes
[ ] [ 1
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Other conditions
15. Do you have any medical conditions (apart from 
asthma/hayfever/eczema)?
No Yes
[ ] [ 1
I f  yes to 15:
15a) Please list medical conditions
16. Are you on any medication (apart from any for asthma)?
No Yes
[ ] [ ] 
If yes to 16:
16a) Please list medications
Smoking______________________________________________
17. Have you ever smoked for as long as one year?
No Yes
[ ] [ ]
If yes to 17: Check one
18. Do (did) you usually smoke:
cigarettes? [ ] 
pipe? [ ] 
cigars? [ ] 
Other (precise please)_____________
19. How many cigarettes do (did) you smoke each day, on 
average?___________
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20. Have you: Check one:
continued to smoke? [ ]
given up smoking altogether, but less than 4 weeks ago? [ ]
given up smoking altogether, at least 4 weeks ago? [ ]
21. For how many years have you smoked (did you smoke)
Your family___________________________________________________
22. Did your (natural) mother ever have asthma? No Yes Don’t know
[ ] [ ] [ 1
23. Did your (natural) mother ever have eczema, skin or nasal allergy or
hayfever?
No Yes Don’t know
[ ]  [ I [ I
24. Did your (natural) father ever have asthma? No Yes Don’t know
[ ] [ ] [ ]
25. Did your (natural) father ever have eczema, skin or nasal allergy or 
hayfever?
No Yes Don’t know
[ ] [ 1 [ ]
26. How many brothers do or did you have? NUMBER
IF ‘NONE’ GO TO QUESTION 27, IF ‘YES’:
26.1 How many older brothers?
26.2 How many younger brothers?
26.3 How many of your brothers ever had asthma?
26.4 How many o f your other brothers ever had eczem a, 
skin or nasal allergy or hayfever?
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27. How many sisters do or did you have? NUMBER
IF ‘NONE’ GO TO QUESTION 28, IF ‘YES’:
27.1 How many older sisters?
27.2 How many younger sisters?
27.3 How many of your sisters ever had asthma?
27.4 How many of your other sisters ever had eczem a, 
skin or nasal allergy or hayfever?
More about yourself_______________________
28. When were you born day month year
29. Are you Male Female
30. What is today’s date? day month year
31. How old are you Years
32. Are you a student (undergraduate/postgraduate)?
No Yes
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33. What is your ethnic group?
a) White [ ]
b) Black African [ j
c) Black Caribbean [ ]
d) Black other [ ]
e) Indian [ j
f) Pakistani [ ]
g) Bangladeshi [ j
h) Chinese [ ]
i) Arab [ ]
j) Turkish [ ]
k) Other ethnic group [ ]
I) If other, please state [e.g. a) and b)]
34. Contact details:
NAME:_____________________  ______________________  ______
(Last) (First) (Middle
initial)
CONTACT ADDRESS:
PHONE NUMBER: 
E MAIL:________
Original questionnaire prepared for the Respiratory Disease Committee 
of the International Union Against Tuberculosis and Lung Disease 
(UNION)
Study reference for UNION questionnaire and validation:
Burney PG, LaitinenLA, PerdrizetS, HuckaufH, Tattersfield AE, ChinnS, etal. Validity and 
repeatability o f the IUATLD (1984) bronchial questionnaire : cm international comparison. 
Eur Respir J, 1989; 2: 940-5
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APPENDIX V
MODIFIED ECRHS II INTERVIEW QUESTIONNAIRE
FOR VOLUNTEERS WITH ASTHMA
Volunteer 
number 
Interviewer 
number
Date
DAY MONTH YEAR
I AM GOING TO ASK YOU SOME QUESTIONS ABOUT YOUR ASTHMA. WHEREVER 
POSSIBLE, I WOULD LIKE YOU TO ANSWER ‘YES’ OR ‘NO’.
1. Have you had an attack of asthma in the last 12 months? NO YES
IF  ‘N O ’ GO TO QUESTION 1.3, IF  YES
1.1 How many attacks of asthma have you had in the last 12 months? _
1.2 How many attacks of asthma have you had in the last 3 months! _ 
GO TO QUESTION 2
1.3 How old were you when you had your most recent attack o f asthma?
ATTACKS
ATTACKS
YEARS
2. How many times have you woken up because o f your asthma in the last 3 months?
every night or almost every night
more than once a week, but not most nights
at least twice a month, but not more than once a week
less than twice a month
not at all
TICK ONE BOX ONLY 
1
3. How often have you had trouble with your breathing because of your asthma
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in the last 3 months?
continuously 
about once a day
at least once a week, but less than once a day 
less than once a week 
not at all
TICK ONE BOX ONLY 
1 
2
3
4
5
4. Do you have written instructions from your doctor on
how to manage your asthma if it gets worse or if  you have an attack?
NO YES
5. Are you currently taking any medicines including inhalers, 
aerosols or tablets for asthma?
6. Have you used any inhaled medicines to help your breathing at any time
in the last 12 months'?
IF NO' GO TO QUESTION 7, IF 'YES':
Which of the following have you used in the last 12 months?
6.1 short acting beta-2-agonist inhalers
NO
NO
NO
(Please include combinations that include beta 2 and steroids in section 6.5)
6.1.1 If used, which one? ______________________________
6.1.2 What type of inhaler do you use?
6.1.3. What is the dose per puff (in micrograms)?
YES
YES
YES
6.1.4. In the last 3 months, how have you used them:
TICK ONE BOX ONLY
a) when needed 1
b) in short courses 2
c) continuously 3
d) not at all 4
I f  answer to 6.1.4 is when needed:
6.1.5 Number of puffs per month
I f  answer to 6.1.4 is in short courses
6.1.6 number of courses
6.1.7 number of puffs per day
6.1.8 average number of days per month 
I f  answer to 6.1.4 is continuously
6.1.9 number of puffs per day
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6.2 long acting beta-2-agonist inhalers
NO YES
(Please include combinations that include beta 2 and steroids in section 76.5)
6.2.1 If used, which one?________________________________
6.2.2 What type of inhaler do you use?
6.2.3. What is the dose per puff (in micrograms)?
6.2.4. In the last 3 months, how have you used them:
TICK ONE BOX ONLY
a) when needed 1
b) in short courses 2
c) continuously 3
d) not at all 4
I f  answer to 6.2.4 is when needed:
6.2.5 Number of puffs per month
I f  answer to 6.2.4 is in short courses
6.2.6 number of courses
6.2.7 number of puffs per day
6.2.8 average number of days per month 
I f  answer to 6.2.4 is continuously
6.2.9 number of puffs per day
6.3 non-specific adrenoreceptor agonist inhalers
NO i¥ES-
6.3.1 If used, which one?
NO YES
6.4 anti-muscarinic inhalers _____  ____
6.4.1 If used, which one?
6.4.2 What type of inhaler do you use?
6.4.3. What is the dose per puff (in micrograms)?
6.4.4. In the last 3 months, how have you used them:
TICK ONE BOX ONLY
a) when needed 1
b) in short courses 2
c) continuously 3
d) not at all 4
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If answer to 6.4.4 is when needed:
6.4.5 Number of puffs per month
I f  answer to 6.4.4 is in short courses
6.4.6 number of courses
6.4.7 number of puffs per day
6.4.8 average number of days per month 
I f  answer to 6.4.4 is continuously
6.4.9 number of puffs per day
6.5 inhaled steroids NO YES
(if combined B2 and steroid please insert inhaled steroid dose)
6.5.1 If used, which one?
6.5.2 What type of inhaler do you use?
6.5.3. What is the dose per puff (in micrograms)? ------- ----------------------
6.5.4. In the last 3 months, how have you used them:
TICK ONE BOX ONLY
a) when needed 1
b) in short courses 2
c) continuously 3
d) not at all 4
I f  answer to6.5.4 is when needed:
6.5.5 Number of puffs per month
I f  answer to 6.5.4 is in short courses
6.5.6 number of courses
6.5.7 number of puffs per day
6.5.8 average number of days per month
I f  answer to 6.5.4 is continuously
6.5.9 number of puffs per day
NO YES
6.6 inhaled cromoglycate/nedocromil
□  □
6.6.1 If used, which one?
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6.6.2. What is the dose per puff (in micrograms)?
6.6.3. In the last 3 months, how have you used them
a) when needed
b) in short courses
c) continuously
d) not at all
I f  answer to 6.6.3 is when needed:
6.6.4 Number of puffs per month
TICK ONE BOX ONLY 
1 
2
3
4
I f  answer to 6.6.3 is in short courses
6.6.5 number of courses
6.6.6 number of puffs per day
6.6.7 average number o f days per month
I f  answer to 6.6.3 is continuously
6.6.8 number of puffs per day
6.7 inhaled compounds
6.7.1 If used, which one?
6.7.2 What type of inhaler do you use?
6.7.3. What is the dose per puff (in milligrams)?
NO YES□
NO YES
7. Have you used any pills, capsules, tablets or medicines, other than----------------   i-------1
inhaled medicines, to help your breathing at any time in the last 12 months?   I------- 1
IF 'NO* GO TO QUESTION 8, IF ’YES’:
Which of the following have you used in the last 12 months!
7.1 oral beta-2-agonists
7.1.1 If used, which one?
7.1.2. What is the dose of tablet?
7.1.3. In the last 3 months, how have you used them
TICK ONE BOX ONLY
a) when needed 1
b) in short courses 2
c) continuously 3
d) not at all 4
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I f  answer to 7.1.3 is when needed:
7.1.4 Number of tablets per month
I f  answer to 7.1.3 is in short courses
7.1.5 number of courses
7.1.6 tablets per day
7.1.7 average number of days per month
I f  answer to 7.1.3 is continuously 
7.1.8 tablets per day
7.2 oral methylxanthines
7.2.1 If used, which one?
7.2.2. What is the dose of tablet?
NO YES
7.2.3. In the last 3 months, how have you used them
a) when needed
b) in short courses
c) continuously
d) not at all
TICK ONE BOX ONLY 
1 
2
3
4
I f  answer to 7.2.3 is when needed:
7.2.4 Number of tablets per month
I f  answer to 7.2.3 is in short courses
7.2.5 number of courses
7.2.6 tablets per day
7.2.7 average number o f days per month
If answer to 7.2.3 is continuously
7.2.8 tablets per day
7.3 oral steroids
7.3.1 If used, which one?
7.3.2. What dose of tablet?
NO YES
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7.3.3. In the last 3 months, how have you used them
TICK ONE BOX ONLY
a) when needed 1
b) in short courses 2
c) continuously 3
d) not at all 4
I f  answer to 7.3.3 is when needed:
7.3.4 Number of tablets per month
I f  answer to 7.3.3 is in short courses
7.3.5 number of courses
7.3.6 tablets per day
7.3.7 average number of days per month
I f  answer to 7.3.3 is continuously
7.3.8 tablets per day
7.3.9. Have you used them in the last 3 months?
NO YES
7.4 oral anti-leukotrienes --------- -------
7.4.1 If used, which one?
7.4.2. What is the dose of tablet?
7.4.3. In die last 3 months, how have you used them
TICK ONE BOX ONLY
a) when needed 1
b) in short courses 2
c) continuously 3
d) not at all 4
I f  answer to 7.4.3 is when needed:
7.4.4 Number o f tablets per month
If answer to 7.4.3 is in short courses
7.4.5 number of courses
7.4.6 tablets per day
7.4.7 average number of days per month
I f  answer to 7.4.3 is continuously
7.4.8 tablets per day
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7.5 ketotifen NO YES
7.5.1 If used, which one?
7.5.2. What dose of tablet?
7.5.3. In the last 3 months, how have you used them
a) when needed
b) in short courses
c) continuously
d) not at all
I f  answer to 7.S.3 is when needed:
7.5.4 Number of tablets per month
TICK ONE BOX ONLY 
1 
2
3
4
I f  answer to 7.5.3 is in short courses
7.5.5 number of courses
7.5.6 tablets per day
7.5.7 average number of days per month
I f  answer to 7.5.3 is continuously
7.5.8 tablets per day
NO8. Have you ever used inhaled steroids (show list)?
IF NO GO TO QUESTION 9, IF YES
8.1. How old were you when you first started to use inhaled steroids?
8.2. Have you now stopped using inhaled steroids?
IF  NO, GO TO Q8.3, IF  YES
YES
YEARS
YES
YEARS
8.2.1 How old were you when you stopped using inhaled steroids?
8.3 Have (did) you used inhaled steroids every year since you started 
using them?
NO YES
IF  NO GO TO QUESTION 8.4, IF  YES
8.3.1. On average how many months each year have you taken 
them (or did you take them)?
NOW GO TO Q9
MONTHS
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YEARS
8.4 How many of the years since you started using them have you t a k e n -----------
inhaled steroids? --------------
them?
8.5 On average how many months of each of these years have you taken MONTHS
9. Have you visited a hospital casualty department or emergency room NO YES
because o f asthma, shortness of breath or wheezing in the last 12 months? | |
IF  NO GO TO 10, IF YES TIMES
9.1 How many times in the last 12 months'! --------------
10. Have you spent a night in hospital because of asthma, shortness of 
breath or wheezing in the last 12 months?
IF NO GO TO Q ll, IF YES
10.1 How many nights have you spent in hospital because o f asthma, 
shortness of
breath or wheezing in the last 12 months?
NO YES
NIGHTS
10.2 Have you spent a night in ITU because o f asthma, shortness of 
breath or wheezing in the last 12 months?
NO YES
IF NO GO TO Q ll, IF YES
10.2.1 How many nights have you spent in ITU because of asthma, 
shortness of breath or wheezing in the last 12 months'?
NIGHTS
NO YES
11. Have you been seen by a doctor because of asthma, shortness o f------------------- --------  -------
breath or wheezing in the last 12 months? --------  -------
IF NO GO TO Q12, IF YES
11.1 Have you been seen by a general practitioner because o f asthma, n o  YES
shortness of breath or wheezing in the last 12 months! -------- -------
TIMES
IF  NO GO TO Q11.2, IF  YES  r--
11.1.1 How many times have you been seen by your general 
practitioner because of asthma, shortness o f breath or wheezing in the last 12 months'?
NO YES
11.2 Have you seen a specialist (chest physician, allergy-------------------------------  -------
specialist, internal medicine specialist, ENT doctor) because of asthma, --------  -------
shortness of breath or wheezing in the last 12 months?
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12. Have there been days when you have had to give up work or other activities NO YES 
because of asthma, shortness o f breath or wheezing in the last 12 months?
IF NO YOU HAVE FINISHED THE QUESTIONNAIRE, IF YES --------  -------
12.1 How many days on average each month?
END
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APPENDIX VI
Table 9.1 Summary o f variants where overall association with dichotomous 
outcomes approached significance with p<.05 for difference between individual 
pairs o f genotypes.______________________________________________________
Location Outcome 
OR (95% Cl)
P value
IL13
SNP 1 Promoter Current eczema .1311
-1024C/T 2.19(1.02-4.71) .0442
SNP 10 Promoter Current eczema .121
-1512A/C 2.28(1.01-5.12) .046
IL4RA
SNP 12 Exon 12 Asthma ever .134
Pro478Val
G /G vsA /A 1.40(1.00-1.97) .049
SNP 5 Exon 5 Hayfever .134
Ile50Val 1.38(1.01-1.89) .046
STAT6
SNP 1 3’UTR Asthma ever .091
A/A vs G/G 1.75(1.01-3.02) .029
SNP 12 Intron 17 Eczema ever .084
C/C vs T/T 1.52(1.05-2.19) .027
SNP 2 3’UTR Current eczema .125
G/G vs A/A 1.70(1.02-2.83) .043
1 Overall p value ]'or association at this locus, after adjusting for relevant covariates.
2 P value between individual genotypes shown.
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APPENDIX VII
T able 9.2 Summary o f variants where overall association with quantitative 
outcomes approached significance with p<.05 for difference individual pairs of 
genotypes.
Location Outcome P  va/we
IL13
SNP 10 Promoter FEV1 .0671
A/C vs A/A -1512A/C .0212
IL4RA
SNP 7 Intron 8 Eosinophil count .067
C/G vs C/C .040
SNP 13 Exon 12 FEF 25-75 .102
A/G vs G/G Arg551Gln .034
% FEF 25-75 .125
A/G vs G/G .042
SNP 16 3’UTR FEV1/FVC .051
C/T vs C/C .015
STAT6
SNP 1 3’UTR % FEV1 .128
A/G vs A/A .044
G/G vs A/A % FEF 25-75 .135
.046
Overall p value for association at this locus, after adjusting for relevant covariates.
P value between individual genotypes shown.
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